CA2431171A1

CA2431171A1 - Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof

Info

Publication number: CA2431171A1
Application number: CA002431171A
Authority: CA
Inventors: Masami Kusaka; Noritaka Kuroda; Yoshi Nara; Shohei Hashiguchi; Akihiro Tasaka; Masuo Yamaoka; Tomohiro Kaku
Original assignee: Individual
Current assignee: Takeda Pharmaceutical Co Ltd
Priority date: 2000-12-08
Filing date: 2001-12-07
Publication date: 2002-06-13
Also published as: JP2008266349A; US7067537B2; WO2002046186A1; EP1348706B1; EP1348706A1; EP1348706A4; ATE440096T1; DE60139639D1; AU2002221080A1; US20040072876A1

Abstract

Pharmaceutical compositions which have steroid C17,20 lyase inhibiting activity and are useful as preventive or therapeutic agents for prostatism or tumors such as breast cancer, more particularly, steroid C17,20 lyase inhibitors characterized by containing a compound of the general formula (I) or a salt or prodrug thereof, wherein A1 is an optionally substituted aromatic hydrocarbon group or an optionally substituted heterocyclic group; and one of A2 or A3 is hydrogen, halogeno, an optionally substituted C1-4 aliphatic hydrocarbon group, or optionally esterified carboxyl, and the other is an optionally substituted heterocyclic group, with the proviso that at least one of A1, A2, and A3 is optionally substituted 3-pyridyl.

Description

' CA 02431171 2003-06-06 DESCRIPTION
SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF
TeChniC81 Field s The present invention relates to a novel thiazole derivative having an inhibitory activity on steroid Cl~,zo-lyase, a salt thereof and to a pharmaceutical composition containing the same.
BBCkground Art io Androgen and estrogen, which are sex hormones, show a great diversity of physiological activities inclusive of differentiation and proliferation of cells. On the other hand, it has been clarified that androgen and estrogen act as an exacerbation factor in certain diseases. It is known that is steroid Cl,,za-lyase is responsible for the final stage of the biosynthesis of androgen in the body. That is, steroid Cl~,zo-lyase produces dehydroepiandrosterone and androstenedione using, as a substrate, 17-hydroxypregnenolone and 17-hydroxyprogesterone, which are generated by cholesterol.
2o Therefore, a pharmaceutical agent inhibiting steroid Cl~,zo-lyase suppresses production of androgen, as well as production of estrogen synthesized using androgen as a substrate. Such pharmaceutical agent is useful as an agent for the prevention and therapy of diseases wherein androgen and estrogen are a5 exacerbation factors. Examples of the diseases, in which androgen or estrogen is an exacerbation factor, include prostate cancer, prostatic hypertrophy, masculinism, hypertrichosis, male-type baldness, male infant-type prematurity, breast cancer, uterine cancer, ovarian cancer, so mastopathy, hysteromyoma, endometriosis, adenomyosis of uterus, polycystic ovary syndrome and the like.
Steroid-type compounds and non-steroid type compounds are already known as steroid Cl~,zo-lyase inhibitors. Steroid-type compounds are disclosed in, for example, W092/15404, W093/20097, EP-A-288053, EP-A-413270 and the like. As non-steroid type compounds, for example, JP-A-64-85975 discloses (1H-imidazol-1-yl)methyl-substituted benzimidazole derivatives, s W094/27989 and W096/14090 disclose carbazole derivatives, W095/09157 discloses azole derivatives, US 5,491,161 discloses 1H-benzimidazole derivatives and W099/18075 discloses dihydronaphthalene derivatives.
Heretofore, there has not been obtained a steroid Cl~,zo-zo lyase inhibitor applicable to clinical situations, and early development of a steroid Cl~,TO-lyase inhibitor highly useful as a pharmaceutical is desired.
Disclosure of the Invention The present inventors have conducted intensive studies in is an attempt to find a superior steroid Cl~,2o-lyase inhibitor and found that a compound of the formula (I) unexpectedly has a superior pharmaceutical use, particularly a superior steroid ~m,zo-lyase-inhibitory activity, and shows less toxicity and superior properties as a pharmaceutical product, based on its 2o unique chemical structure.
Accordingly, the present invention relates to the following:
[1] A steroid Cl~,2o-lyase inhibitor comprising a compound represented by the formula:

A~ ~-A' (I) as A3/ 'S
wherein A1 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, 30 one of Az and A3 is a hydrogen atom, a halogen atom, a Cl_4 aliphatic hydrocarbon group optionally having substituents or an optionally esterified carboxyl group, the other of Az and A3 s is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, and at least one of Al, Az and A3 is a 3-pyridyl group optionally having substituents, io or a salt thereof or a prodrug thereof, [2] the steroid Cl,,zo-lyase inhibitor of the above-mentioned [1), wherein one of A1, Az and A3 is a 3-pyridyl group optionally having substituents, [3] the steroid Cl~,zo-lyase inhibitor of the above-mentioned is [2], wherein (1) A1 is a 3-pyridyl group optionally having substituents and Az is a C6_14 aryl group optionally having substituents, or (2) A1 is a 3-pyridyl group optionally having substituents and Az is a 3-pyridyl group optionally having substituents or ( 3 ) A1 is a C6_14 aryl group optionally having ao substituents and Az is a 3-pyridyl group optionally having substituents, [4] the steroid Cl,,zo-lyase inhibitor of the above-mentioned [2), wherein one of Az and A3 is 1) a hydrogen atom, 2) a C1_ aliphatic hydrocarbon group optionally having substituents, 3) 25 an optionally esterified carboxyl group or 4) a halogen atom, the substituent of the "3-pyridyl group optionally having substituents", which is one of A1, Az and A3, is 1 to 4 groups selected from 1) a C1_6 aliphatic hydrocarbon group optionally having substituents, 2) an optionally esterified carboxyl 3o group, 3) a carbamoyl optionally having 1 or 2 substituents, 4) a cyclic aminocarbonyl optionally having substituents, 5) an amino optionally having substituents, 6) a cyclic amino optionally having substituents, 7) an alkylthio optionally having substituents, 8) an alkoxy optionally having substituents and 9) a halogen, or one saturated or unsaturated divalent C3_5 carbon chain, and the other of AZ and A3 and the aromatic hydrocarbon group optionally having substituents or s heterocyclic group optionally having substituents for A1 are (a) a C6_14 aryl optionally having, as a substituent, 1 to 5 groups selected from 1) a C1_4 alkyl optionally having substituents, 2) a phenyl optionally having substituents, 3) a C1_4 alkoxycarbonyl, 4) a carbamoyl optionally having so substituents; 5) a C1_2 alkylenedioxy, 6) an amino optionally having substituents, 7) a vitro, 8) a hydroxy optionally having substituents, 9) an optionally esterified carboxyl, 10) an alkylsulfonyl, 11) a sulfamoyl optionally having substituents and 12) a halogen, or (b) a pyridyl, I5 [5] the steroid Cl~,2a-lyase inhibitor of the above-mentioned [2], wherein one of AZ and A3 is 1) a hydrogen atom, 2) a Cl alkyl optionally substituted by hydroxy, 3) a carboxyl, 4) a C1_4 alkoxycarbonyl or 5 ) a halogen, and the other of AZ and A3 and the aromatic hydrocarbon group optionally having 2o substituents or heterocyclic group optionally having substituents for A1 are (a) a C6_14 aryl optionally having, as a substituent, 1 to 5 groups selected from 1) a C1_4 alkyl optionally having halogen, 2) a phenyl optionally having C1_4 alkoxy, 3) a C1_4 alkoxycarbonyl, 4j a carbamoyl optionally 2s having 1 or 2 C1_4 alkyl, 5 ) a Cl_2 alkylenedioxy, 6 ) an amino optionally having 1 or 2 substituents selected from C1_4 alkyl, Cl_6 alkanoyl and Cl_4 alkylsulfonyl, 7 ) a vitro, 8 ) a hydroxy, 9 ) a C1_4 alkoxy, 10 ) a Cl_4 alkanoyloxy, 11 ) a C1_4 alkylsulfonyl, 12) a sulfamoyl optionally having 1 or 2 substituents selected 3o from C1_4 alkyl and benzyl and 13) a halogen or (b) a pyridyl, and the substituent of the "3-pyridyl group optionally having substituents", which is one of Al, AZ and A3, is 1 to 4 groups selected from 1) a C1_6 alkyl group optionally having, as a ' CA 02431171 2003-06-06 substituent, halogen or hydroxy, 2) a carboxyl group, 3) a Cl_4 alkoxycarbonyl group, 4) a carbamoyl optionally having, as a substituent, 1 or 2 C1_4 alkyl, 5) a 4-benzylpiperidinocarbonyl, 6) an amino optionally having, as a substituent, 1 or 2 groups s selected from carbamoylmethyl, C1_4 alkyl and benzyl, 7) a morpholino, 8) a 4-(4-chlorophenyl)-4-hydroxypiperidino, 9) a Cl_4 alkylthio, 10 ) a Cl_4 alkoxy, 11 ) a halogen and 12 ) a butadienylene, [6] the steroid Cl~,zo-lyase inhibitor of the above-mentioned io [ 2 ] , wherein 'one of Az and A3 is a hydrogen atom, a methyl group, a chlorine atom or a fluorine atom, the other of Az and A3 and the aromatic hydrocarbon group optionally having substituents or heterocyclic group optionally having substituents for A1 are 1) a phenyl group optionally having, as is a substituent, 1 or 2 groups selected from methyl, methoxycarbonyl, carbamoyl, trifluoromethyl, diethylamino, acetylamino, methylsulfonylamino, hydroxy, methoxy, sulfamoyl, methylsulfamoyl, fluorine and chlorine, 2) a naphthyl group or 3) a 3-pyridyl group, and the substituent of the "3-pyridyl 2o group optionally having substituents", which is one of A1, Az and A3, is methyl, ethyl, trifluoromethyl, 1-hydroxy-1-methylethyl, carbamoylmethylamino, dimethylamino, morpholino, methylbenzylamino, methylthio, methoxy, isopropoxy or butadienylene, 2s [7] the steroid Cl~,zo-lyase inhibitor of the above-mentioned [3), wherein the 3-pyridyl group optionally having substituents is a 4-methyl-3-pyridyl group or a 4-trifluoromethyl-3-pyridyl group, [8] the steroid Cl~,zo-lyase inhibitor of the above-mentioned 30 [2], wherein A3 is a hydrogen atom, a halogen atom, a C1_4 alkyl group or a C1_4 alkoxycarbonyl group, [9] the steroid Cl7,zo-lyase inhibitor of the above-mentioned [3], wherein 3-pyridyl group optionally having substituents is ' CA 02431171 2003-06-06 a 3-pyridyl group, a 4-methyl-3-pyridyl group, a 4-trifluoromethyl-3-pyridyl group, a 4-methoxy-3-pyridyl group, a 4,5-butadienylene-3-pyridyl group, a 4-dimethylamino-3-pyridyl group, a 4-methylthio-3-pyridyl group, a 4-s benzylmethylamino-3-pyridyl group, a 4-isopropoxy-3-pyridyl group, a 5-ethoxycarbonyl-3-pyridyl group, a 4-morpholino-3-pyridyl group, a 1-hydroxyisopropyl-3-pyridyl group, a 6-dimethylcarbamoyl-3-pyridyl group, a 4-hydroxy-4-(4-chlorophenyl)piperidino-3-pyridyl group, a 4-(N-io methylcarbamoyl)-3-pyridyl group, a 4-ethyl-3-pyridyl group, a 4-carbamoylmethylamino-3-pyridyl group, a 4-carbamoyl-3-pyridyl group or a 4-(4-benzylpiperidinocarbonyl)-3-pyridyl group, and the C6_14 aryl group optionally having substituents is a phenyl group, a 4-phenylphenyl group, a 3-nitrophenyl is group, a 4-nitrophenyl group, a 4-hydroxyphenyl group, a 2-chlorophenyl group, a 3-chlorophenyl group, a 4-chlorophenyl group, a 3,4-dichlorophenyl group, a 2-fluorophenyl group, a 3-fluorophenyl group, a 4-fluorophenyl group, a 4-bromophenyl group, a 4-methylphenyl group, a 2,4-dimethylphenyl group, a zo 3,4-dimethylphenyl group, a 4-trifluoromethylphenyl group, a 2,4-bistrifluoromethylphenyl group, a 2-methoxyphenyl group, a 3-methoxyphenyl group, a 4-methoxyphenyl group, a 2,4-dimethoxyphenyl group, a 4-aminophenyl group, a 4-diethylaminophenyl group, a 4-methoxycarbonylphenyl group, a Zs 4-ethoxycarbonylphenyl group, a 3-methylcarbamoylphenyl group, a 4-sulfamoylphenyl group, a 4-methylsulfamoylphenyl group, a 3,4-ethylenedioxyphenyl group, a 4-acetoxyphenyl group, a 4-methylsulfonylphenyl group, a 4-dibenzylsulfamoylphenyl group, 3-acetylaminophenyl group, a 4-acetylaminophenyl group, a 4-3o methylsulfonylaminophenyl group, a 3-methylsulfonylaminophenyl group, a 4-carbamoylphenyl group or a 2-naphthyl group, [10] the steroid Cl~,ZO-lyase inhibitor of the above-mentioned (2], which is a prophylactic or therapeutic agent of a sex ' CA 02431171 2003-06-06 hormone dependent disease, [11] the steroid Cl~,zo-lyase inhibitor of the above-mentioned [2], which is a prophylactic or therapeutic agent of prostatic hypertrophy, masculinism, hypertrichosis, male-type baldness, s male infant-type prematurity, endometriosis, hysteromyoma, adenomyosis of uterus, mastopathy or polycystic ovary syndrome, [12] an androgen or estrogen reducing agent, which comprises a steroid Cl~,zo-lyase inhibitor and an LHRH receptor modulator in combination, io [13] an androgen or estrogen reducing agent comprising a compound represented by the formula:
N
~~--A~ C I ) A3 ''S
wherein A1 is an aromatic hydrocarbon group optionally having is substituents or a heterocyclic group optionally having substituents, one of Az and A3 is a hydrogen atom, a halogen atom, a C1_4 aliphatic hydrocarbon group optionally having substituents or an ao optionally esterified carboxyl group, the other of AZ and A3 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, and 2s at least one of Al, Az and A3 is a 3-pyridyl group optionally having substituents, or a salt thereof or a prodrug thereof, and an LHRH receptor modulator in combination, [14] a method for inhibiting steroid Cl~,zo-lyase, which 3o comprises administering an effective amount of a compound ' CA 02431171 2003-06-06 represented by the formula:

I ~~--A~ . C I ) A3 ''S
wherein A1 is an aromatic hydrocarbon group optionally having s substituents or a heterocyclic group optionally having substituents, one of AZ and A3 is a hydrogen atom, a halogen atom, a C1_4 aliphatic hydrocarbon group optionally having substituents or an ~o optionally esterified carboxyl group, the other of A2 and A3 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, and i5 at least one of Al, AZ and A3 is a 3-pyridyl group optionally having substituents, or a salt thereof or a prodrug thereof, [15] use of a compound represented by the formula:
AZ N
I ~A~ CI) A3 ~'' S
2o wherein A1 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, one of A~ and A3 z5 is a hydrogen atom, a halogen atom, a C1_4 aliphatic hydrocarbon group optionally having substituents or an optionally esterified carboxyl group, s ' CA 02431171 2003-06-06 the other of AZ and A3 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, and s at least one of Al, A2 and A3 is a 3-pyridyl group optionally having substituents, or a salt thereof or a prodrug thereof for the production of a steroid Cl,,ZO-lyase inhibitor, [16~ a compound represented by the formula:
(R1a)~ N v R2 \ ~ ~( )m ( I8 ) io K~ S -N
wherein n is an integer of 1 to 5, R1° is a sulfamoyl group optionally having substituents or an alkylsulfonyl group optionally having substituents, is or two R1° substituting adjacent carbon atoms are bonded to designate a C1_2 alkylenedioxy group, and when n is not less than 2, R18 in the number of n may be the same or different, m is an integer of 1 to 5, ao R2 is 1) a hydrogen atom, 2) a C1_4 aliphatic hydrocarbon group optionally having substituents, 3) an optionally esterified carboxyl group, 4) a carbamoyl group optionally having substituents, 5) an amino group optionally having substituents, 6) a cyclic amino group, 2s 7) an alkylthio group optionally having substituents or 8) an alkoxy group optionally having substituents, or two R2 substituting adjacent carbon atoms may be bonded to form 9) a saturated or unsaturated divalent C3_5 carbon chain, and when m is not less than 2, RZ in the number of m may be the same or different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1_4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl s group, or a salt thereof, [17] the compound of the above-mentioned [16], wherein R1° is 1) a sulfamoyl group optionally having C1_4 alkyl or C~_9 aralkyl as a substituent or 2) a C1_4 alkylsulfonyl group, or io two R1° substituting adjacent carbon atoms are bonded to designate a C1_2 alkylenedioxy group, R2 is 1) a hydrogen atom, 2) a C1_4 alkyl optionally having halogen or hydroxy as a substituent, 3) a carboxyl group, 4) a C1_4 alkoxycarbonyl group, 5) a carbamoyl group optionally having C1_4 alkyl or C~_9 i5 aralkyl as a substituent, 6) an amino group optionally having 4 alkyl, carbamoyl-C1_4 alkyl or C~_lo aralkyl as a substituent, 7) a piperidino group, 8) a morpholino group, 9) a C1_4 alkylthio group or 10) a C1_4 alkoxy group, or two adjacent R2 are bonded to form 11) a butadienylene group, and R3 is 1) a Zo hydrogen atom, 2) a halogen atom, 3) a C1_4 alkyl group, 4) a carboxyl group or 5) a C1_4 alkoxycarbonyl group, [18] the compound of the above-mentioned [16], wherein R1° is a sulfamoyl group, a methylsulfamoyl group, a dibenzylsulfamoyl group or a methylsulfonyl group, or two R1° substituting 25 adjacent carbon atoms are bonded to designate an ethylenedioxy group, R2 is a hydrogen atom, a methyl group, a trifluoromethyl group or a methoxy group, or two adjacent RZ are bonded to form a butadienylene group, and R3 is a hydrogen atom or a chlorine atom, 30 [19] a prodrug of a compound represented by the formula:

(R1a)~ N v RZ
\ ~ ~( )m ( I2 ) K_ S -N
wherein n is an integer of 1 to 5, Rla is a sulfamoyl group optionally having substituents or s an alkylsulfonyl group optionally having substituents, or two R1° substituting adjacent carbon atoms are bonded to designate a C1_Z alkylenedioxy group, and when n is not less than 2, R1° in the number of n may be the same or different, io m is an integer of 1 to 5, R2 is 1) a hydrogen atom, 2) a C1_4 aliphatic hydrocarbon group optionally having substituents, 3) an optionally esterified carboxyl group, 4) a carbamoyl group optionally having substituents, 5) an amino group is optionally having substituents, 6) a cyclic amino group, 7) an alkylthio group optionally having substituents or 8) an alkoxy group optionally having substituents, or two R2 substituting adjacent carbon atoms may be bonded to form 9) a saturated or unsaturated divalent C3_s ao carbon chain, and when m is not less than 2, RZ in the number of m may be the same or different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1_4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl 2s group, or a salt thereof, [20] a compound represented by the formula:
1i ' CA 02431171 2003-06-06 R2a R2b (R1a)~
\ ~ ~ (Ia1) S ~N
K"
wherein n is an integer of 1 to 5, R1° is a sulfamoyl group optionally having substituents or s an alkylsulfonyl group optionally having substituents, or two' R1° substituting adjacent carbon atoms are bonded to designate a Cl_2 alkylenedioxy group, and when n is not less than 2, R1° in the number of n may be the same or different, io R2° and Rzb are the same or different and each is 1) a hydrogen atom, 2) a C1_4 aliphatic hydrocarbon group optionally having substituents, 3) an optionally esterified carboxyl group, 4) a carbamoyl group optionally having substituents, 5) is an amino group optionally having substituents, 6) a cyclic amino group, 7) an alkylthio group optionally having substituents or 8) an alkoxy group optionally having substituents, or R2° and RZb may be bonded to form 9) a saturated or unsaturated divalent C3_5 carbon chain, ao and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1_4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, 2s or a salt thereof, [21] the compound of the above-mentioned [20], wherein R1° is 1) a sulfamoyl group optionally having C1_4 alkyl or a C~_9 aralkyl as a substituent or 2) a C1_4 alkylsulfonyl group, or two R1° substituting adjacent carbon atoms are bonded to ' CA 02431171 2003-06-06 designate a Cl_2 alkylenedioxy group, Rz° and R2b are the same or different and each is 1) a hydrogen atom, 2) a C1_4 alkyl optionally having halogen or hydroxy as a substituent, 3) a carboxyl group or a C1_4 alkoxycarbonyl group, 4) a carbamoyl s group optionally having Cl_4 alkyl or C~_9 aralkyl as a substituent, 5) an amino group optionally having C1_4 alkyl, carbamoyl-C1_4 alkyl or C~_lo aralkyl as a substituent, 6) a piperidino group or morpholino group, 7) a C1_4 alkylthio group or 8 ) a Cl_4 alkoxy group, or R2° and R2b are bonded to form a io butadienylene group, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3 ) a Cl_4 alkyl group, 4 ) a carboxyl group or 5 ) a C1_4 alkoxycarbonyl group, [22] the compound of the above-mentioned [20], wherein R1° is a sulfamoyl group, a methylsulfamoyl group, a dibenzylsulfamoyl is group or a methylsulfonyl group, or two R1° substituting adjacent carbon atoms are bonded to designate an ethylenedioxy group, R2° is a hydrogen atom, a methyl group, a trifluoromethyl group or a methoxy group, R2b is a hydrogen atom, or R2° and R2b are bonded to form a butadienylene group, ao and R3 is a hydrogen atom or a chlorine atom, [23] a prodrug of a compound represented by the formula:
R2a R2b (R1a)~
(Ia1) R" S ~=N
wherein n is an integer of 1 to 5, zs R1° is a sulfamoyl group optionally having substituents or an alkylsulfonyl group optionally having substituents, or two R1° substituting adjacent carbon atoms are bonded to designate a C1_2 alkylenedioxy group, and when n is not less than 2, R1° in the number of n may be the same or different, R2a and Rzb are the same or different and each is 1) a hydrogen atom, 2) a C1_4 aliphatic hydrocarbon group optionally having s substituents, 3) an optionally esterified carboxyl group, 4) a carbamoyl group optionally having substituents, 5) an amino group optionally having substituents, 6) a cyclic amino group, 7) an alkylthio group optionally having substituents or 8) an alkoxy group optionally io having substituents, or R2° and R2b may be bonded to form 9) a saturated or unsaturated divalent C3_5 carbon chain, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1_4 aliphatic hydrocarbon group optionally having is substituents or 4) an optionally esterified carboxyl group, or a salt thereof, [24] a compound represented by the formula:
(R~b)~
(Ia2) 2o wherein K
n is an integer of 1 to 5, Rlb is 1) a sulfamoyl group optionally having substituents, 2) a carbamoyl group optionally having substituents, 3) an alkyl group optionally having substituents, 4) an z5 optionally esterified carboxyl group, 5) a halogen atom, 6) an amino group optionally having substituents, 7) a nitro group, 8) a hydroxy group optionally having substituents or 9) an alkylsulfonyl group optionally having substituents, or two Rlb substituting adjacent carbon atoms are bonded to designate a C1_2 alkylenedioxy group, and when n is not less than 2, Rib in the number of n may be the same or different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1_4 s aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, or a salt thereof, [25] the compound of the above-mentioned [24], wherein Rlb is io 1 ) a sulfamoyl group optionally having C1_4 alkyl or C7_9 aralkyl as a substituent, 2) a carbamoyl group optionally having Cl_4 alkyl or C~_9 aralkyl as a substituent, 3 ) a C1_4 alkyl group optionally having halogen as a substituent, 4) a carboxyl group, 5) a C1_4 alkoxycarbonyl group, 6) a halogen i5 atom, 7) an amino group optionally having C1_6 alkanoyl, C1_4 alkyl or C1_4 alkylsulfonyl as a substituent, 8) a vitro group, 9 ) a hydroxy group optionally having Cl_4 alkyl or C1_6 alkanoyl as a substituent or 10j a C1_4 alkylsulfonyl group, or two Rlb substituting adjacent carbon atoms are bonded to designate a 2o Cl_2 alkylenedioxy group, and R3 is 1 ) a hydrogen atom, 2 ) a halogen atom, 3) a Cl_4 alkyl group, 4) a carboxyl group or 5) a Cl_4 alkoxycarbonyl group, [26] the compound of the above-mentioned [24], wherein Rlb is a sulfamoyl group, a methylsulfamoyl group, a dibenzylsulfamoyl 2s group, a carbamoyl group, a methylcarbamoyl group, an ethylcarbamoyl group, a dimethylcarbamoyl group, an azetidine-1-ylcarbonyl group, a methyl group, a trifluoromethyl group, a carboxyl group, an ethoxycarbonyl group, a chlorine atom, a fluorine atom, a vitro group, a hydroxy group, a methoxy group 30 or a methylsulfonyl group, or two Rlb substituting adjacent carbon atoms are bonded to designate an ethylenedioxy group, and R3 is a hydrogen atom, a chlorine atom, a fluorine atom or a methyl group, ' CA 02431171 2003-06-06 [27] a prodrug a compound represented by the formula:
(Ia2) wherein K"
n is an integer of 1 to 5, s Rlb is 1) a sulfamoyl group optionally having substituents, 2) a c~arbamoyl group optionally having substituents, 3) an alkyl group optionally having substituents, 4) an optionally esterified carboxyl group, 5) a halogen atom, 6) an amino group optionally having substituents, 7) a io nitro group, 8j a hydroxy group optionally having substituents or 9) an alkylsulfonyl group optionally having substituents, or two Rlb substituting adjacent carbon atoms are bonded to designate a C1_2 alkylenedioxy group, and when n is not less than 2, Rlb in the number is of n may be the same or different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1_4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, 20 or a salt thereof, [28] a compound represented by the formula:

Y1\~ ~ ~,~RZ~m (Ia3) Ra/\S' wherein m is an integer of 1 to 5, zs R2 is 1 ) a hydrogen atom, 2 ) a Cl_4 aliphatic hydrocarbon ' CA 02431171 2003-06-06 group optionally having substituents, 3) an optionally esterified carboxyl group, 4) a carbamoyl group optionally having substituents, 5) an amino group optionally having substituents, 6) a cyclic amino group, s 7) an alkylthio group optionally having substituents or 8) an alkoxy group optionally having substituents, or two Rz substituting adjacent carbon atoms may be bonded to form 9) a saturated or unsaturated divalent C3_s carbon chain, and when m is not less than 2, R2 in the io number of m may be the same or different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1_4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, is or a salt thereof, [29] the compound of the above-mentioned [28], wherein R2 is 1) a hydrogen atom, 2) a C1_4 alkyl optionally having halogen or hydroxy as a substituent, 3) a carboxyl group, 4) a C1_4 alkoxycarbonyl group, 5) a carbamoyl group optionally having 2o Cl_4 alkyl or C~_9 aralkyl as a substituent, 6) an amino group optionally having Cl_4 alkyl, carbamoyl-Cl_4 alkyl or C~_lo aralkyl as a substituent, 7) a piperidino group, 8) a morpholino group, 9) a C1_4 alkylthio group or 10) a C1_4 alkoxy group, or two adjacent RZ are bonded to form 11) a zs butadienylene group, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1_4 alkyl group, 4) a carboxyl group or 5) a C1_4 alkoxycarbonyl group, (30] the compound of the above-mentioned [28], wherein R2 is a hydrogen atom, a methyl group or a trifluoromethyl group, and 3o R3 is a hydrogen atom, [31] a prodrug of a compound represented by the formula:

' CA 02431171 2003-06-06 NOC
~~RZ)m (Ia3) Ra S
wherein m is an integer of 1 to 5, R2 is 1) a hydrogen atom, 2) a C1_4 aliphatic hydrocarbon group optionally having substituents, 3) an optionally esteri~fied carboxyl group, 4) a carbamoyl group optionally having substituents, 5) an amino group optionally having substituents, 6) a cyclic amino group, 7) an alkylthio group optionally having substituents or io 8) an alkoxy group optionally having substituents, or two RZ substituting adjacent carbon atoms may be bonded to form 9) a saturated or unsaturated divalent C3_s carbon chain, and when m is not less than 2, Rz in the number of m may be the same or different, and is R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1_4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, or a salt thereof, 20 [32] a compound represented by the formula:
,a R' ' N
R \ ~ ~ (Ia4) S ~N
wherein p is 0 or an integer of 1 to 5, R° and Rb as are the same or different and each is a hydrogen atom, a Cl_6 lower alkyl group, or R° and Rb may be bonded together with a nitrogen atom to form a ring, Rld is 1) a hydrogen atom, 2) a C1_4 aliphatic hydrocarbon group optionally having substituents, 3) a sulfamoyl s group optionally having substituents, 4) a carbamoyl group optionally having substituents, 5) an optionally esterified carboxyl group, 6) a halogen atom, 7) an amino group optionally having substituents, 8) a cyclic amino group, 9) a hydroxy group optionally having so substituents, 10) an alkylthio group optionally having substituents, 11) a nitro group, 12) an alkylsulfonyl group optionally having substituents, or~l3) two Ria substituting adjacent carbon atoms may be bonded to form 13a) a C1_Z alkylenedioxy group or 13b) a saturated or is unsaturated divalent C3_5 carbon chain, and when p is not less than 2, Rld in the number of p may be the same or different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a Cl_4 aliphatic hydrocarbon group optionally having 2o substituents or 4) an optionally esterified carboxyl group, or a salt thereof, [33] the compound of the above-mentioned [32], wherein R° and Rb are the same or different and each is hydrogen atom, a 2s methyl group or an ethyl group, or R° and Rb are bonded together with a nitrogen atom to designate an azetidin-1-yl group, Rid is a hydrogen atom, and R3 is a hydrogen atom, [34] a prodrug of a compound represented by the formula:
J
HaC
N
(Ia4) S ~N

' CA 02431171 2003-06-06 wherein p is 0 or an integer of 1 to 5, R° and Rb are the same or different and each is a hydrogen atom, a s Cl_6 lower alkyl group, or R° and Rb may be bonded together with a nitrogen atom to form a ring, Rld is 1) a hydrogen atom, 2) a C1_4 aliphatic hydrocarbon group optionally having substituents, 3) a sulfamoyl group optionally having substituents, 4) a carbamoyl io group optionally having substituents, 5) an optionally esterified carboxyl group, 6) a halogen atom, 7) an amino group optionally having substituents, 8) a cyclic amino group, 9) a hydroxy group optionally having substituents, 10) an alkylthio group optionally having ss substituents, 11) a nitro group, 12) an alkylsulfonyl group optionally having substituents, or 13) two Rla substituting adjacent carbon atoms may be bonded to form 13a) a C1_2 alkylenedioxy group or 13b) a saturated or unsaturated divalent C3_5 carbon chain, and when p is not 20 less than 2, Rld in the number of p may be the same or different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1_4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl 2s group, or a salt thereof, [35] a compound represented by the formula:
R2)m ~R~~)n (Ib) wherein ' CA 02431171 2003-06-06 n is an integer of 1 to 5, R1° is a carbamoyl group optionally having substituents or an alkylsulfonyl group optionally having substituents, or two R1~ substituting adjacent carbon atoms are bonded s to designate a C1_2 alkylenedioxy group, and when n is not less than 2, R1~ in the number of n are the same or different, m is an integer of 1 to 5, R2 is 1) a hydrogen atom, 2) a C1_4 aliphatic hydrocarbon group optionally having substituents, 3) an optionally so esterified carboxyl group, 4) a carbamoyl group optionally having substituents, 5) an amino group optionally having substituents, 6) a cyclic amino group, 7) an alkylthio group optionally having substituents or 8) an alkoxy group optionally having substituents, or is two R2 substituting adjacent carbon atoms may be bonded to form 9) a saturated or unsaturated divalent C3_s carbon chain, and when m is not less than 2, R2 in the number of m may be the same or different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1_4 ao aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, or a salt thereof, [36] the compound of the above-mentioned [35], wherein R1° is 2s 1 ) a carbamoyl group optionally having C1_4 alkyl or C~_9 aralkyl as a substituent or 2) a C1_4 alkylsulfonyl group, or two Rlb substituting adjacent carbon atoms are bonded to designate a C1_z alkylenedioxy group, R2 is 1) a hydrogen atom, 2) a C1_4 alkyl optionally having halogen or hydroxy as a 3o substituent, 3) a carboxyl group, 4) a C1_4 alkoxycarbonyl group, 5) a carbamoyl group optionally having C1_4 alkyl or C~_9 aralkyl as a substituent, 6) an amino group optionally having alkyl, carbamoyl-C1_4 alkyl or C~_lo aralkyl as a substituent, 7) a piperidino group, 8) a morpholino group, 9) a C1_4 alkylthio group or 10) a C1_4 alkoxy group, or two R2 substituting adjacent carbon atoms are bonded to form 11) a butadienylene group, and R3 is 1) a hydrogen atom, 2) a halogen s atom, 3 ) a Cl_4 alkyl group, 4 ) a carboxyl group or 5 ) a C1_4 alkoxycarbonyl group, [37] the compound of the above-mentioned [35], wherein R1~ is a carbamoyl group, a methylcarbamoyl group, or a dimethylcarbamoyl group, RZ is a hydrogen atom, a methyl group, io an ethyl group or an isopropyl group, and R3 is a hydrogen atom, a chlorine atom, a methyl group or an isopropyl group, [38] a prodrug of a compound represented by the formula:
R2)m N\ I cR~~)n (Ib) wherein is n is an integer of 1 to 5, R1~ is a carbamoyl group optionally having substituents or an alkylsulfonyl group optionally having substituents, or two Rl° substituting adjacent carbon atoms are bonded to designate a C1_2 alkylenedioxy group, and when n is 2o not less than 2, R1~ in the number of n are the same or different, m is an integer of 1 to 5, R2 is 1) a hydrogen atom, 2) a C1_4 aliphatic hydrocarbon group optionally having substituents, 3) an optionally esterified carboxyl group, 4) a carbamoyl group as optionally having substituents, 5) an amino group optionally having substituents, 6) a cyclic amino group, 7) an alkylthio group optionally having substituents or 8) an alkoxy group optionally having substituents, or two R2 substituting adjacent carbon atoms may be bonded ' CA 02431171 2003-06-06 to form 9) a saturated or unsaturated divalent C3_s carbon chain, and when m is not less than 2, R2 in the number of m may be the same or different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a Cl_4 s aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, or a salt thereof, [39] a compound represented by the formula:
(Ib1 ) v io wherein n is an integer of 1 to 5, R1° is a carbamoyl group optionally having substituents or an alkylsulfonyl group optionally having substituents, is or two R1° substituting adjacent carbon atoms are bonded to designate a C1_2 alkylenedioxy group, and when n is not less than 2, R1~ in the number of n are the same or different, R2a and R2b 2o are the same or different and each is 1) a hydrogen atom, 2) a C1_4 aliphatic hydrocarbon group optionally having substituents, 3) an optionally esterified carboxyl group, 4) a carbamoyl group optionally having substituents, 5) an amino group optionally having substituents, 6) a 25 cyclic amino group, 7) an alkylthio group optionally having substituents or 8) an alkoxy group optionally having substituents, or R2° and R2b may be bonded to form 9) a saturated or unsaturated divalent C3_s carbon chain, ' CA 02431171 2003-06-06 and R3 is 1) a hydrogen atom, 2j a halogen atom, 3) a C1_4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl s group, or a salt thereof, [40] the compound of the above-mentioned (39], wherein R1° is 1 ) a carbamoyl group optionally having C1_4 alkyl or C~_9 aralkyl as a substituent or 2) a C1_4 alkylsulfonyl group, or io two Rlb substituting adjacent carbon atoms are bonded to designate a Cl_Z alkylenedioxy group, Ra° and R2b are the same or different and each is 1) a hydrogen atom, 2) a C1_4 alkyl optionally having halogen or hydroxy as a substituent, 3) a carboxyl group or C1_4 alkoxycarbonyl group, 4) a carbamoyl is group optionally having Cl_4 alkyl or C~_9 aralkyl as a substituent, 5) an amino group optionally having C1_4 alkyl, carbamoyl-C1_4 alkyl or C~_lo aralkyl as a substituent, 6) a piperidino group or morpholino group, 7) a C1_4 alkylthio group or 8 ) a Cl_4 alkoxy group, or R2° and R2° are bonded to form a zo butadienylene group, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a Cl_4 alkyl group, 4) a carboxyl group or 5) a C1_4 alkoxycarbonyl group, [41] the compound of the above-mentioned [39], wherein R1~ is a carbamoyl group, a methylcarbamoyl group, or a Zs dimethylcarbamoyl group, R2° is a methyl group, an ethyl group or an isopropyl group, R2b is a hydrogen atom, and R3 is a hydrogen atom, a chlorine atom, a methyl group or an isopropyl group, [42] a prodrug of a compound represented by the formula:

i (R1c)~ (Ib1 ) K.. S
wherein n is an integer of 1 to 5, R1° is a carbamoyl group optionally having substituents or s an alkylsulfonyl group optionally having substituents, or two R1~ substituting adjacent carbon atoms are bonded to designate a C1_2 alkylenedioxy group, and when n is not less than 2, R1~ in the number of n are the same or different, so RZ° and R2b are the same or different and each is 1) a hydrogen atom, 2) a C1_4 aliphatic hydrocarbon group optionally having substituents, 3) an optionally esterified carboxyl group, 4) a carbamoyl group optionally having substituents, 5) is an amino group optionally having substituents, 6) a cyclic amino group, 7) an alkylthio group optionally having substituents or 8) an alkoxy group optionally having substituents, or R2° and R2b may be bonded to form 9) a saturated or unsaturated divalent C3_5 carbon chain, Zo and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1_4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, 2s or a salt thereof, [43] a compound represented by the formula:

' CA 02431171 2003-06-06 ru"
(R~b)n (Ib2) S
wherein n is an integer of 1 to 5, Rlb is 1) a sulfamoyl group optionally having substituents, s 2) a carbamoyl group optionally having substituents, 3) an alkyl group optionally having substituents, 4) an optionally esterified carboxyl group, 5) a halogen atom, 6) an amino group optionally having substituents, 7) a nitro group, 8) a hydroxy group optionally having io substituents or 9) an alkylsulfonyl group optionally having substituents, or two Rlb substituting adjacent carbon atoms are bonded to designate a C1_z alkylenedioxy group, and when n is not less than 2, Rlb in the number of n may be the same or different, and is R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1_4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, or a salt thereof, 20 (44] the compound of the above-mentioned [43], wherein Rlb is 1 ) a sulfamoyl group optionally having C1_4 alkyl or C~_9 aralkyl as a substituent, 2) a carbamoyl group optionally having Cl_4 alkyl or C~_9 aralkyl as a substituent, 3 ) a C,_4 alkyl group optionally having halogen as a substituent, 4) a 2s carboxyl group, 5) a C1_4 alkoxycarbonyl group, 6) a halogen atom, 7) an amino group optionally having C1_6 alkanoyl, C1_a alkyl or C1_4 alkylsulfonyl as a substituent, 8) a nitro group, 9j a hydroxy group optionally having C1_4 alkyl or C1_6 alkanoyl as a substituent or 10) a C1_4 alkylsulfonyl group, or two Rlb ' CA 02431171 2003-06-06 substituting adjacent carbon atoms are bonded to designate a C1_2 alkylenedioxy group, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1_4 alkyl group, 4) a carboxyl group or 5) a C1_4 alkoxycarbonyl group, s [45] the compound of the above-mentioned [43], wherein Rlb is a sulfamoyl group, a carbamoyl group, a methylcarbamoyl group, a dimethylcarbamoyl group, a pyrrolidin-1-ylcarbonyl group, a methyl group, a chlorine atom, a fluorine atom, an acetylamino group, a formylamino group or nitro group, and R3 is a hydrogen io atom, a chlorine atom, a methyl group or an isopropyl group, [46] a prodrug of a compound represented by the formula:

~R16)n (Ib2) Ra S
wherein n is an integer of 1 to 5, 15 Rlb is 1) a sulfamoyl group optionally having substituents, 2) a carbamoyl group optionally having substituents, 3) an alkyl group optionally having substituents, 4) an optionally esterified carboxyl group, 5) a halogen atom, 6) an amino group optionally having substituents, 7) a 2o nitro group, 8) a hydroxy group optionally having substituents or 9) an alkylsulfonyl group optionally having substituents, or two Rlb substituting adjacent carbon atoms are bonded to designate a C1_2 alkylenedioxy group, and when n is not less than 2, Rlb in the number as of n may be the same or different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a Cl_4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, ' CA 02431171 2003-06-06 or a salt thereof, [47] a compound represented by the formula:
R2)m I ~ $OzNHz (Ib3) Ra S
wherein s m is an integer of 1 to 5, RZ is 1) a hydrogen atom, 2) a C,_4 aliphatic hydrocarbon group optionally having substituents, 3) an optionally esterified carboxyl group, 4) a carbamoyl group optionally having substituents, 5) an amino group io optionally having substituents, 6) a cyclic amino group, 7) an alkylthio group optionally having substituents or 8) an alkoxy group optionally having substituents, or two R2 substituting adjacent carbon atoms are bonded to form 9) a saturated or unsaturated divalent C3_5 carbon is chain, and when m is not less than 2, R2 in the number of m may be the same or different, and R3 is 1) a hydrogen atom, 2a a halogen atom, 3) a C1_4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carbonyl 2o group, or a salt thereof, [48] the compound of the above-mentioned [47], wherein R2 is 1) a hydrogen atom, 2) a C1_4 alkyl optionally having halagen or hydroxy as a substituent, 3) a carboxyl group, 4) a C1_4 2s alkoxycarbonyl group, 5) a carbamoyl group optionally having 4 alkyl or C~_9 aralkyl as a substituent, 6) an amino group optionally having C1_4 alkyl, carbamoyl-C1_4 alkyl or C~_lo aralkyl as a substituent, 7) a piperidino group, 8) a morpholino group, 9) a C1_4 alkylthio group or 10) a C1_4 alkoxy ' CA 02431171 2003-06-06 group, or two adjacent R2 are bonded to form 11) a butadienylene group, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3 ) a Cl_4 alkyl group, 4 ) a carboxyl group or 5 ) a C1_a alkoxycarbonyl group, s [49] the compound of the above-mentioned [47], wherein RZ is a hydrogen atom, a methyl group or an ethyl group and R3 is a hydrogen atom or a methyl group, [50] a prodrug of a compound represented by the formula:
R2)m I ~ $OzNHZ
\ ~ I ~ (Ib3) Ra S
io wherein m is an integer of 1 to 5, R2 is 1) a hydrogen atom, 2) a C1_4 aliphatic hydrocarbon group optionally having substituents, 3) an optionally esterified carboxyl group, 4) a carbamoyl group is optionally having substituents, 5) an amino group optionally having substituents, 6) a cyclic amino group, 7) an alkylthio group optionally having substituents or 8) an alkoxy group optionally having substituents, or two Rz substituting adjacent carbon atoms are bonded to 2o form 9) a saturated or unsaturated divalent C3_5 carbon chain, and when m is not less than 2, RZ in the number of m may be the same or different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1_a aliphatic hydrocarbon group optionally having 2s substituents or 4) an optionally esterified carboxyl group, or a salt thereof, [51] a compound represented by the formula:

' CA 02431171 2003-06-06 Ra N
~ b R (Ib4) wherein p is 0 or an integer of 1 to 5, R° and Rb s are the same or different and each is a hydrogen atom or a C1_6 lower alkyl group, or R° and Rb may be bonded together with a nitrogen atom to form a ring, Rla is 1) a hydrogen atom, 2) a C1_4 aliphatic hydrocarbon group optionally having substituents, 3) a sulfamoyl io group optionally having substituents, 4) a carbamoyl group optionally having substituents, 5) an optionally esterified carboxyl group, 6j a halogen atom, 7) an amino group optionally having substituents, 8) a cyclic amino group, 9) a hydroxy group optionally having is substituents, 10) an alkylthio group optionally having substituents, 11) a nitro group, 12) an alkylsulfonyl group optionally having substituents, or 13) two Ria substituting adjacent carbon atoms may be bonded to form 13a) a C1_Z alkylenedioxy group or l3bj a saturated or 2o unsaturated divalent C3_5 carbon chain, and when p is not less than 2, Rla in the number of p may be the same or different, and R3 is 1) a hydrogen atom, 2j a halogen atom, 3) a C1_4 aliphatic hydrocarbon group optionally having 2s substituents or 4) an optionally esterified carboxyl group, or a salt thereof, [52] the compound of the above-mentioned [51], wherein R° and K

Rb are the same or different and each is a hydrogen atom or a methyl group, or R° and Rb are banded together with a nitrogen atom to form a pyrrolidin-1-yl group, Rld is a hydrogen atom, a methyl group, a chlorine atom or a fluorine atom, and R3 is a s hydrogen atom, a chlorine atom, a methyl group or an isopropyl group, [53] a prodrug of a compound represented by the formula:
a CH3 0 ~R
N~ b . N, ~ v R (Ib4) wherein ~ ~r so p is 0 or an integer of 1 to 5, R° and Rb are the same or different and each is a hydrogen atom or a C1_6 lower alkyl group, or Ra and Rb may be bonded together with a nitrogen atom to form a ring, s5 Rld is 1) a hydrogen atom, 2) a C1_4 aliphatic hydrocarbon group optionally having substituents, 3) a sulfamoyl group optionally having substituents, 4) a carbamoyl group optionally having substituents, 5) an optionally esterified carboxyl group, 6) a halogen atom, 7) an Zo amino group optionally having substituents, 8) a cyclic amino group, 9) a hydroxy group optionally having substituents, 10) an alkylthio group optionally having substituents, 11) a nitro group, 12) an alkylsulfonyl group optionally having substituents, or 13) two Rla 2s substituting adjacent carbon atoms may be bonded to form 13a) a C1_2 alkylenedioxy group or 13b) a saturated or unsaturated divalent C3_5 carbon chain, and when p is not less than 2, Rld in the number of p may be the same or ' CA 02431171 2003-06-06 different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1_4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally estexified carboxyl s group, or a salt thereof, [54] a compound represented by the.formula:

~R~b)q N~ N
(Ic1) / A
R3 S Aa-Ab wherein io q is 0 or an integer of 1 to 5, Rlb is 1) a sulfamoyl group optionally having substituents, 2) a carbamoyl group optionally having substituents, 3) an alkyl group optionally having substituents, 4) an optionally esterified carboxyl group, 5) a halogen atom, is 6) an amino group optionally having substituents, 7) a nitro group, 8) a hydroxy group optionally having substituents or 9) an alkylsulfonyl group optionally having substituents, or 10) two Rlb substituting adjacent carbon atoms are bonded to designate a C1_z ao alkylenedioxy group, and when q is not less than 2, Rlb in the number of q may be the same or different, R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1_4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl Zs group, and Aa, Ab and A°
are the same or different and each is a n~.trogen atom or a methine group, or a salt thereof, ' CA 02431171 2003-06-06 [55] the compound of the above-mentioned [54], wherein Rlb is a sulfamoyl group, a carbamoyl group, a methylcarbamoyl group, a dimethylcarbamoyl group, an ethylcarbamoyl group, a pyrrolidin-1-ylcarbonyl group, a methyl group, a chlorine atom, s a fluorine atom, an acetylamino group, a formylamino group or a vitro group, R3 is a hydrogen atom, a chlorine atom, a methyl group or an isopropyl group, and A°, Ab and A~ are the same or different and each is a nitrogen atom or a methine group, [56] a prodrug of a compound represented by the formula:
CH .
N~ N
(Ic1) \ ~ A
io R3 $ Aa-Ab wherein q is 0 or an integer of 1 to 5, Rlb is 1) a sulfamoyl group optionally having substituents, 2) a carbamoyl group optionally having substituents, 3) is an alkyl group optionally having substituents, 4) an optionally esterified carboxyl group, 5) a halogen atom, 6) an amino group optionally having substituents, 7) a vitro group, 8) a hydroxy group optionally having substituents or 9) an alkylsulfonyl group optionally zo having substituents, or 10) two Rlb substituting adjacent carbon atoms are bonded to designate a C1_z alkylenedioxy group, and when q is not less than 2, Rlb in the number of q may be the same or different, R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1_a 2s aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, and Aa, Ab and A°
are the same or different and each is a nitrogen atom or a methine group, or a salt thereof, [57] a compound represented by the formula:
b A i ~A ~..Aa (Rib)q ~ ~
,,;--- ( Ic2 ) Rs i ,.5 s wherein q is 0 or an integer of 1 to 5, Rlb is 1) a sulfamoyl group optionally having substituents, 2) a carbamoyl group optionally having substituents, 3) an alkyl group optionally having substituents, 4) an io optionally esterified carboxyl group, 5) a halogen atom, 6) an amino group optionally having substituents, 7) a nitro group, 8) a hydroxy group optionally having substituents or 9) an alkylsulfonyl group optionally having substituents, or 10) two Rlb substituting is adjacent carbon atoms are bonded to designate a C1_z alkylenedioxy group, and when q is not less than 2, Rlb in the number of q are the same or different, R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1_4 aliphatic hydrocarbon group optionally having 2o substituents or 4) an optionally esterified carboxyl group, and Aa, Ab and A~
are the same or different and each is a nitrogen atom or a methine group, 2s or a salt thereof, [58] the compound of the above-mentioned [57], wherein Rlb is a sulfamoyl group, a methylsulfamoyl group, a dibenzylsulfamoyl group, a carbamoyl group, a methylcarbamoyl group, an ethylcarbamoyl group, a dimethylcarbamoyl group, an azetidin-' CA 02431171 2003-06-06 1-ylcarbonyl group, a methyl group, a trifluoromethyl group, a carboxyl group, an ethoxycarbonyl group, a chlorine atom, a fluorine atom, a nitro group, a hydroxy group, a methoxy group or a methylsulfonyl group, or two Rib substituting adjacent s carbon atoms are bonded to designate an ethylenedioxy group, R3 is a hydrogen atom, a chlorine atom, a fluorine atom or a methyl group, A° is a methine, Ab is a nitrogen atom or a methine, and A~ is a nitrogen atom or a methine, [59] a prodrug of a compound represented by the formula:
b' c ~Aw a I i H3~
(Ic2) so wherein q is 0 or an integer of 1 to 5, Rlb is 1) a sulfamoyl group optionally having substituents, 2) a carbamoyl group optionally having substituents, 3) is an alkyl group optionally having substituents, 4) an optionally esterified carboxyl group, 5) a halogen atom, 6) an amino group optionally having substituents, 7) a nitro group, 8) a hydroxy group optionally having substituents or 9) an alkylsulfonyl group optionally zo having substituents, or 10) two Rlb substituting adjacent carbon atoms are bonded to designate a C1_2 alkylenedioxy group, and when q is not less than 2, Rlb in the number of q are the same or different, R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1_4 Zs aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, and A°, Ab and A°
are the same or different and each is a nitrogen atom or a methine group, or a salt thereof, [60] 3-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-4-methylpyridine, 3-[4-(4-fluorophenyl)-1,3-thiazol-2-yl]-4-methylpyridine, 4-s [2-(4-methyl-pyridin-3-yl)-1,3-thiazol-4-yl]benzenesulfonamide, 3-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]-4-methylpyridine, 4-[4-(4-methyl-pyridin-3-yl)-1,3-thiazol-2-yl]benzenesulfonamide or a salt thereof, and the like.
1o DETAILED DESCRIPTION OF THE INVENTION
The compound represented by the aforementioned formula (I) or a salt thereof [hereinafter to be referred to as compound (I)] is a compound wherein 1) A1 is a 3-pyridyl group optionally having substituents, A2 is an aromatic hydrocarbon is group optionally having substituents or a heterocyclic group optionally having substituents, A3 is a hydrogen atom, a halogen atom, a Cl_4 aliphatic hydrocarbon group optionally having substituents or an optionally esterified carboxyl group, or a salt thereof [hereinafter to be referred to as compound 2o (I-1)], 2) a compound wherein A1 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, AZ is a 3-pyridyl group optionally having substituents, A3 is a hydrogen atom, a halogen atom, a C1_4 aliphatic hydrocarbon group optionally as having substituents or an optionally esterified carboxyl group, or a salt thereof [hereinafter to be referred to as compound (I-2)], 3) a compound wherein A1 is a 3-pyridyl group optionally having substituents, A3 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group 30 optionally having substituents, A2 is a hydrogen atom, a halogen atom, a C1_4 aliphatic hydrocarbon group optionally having substituents or an optionally esterified carboxyl group, or a salt thereof [hereinafter to be referred to as compound ' CA 02431171 2003-06-06 (I-3)] or 4) a compound wherein A1 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, A3 is a 3-pyridyl group optionally having substituents, A~ is a hydrogen atom, a s halogen atom, a C1_4 aliphatic hydrocarbon group optionally having substituents or an optionally esterified carboxyl group, or a salt thereof [hereinafter to be referred to as compound (I-4)]. Of these, compound (I-1) and compound (I-2) are preferable, and particularly a compound (I-1) wherein AZ is a so C6_14 aryl group optionally having substituents or a 3-pyridyl group optionally having substituents and a compound (I-2), wherein A1 is a C6_14 aryl group optionally having substituents, is preferable.
As the "substituent" of the "3-pyridyl group optionally is having substituents", which is one of the aforementioned A1, AZ
and A3, for example, 1) an oxo, 2) a halogen atom (e. g., fluorine atom, chlorine atom, bromine atom, iodine atom), 3) a nitro, 4) a cyano, 5j a C1_6 aliphatic hydrocarbon group optionally having substituents, 6) a C6_14 aryl (e. g., phenyl, zo 1-naphthyl, 2-naphthyl, 2-biphenylyl, 3-biphenylyl, 4-biphenylyl, 2-anthryl etc.), 7j a 5 to 10-membered aromatic heterocyclic group (e.g., 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 8-quinolyl, 1-isoquinolyl, 3-isoquinolyl, 4-25 isoquinolyl, 5-isoquinolyl, 1-indolyl, 2-indolyl, 3-indolyl, 2-benzothiazolyl, 2-benzo[b]thienyl, 3-benzo[b]thienyl, 2-benzo[b]furanyl, 3-benzo(b]furanyl etc.), 8) an acyl group, 9) a carbamoyl optionally having substituents, 10) a cyclic aminocarbonyl optionally having substituents, 11j a 3o thiocarbamoyl, 12) a sulfamoyl optionally having substituents [e. g., sulfamoyl, C1_6 alkylsulfamoyl group (e. g., methylsulfamoyl etc.), C~_15 aralkylsulfamoyl group (e. g., benzylsulfamoyl etc.)], 13j an amino optionally having ' CA 02431171 2003-06-06 substituents, 14) a cyclic amino optionally having substituents, 15) a mercapto group optionally having substituents, 16) a C1_6 alkylsulfonyl (e. g., methylsulfonyl, ethylsulfonyl etc . ) , 17 ) a C6_14 arylsulfonyl ( a . g . , s phenylsulfonyl, 1-naphthylsulfonyl, 2-naphthylsulfonyl etc.), 18) a C1_6 alkylsulfinyl (e. g., methylsulfinyl, ethylsulfinyl etc.), 19) a C6_14 arylsulfinyl (e.g., phenylsulfinyl, 1-naphthylsulfinyl, 2-naphthylsulfinyl etc.), 20) a sulfo, 21) a sulfinamoyl, 22) a sulfenamoyl and 23) a hydroxy group io optionally having substituents, and divalent groups such as 24) a saturated or unsaturated divalent C3_5 carbon chain (e. g., trimethylene, tetramethylene, butadienylene etc.), 25) a C1_3 alkylenedioxy (e.g., methylenedioxy, ethylenedioxy etc.) and the like can be mentioned.
is As the above-mentioned Cl_6 aliphatic hydrocarbon group optionally having substituents, an optionally halogenated C1_s alkyl [e. g., C1_6 alkyl (e. g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tart-butyl, pentyl, hexyl etc.) optionally having 1 to 5, preferably 1 to 3, halogen atoms 20 (e.g., fluorine, chlorine, bromine, iodine etc.), such as methyl, chloromethyl, difluoromethyl, trichloromethyl, trifluoromethyl, ethyl, 2-bromoethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, propyl, 3,3,3-trifluoropropyl, isopropyl, butyl, 4,4,4-trifluorobutyl, isobutyl, sec-butyl, tart-butyl, 2s pentyl, isopentyl, neopentyl, 5,5,5-trifluoropentyl, hexyl, 6,6,6-trif luorohexyl etc.), a hydroxy-C1_6 alkyl (e. g., hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxy-isopropyl etc.), an optionally halogenated CZ_6 alkenyl [e. g., C2_6 alkenyl (e.g., vinyl, propenyl, isopropenyl, 2-buten-1-yl, 4-penten-1-3o y1, 5-hexen-1-yl etc.) optionally having 1 to 5, preferably 1 to 3, halogen atoms (e. g., fluorine, chlorine, bromine, iodine etc.)], a carboxy C2_6 alkenyl (e.g., 2-carboxyethenyl, 2-carboxy-2-methylethenyl etc.), an optionally halogenated Cz_s alkynyl [e.g., C2_g alkynyl (e.g., 2-butyn-1-yl, 4-pentyn-1-yl, 5-hexyn-1-yl etc.) optionally having 1 to 5, preferably 1 to 3, halogen atoms (e. g., fluorine, chlorine, bromine, iodine etc.)], an optionally halogenated C3_6 cycloalkyl [e. g., C3_s s cycloalkyl (e. g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl etc.) optionally having 1 to 5, preferably 1 to 3, halogen atoms (e. g., fluorine, chlorine, bromine, iodine etc.) such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4,4-dichlorocyclohexyl, 2,2,3,3-tetrafluorocyclopentyl, 4-io chlorocyclohexyl etc.] and the like can be mentioned.
As the above-mentioned acyl group, an optionally esterified carboxyl group [e. g., unsubstituted carboxyl group etc., a C1_6 alkoxy-carbonyl (e. g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl etc.)], a 15 C6_14 aryloxy-carbonyl ( a . g . , phenoxycarbonyl etc . ) , a C~_ls aralkyloxy-carbonyl (e. g., benzyloxycarbonyl, phenethyloxycarbonyl etc.), a formyl, a C1_6 alkyl-carbonyl (e. g., acetyl, propionyl etc.), a C3_6 cycloalkyl-carbonyl (e. g., cyclopropylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl Zo etc.), a C6_14 aryl-carbonyl (e.g., benzoyl, 1-naphthoyl, 2-naphthoyl etc.), a C,_16 aralkyl-carbonyl (e. g., phenylacetyl, 3-phenylpropionyl etc.), a 5 or 6-membered heterocyclic ring carbonyl (e. g., nicotinoyl, isonicotinoyl, thenoyl, furoyl etc.) and the like can be mentioned.
as As the above-mentioned carbamoyl optionally having substituents, for example, an unsubstituted carbamoyl, and a mono-C1_6 alkyl-carbamoyl (e. g., methylcarbamoyl, ethylcarbamoyl etc.), a di-C1_6 alkyl-carbamoyl (e. g., dimethylcarbamoyl, diethylcarbamoyl, ethylmethylcarbamoyl etc.), a C6_14 aryl-3o carbamoyl (e.g., phenylcarbamoyl, 1-naphthylcarbamoyl, 2-naphthylcarbamoyl etc.), a 5 or 6-membered heterocyclic carbamoyl (e.g., 2-pyridylcarbamoyl, 3-pyridylcarbamoyl, 4-pyridylcarbamoyl, 2-thienylcarbamoyl, 3-thienylcarbamoyl etc.) and the like can be mentioned.
As the above-mentioned cyclic aminocarbonyl optionally having substituents, for example, morpholinocarbonyl, thiomorpholinocarbonyl, piperazin-1-ylcarbonyl, 4-s methylpiperazin-1-ylcarbonyl, pyrrolidin-1-ylcarbonyl, 3-methylpyrrolidin-1-ylcarbonyl and the like can be mentioned.
As the above-mentioned amino optionally having substituents, an unsubstituted amino, and a mono-C1_6 alkylamino (e. g., methylamino, ethylamino etc.), a mono-C6_14 arylamino io (e.g., phenylamino, 1-naphthylamino, 2-naphthylamino etc.), a di-C1_6 alkylamino (e. g., dimethylamino, diethylamino, ethylmethylamino etc.), a dl-C6_14 arylamino (e. g., diphenylamino etc.), a formylamino, a C1_6 alkyl-carbonylamino (e. g., acetylamino etc.), a C6_14 aryl-carbonylamino (e. g., is benzoylamino, naphthoylamino etc.), a C1_6 alkoxy-carbonylamino (e. g., methoxycarbonylamino, ethoxycarbonylamino, propoxycarbonylamino, butoxycarbonylamino etc.), a C1_6 alkylsulfonylamino (e. g., methylsulfonylamino, ethylsulfonylamino etc.), a C6_14 arylsulfonylamino (e. g., ao phenylsulfonylamino, 2-naphthylsulfonylamino, 1-naphthylsulfonylamino etc.) and the like can be mentioned.
As the "cyclic amino" of the above-mentioned "cyclic amino optionally having substituents", a 5 to 7-membered saturated cyclic amino optionally having, besides one nitrogen a3 atom and carbon atoms, 1 to 4 of 1 or 2 kinds of hetero atoms selected from nitrogen atom, sulfur atom and oxygen atom can be mentioned. Specific examples thereof include pyrrolidin-1-y1, piperidino, piperazin-1-yl, morpholino, thiomorpholino, hexahydroazepin-1-yl and the like.
ao As the "substituent" of the "cyclic amino optionally having substituents", for example, 1 to 3 substituents selected from a C1_6 alkyl (e. g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.), a C6_14 aryl (e. g., phenyl, 1-naphthyl, 2-naphthyl, 2-biphenylyl, 3-biphenylyl, 4-biphenylyl, 2-anthryl etc.), a C1_6 alkyl-carbonyl (e.g., acetyl, propionyl etc.), a 5 to 10-membered aromatic heterocyclic group (e.g., 2-thienyl, 3-s thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 8-quinolyl, 1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 1-indolyl, 2-indolyl, 3-indolyl, 2-benzothiazolyl, 2-benzo[b]thienyl, 3-benzo[b]thienyl, 2-benzo[b]furanyl, 3-benzo[b]furanyl etc.), io oxo and the like is/are used.
As the above-mentioned mercapto group optionally having substituents, an unsubstituted mercapto group, and an alkylthio optionally having substituents [e. g., unsubstituted C1_6 alkylthio (e. g., methylthio, ethylthio, propylthio, is butylthio, pentylthio etc.), optionally halogenated C1_s alkylthio], C6_la arylthio (e.g., phenylthio, 1-naphthylthio, 2-naphthylthio etc.), C,_16 aralkylthio (e. g., benzylthio, phenethylthio etc.)] and the like can be mentioned.
As the above-mentioned hydroxy group optionally having 2o substituents, an unsubstituted hydroxy, and an alkoxy optionally having substituents [e. g., optionally halogenated a alkoxy (a. g., a C1_,~ alkoxy (a. g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxy etc.) optionally having 1 to 5, preferably 1 to 3, halogen Zs atoms (e.g., fluorine, chlorine, bromine, iodine etc.) such as methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, 2,2,2-trifluoroethoxy, propoxy, isopropoxy, butoxy, 4,4,4-trifluorobutoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxy, etc.), a C1_6 alkoxy-carbonyl-C1_6 alkoxy (e. g., 3o ethoxycarbonylmethyloxy etc.)], a C6_14 aryloxy (e. g., phenyloxy;
1-naphthyloxy, 2-naphthyloxy etc.), a C,_16 aralkyloxy (e. g., benzyloxy, phenethyloxy etc.), a C1_6 alkyl-carbonyloxy (e. g., acetoxy, propionyloxy etc.), a C6_14 aryl-carbonyloxy (e. g., ' CA 02431171 2003-06-06 benzoyloxy, naphthylcarbonyloxy etc.), a C1_6 alkoxy-carbonyloxy (e. g., methoxycarbonyloxy, ethoxycarbonyloxy, propoxycarbonyloxy, butoxycarbonyloxy etc.), a mono-C~_6 alkyl-carbamoyloxy (e. g., methylcarbamoyloxy, ethylcarbamoyloxy s etc.), a di-C1_6 alkyl-carbamoyloxy (e. g., dimethylcarbamoyloxy, diethylcarbamoyloxy etc.), a C6_14 aryl-carbamoyloxy (e. g., phenylcarbamoyloxy, naphthylcarbamoyloxy etc.), a nicotinoyloxy and the like can be mentioned.
The "3-pyridyl group" may have, for example, l to 5, io preferably l~to 3, of the above-mentioned substituents at substitutable positions. When the number of substituent is not less than 2, respective substituents may be the same or different.
One of AZ and A3 is a hydrogen atom, a halogen atom, a C1_ is 4 hydrocarbon group optionally having substituents or an optionally esterified carboxyl group.
As the halogen atom, a fluorine atom, a chlorine atom, a bromine atom or an iodine atom is used, with preference given to fluorine atom, chlorine atom and bromine atom.
2o As the "C1_4 hydrocarbon group" of the "C1_4 hydrocarbon group optionally having substituents", a C1_4 alkyl group (e. g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl), a C2_4 alkenyl group (e. g., vinyl, allyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-2-as propenyl, 1-methyl-2-propenyl, 2-methyl-1-propenyl etc.), a Cz_ 4 alkynyl group (e. g., ethynyl, propargyl, 1-butynyl, 2-butynyl, 3-butynyl), a C3_q cycloalkyl group (e. g., cyclopropyl, cyclobutyl) and the like are used. Preferred is a C1_4 alkyl group such as methyl, ethyl, propyl and the like, and 3o particularly preferred is a methyl group.
As the "substituent" of the "C1_4 hydrocarbon group optionally having substituents", a halogen atom (e. g., fluorine atom, chlorine atom, bromine atom, iodine atom), ' CA 02431171 2003-06-06 vitro, cyano, optionally halogenated C3_s cycloalkyl (e. g., cyclopropyl, cyclohexyl etc.), a Cs_14 aryl (e.g., phenyl, 1-naphthyl, 2-naphthyl, 2-biphenylyl, 3-biphenylyl, 4-biphenylyl, 2-anthryl etc.), an optionally halogenated C1_4 alkoxy, a C1_s s alkoxy-carbonyl-C1_s alkoxy (e. g., ethoxycarbonylmethyloxy etc.), hydroxy, a Cs_14 aryloxy (e.g., phenyloxy, 1-naphthyloxy, 2-naphthyloxy etc.), a C~_ls aralkyloxy (e. g., benzyloxy, phenethyloxy etc.), a mercapto, an optionally halogenated C1_s alkylthio [e. g., C1_s alkylthio (e. g., methylthio, ethylthio, so propylthio, isopropylthio, butylthio, sec-butylthio, tert-butylthio etc.) optionally having 1 to 5, preferably 1 to 3, halogen atoms (e. g., fluorine, chlorine, bromine, iodine etc.) such as methylthio, difluoromethylthio, trifluoromethylthio, ethylthio, propylthio, isopropylthio, butylthio, 4,4,4-ls trifluorobutylthio, pentylthio, hexylthio etc., and the like], a Cs_14 arylthio (e.g., phenylthio, 1-naphthylthio, 2-naphthylthio etc.), a C~_1s aralkylthio (e. g., benzylthio, phenethylthio etc:), an amino, a mono-C1_s alkylamino (e. g., methylamino, ethylamino etc.), a mono-Cs_14 arylamino (e. g., ao phenylamino, 1-naphthylamino, 2-naphthylamino etc.), a di-C1_s alkylamino (e. g., dimethylamino, diethylamino, ethylmethylamino etc.), a dl-Cs_14 arylamino (e. g., diphenylamino etc.), a formyl, a carboxy, a C1_s alkyl-carbonyl (e. g., acetyl, propionyl etc.), a C3_s cycloalkyl-carbonyl (e. g., zs cyclopropylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl etc.), a C1_s alkoxy-carbonyl (e. g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl etc.), a Cs-14 aryl-carbonyl (e. g., benzoyl, 1-naphthoyl, 2-naphthoyl etc.), a C~_ls aralkyl-carbonyl (e.g., phenylacetyl, 3-3o phenylpropionyl etc.), a Cs_14 aryloxy-carbonyl (e. g., phenoxycarbonyl etc.), a C~_ls aralkyloxy-carbonyl (e. g., benzyloxycarbonyl, phenethyloxycarbonyl etc.), a 5 or 6-membered heterocyelic carbonyl (e. g., nicotinoyl, ~
' CA 02431171 2003-06-06 isonicotinoyl, thenoyl, furoyl, morpholinocarbonyl, thiomorpholinocarbonyl, piperazin-1-ylcarbonyl, pyrrolidin-1-ylcarbonyl etc.), a carbamoyl, a thiocarbamoyl, a mono-C1_s alkyl-carbamoyl (e. g., methylcarbamoyl, ethylcarbamoyl etc.), s a di-C1_6 alkyl-carbamoyl (e. g., dimethylcarbamoyl, diethylcarbamoyl, ethyltnethylcarbamoyl etc . ) , a C6_14 aryl-carbamoyl (e.g., phenylcarbamoyl, 1-naphthylcarbamoyl, 2-naphthylcarbamoyl etc.), a 5 or 6-membered heterocyclic carbamoyl (e.g., 2-pyridylcarbamoyl, 3-pyridylcarbamoyl, 4-io pyridylcarbamoyl, 2-thienylcarbamoyl, 3-thienylcarbamoyl etc.), a C1_6 alkylsulfonyl (e. g., methylsulfonyl, ethylsulfonyl etc.), a C6_14 arylsulfonyl (e. g., phenylsulfonyl, 1-naphthylsulfonyl, 2-naphthylsulfonyl etc:), a C1_6 alkylsulfinyl (e. g., methylsulfinyl, ethylsulfinyl etc.), a C6_14 arylsulfinyl (e. g., is phenylsulfinyl, 1-naphthylsulfinyl, a 2-naphthylsulfinyl etc.), a formylamino, a C1_6 alkyl-carbonylamino (e. g., acetylamino etc.), a C6_14 aryl-carbonylamino (e. g., benzoylamino, naphthoylamino etc.), a C1_6 alkoxy-carbonylamino (e. g., methoxycarbonylamino, ethoxycarbonylamino, Zo propoxycarbonylamino, butoxycarbonylamino etc.), a C1_s alkylsulfonylamino (e. g., methylsulfonylamino, ethylsulfonylamino etc.), a C6_14 arylsulfonylamino (e. g., phenylsulfonylamino, 2-naphthylsulfonylamino, 1-naphthylsulfonylamino etc.), a C1_6 alkyl-carbonyloxy (e. g., as acetoxy, propionyloxy etc.), a C6_14 aryl-carbonyloxy (e. g., benzoyloxy, naphthylcarbonyloxy etc.), a C1_6 alkoxy-carbonyloxy (e. g., methoxycarbonyloxy, ethoxycarbonyloxy, propoxycarbonyloxy, butoxycarbonyloxy etc.), a mono-C1_6 alkyl-carbamoyloxy (e. g., methylcarbamoyloxy, ethylcarbamoyloxy ao etc.), a di-C1_6 alkyl-carbamoyloxy (e. g., dimethylcarbamoyloxy, diethylcarbamoyloxy etc.), a C6_14 aryl-carbamoyloxy (e. g., phenylcarbamoyloxy, naphthylcarbamoyloxy etc.), a nicotinoyloxy, a 5 to 7-membered saturated cyclic amino, a 5 to 10-membered aromatic heterocyclic group (e. g., 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 8-quinolyl, 1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 1-indolyl, 2-s indolyl, 3-indolyl, 2-benzothiazolyl, 2-benzo[b]thienyl, 3-benzo[b]thienyl, 2-benzo[b]furanyl, 3-benzo[b]furanyl etc.), a sulfo, a sulfamoyl, a sulfinamoyl, a sulfenamoyl and the like are used.
As the optionally esterified carboxyl group, carboxyl io group optionally esterified by C1_4 alkyl group and the like, and the like are used, with preference given to a Cl_4 alkoxycarbonyl group such as methoxycarbonyl, ethoxycarbonyl and the like.
As the "aromatic hydrocarbon group" of the "aromatic is hydrocarbon group optionally having substituents" represented by one of A1, AZ and A3, for example, a monocycle having 6 to 14 carbon atoms or a condensed polycyclic (bicyclic or tricyclic) aromatic hydrocarbon group and the like can be mentioned.
Specifically, far example, a C6_14 aryl group such as phenyl, 1-zo naphthyl, 2-naphthyl, 2-biphenylyl, 3-biphenylyl, 4-biphenylyl, 2-anthryl and the like, from which a C6_~o aryl group such as phenyl, 1-naphthyl, 2-naphthyl and the like is preferable, particularly a phenyl group is preferable.
As the "substituent" of the "aromatic hydrocarbon group Zs optionally having substituents", those similar to the substituent of the aforementioned "3-pyridyl group" are used.
The "aromatic hydrocarbon group" may have, for example, 1 to 5, preferably 1 to 3, of the above-mentioned substituents at substitutable position(s). when the number of substituents 3o is not less than 2, each substituent may be the same or different.
As the aromatic hydrocarbon group optionally having substituents, the aforementioned C6_14 aryl group optionally having substituents is preferable.
As the "heterocyclic group" of the "heterocyclic group optionally having substituents", for example, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-quinolyl, 3-s quinolyl, 4-quinolyl, 5-quinolyl, 8-quinolyl, 1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 1-indolyl, 2-indolyl, 3-indolyl, 2-benzothiazolyl, 2-benzo[b)thienyl, 3-benzo[b]thienyl, 2-benzo[b]furanyl, 3-benzo[b]furanyl and the like are mentioned, with preference given to pyridyl, so particularly 3-pyridyl group.
As the "substituent" of the "heterocyclic group optionally having substituents", for example, those similar to the "substituent" of the aforementioned "3-pyridyl group optionally having substituents" are used.
is The "heterocyclic group" may have, for example, 1 to 5, preferably 1 to 3, the above-mentioned substituents at substitutable position(s). When the number of substituents is not less than 2, each substituent may be the same or different.
When a nitrogen atom is contained in the ring of the zo "heterocyclic group", the nitrogen atom may be N-oxidized.
As the substituent of the "3-pyridyl group optionally having substituents" and "heterocyclic group optionally having substituents", which is represented by one of the aforementioned A1, Az and A3, for example, an optionally zs halogenated C1_6 alkyl group (e. g., methyl, ethyl, propyl, trifluoromethyl etc.), a hydroxy-C1_6 alkyl group (e. g., hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxy-isopropyl etc.), a C1_6 alkoxy group (e. g., methoxy, ethoxy, propoxy, isopropoxy etc.), a mono- or di-C1_6 alkylamino group (e. g., 3o methylamino, dimethylamino etc.), a C1_6 alkylthio group (e. g., methylthio, ethylthio group), a (C~_15 aralkyl)(C1_6 alkyl)amino group (e. g., (benzylmethyl)amino etc.), a C1_6 alkoxy-carbonyl group (e. g., methoxy, ethoxy etc.), a mono- or di-C1_s ' CA 02431171 2003-06-06 alkylcarbamoyl group (e. g., methylcarbamoyl, dimethylcarbamoyl etc.), a carbamoyl group, a heterocyclic group containing, besides carbon atoms, 1 to 3 hetero atoms selected from nitrogen atom, sulfur atom and oxygen atom etc. {e. g., s piperidino, piperazino, morpholino, thienyl, furyl, pyridyl, pyrimidinyl, quinolyl, isoquinolyl, imidazolyl etc., hereinafter sometimes to be abbreviated as a heterocyclic group), (C~_15 aralkyl)(heterocyclic group)amino group {e. g., (4-benzylpiperidyl)amino etc.) and the like are preferable, io and methyl, trifluoromethyl and the like are particularly preferable.
As the substituent of the aforementioned "aromatic hydrocarbon group" and "C6_14 aryl group" , a C6_lo aryl group {e. g., phenyl etc.), a nitro group, a hydroxy group, a halogen is atom (e.g., fluorine atom, chlorine atom, bromine atom), an optionally halogenated C1_6 alkyl group (e. g., methyl, ethyl, propyl, isopropyl, trifluoromethyl, bistrifluoromethyl etc.), a C1_6 alkoxy group (e. g., methoxy, ethoxy etc.), an amino group, a mono- or di-C1_6 alkylamino group (e. g., methylamino, zo ethylamino, dimethylamino, diethylamino etc.), a C1_6 alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl etc.), a C1_6 alkylcarbamoyl group (e.g., methylcarbamoyl etc.), a sulfamoyl, a C1_6 alkylsulfamoyl group {e. g., methylsulfamoyl etc.), a CT_ls aralkylsulfamoyl group (e. g., benzylsulfamoyl 2s etc.), a C1_3 alkylenedioxy group (e. g., methylenedioxy, ethylenedioxy etc.), a C1_6 alkyl-carbonyloxy group (e. g., acetoxy etc.), a C1_6 alkylsulfonyl group (e. g., methylsulfonyl etc.), a C1_6 alkyl-carbonylamino group (e. g., acetylamino etc.), a C1_6 alkylsulfonylamino group (e. g., methylsulfonylamino etc.), 3o a carboxy group, a carbamoyl group and the like are preferable, and a halogen atom (e.g., fluorine atom, chlorine atom ), aminosulfonyl group and the like are particularly preferable.
More specifically, as the "3-pyridyl group optionally ~

having substituents" and "pyridyl group optionally having substituents", a 3-pyridyl group, a 4-methyl-3-pyridyl group, a 4-trifluoromethyl-3-pyridyl group, a 4-methoxy-3-pyridyl group, a 4-isoquinolyl-3-pyridyl group, a 4-methylamino-3-s pyridyl group, a 4-dimethylamino-3-pyridyl group, a 4-methylthio-3-pyridyl group, a 4-(benzylmethyl)amino-3-pyridyl group, a 4-isopropoxy-3-pyridyl group, a 5-methoxycarbonyl-3-pyridyl group, a 5-ethoxycarbonyl-3-pyridyl group, a 4-morpholino-3-pyridyl group, a 1-hydroxyisopropyl-3-pyridyl io group, a 6-dimethylcarbamoyl-3-pyridyl group, a 4-carbamoyl-3-pyridyl group, a 4-(4-benzylpiperidino)carbonyl-3-pyridyl group and the like are respectively preferable, and a 4-methyl-3-pyridyl group, a 4-trifluoromethyl-3-pyridyl group and the like are particularly preferable.
i5 As the "aromatic hydrocarbon group optionally having substituents" and "C6_14 aryl group optionally having substituents", a phenyl group, a biphenyl group, a 3-nitro-phenyl group, a 4-nitro-phenyl group, a 4-hydroxy-3-pyridyl group, a 2-chloro-3-phenyl group, a 3-chloro-3-phenyl group, a 20 4-chloro-3-phenyl group, a 3,4-dichloro-3-phenyl group, a 2-fluoro-phenyl group, a 3-fluoro-phenyl group, a 4-fluoro-phenyl group, a 2,4-difluoro-phenyl group, a 4-bromo-phenyl group, a 4-methyl-phenyl group, a 2,4-dimethyl-phenyl group, a 3,4-dimethyl-phenyl group, a 4-trifluoromethyl-phenyl group, 2s 2,4-bistrifluoromethyl-phenyl group, 2-methoxy-phenyl group, a 3-methoxy-phenyl group, a 4-methoxy-phenyl group, a 2,4-dimethoxy-phenyl group, a 2,5-dimethoxy-phenyl group, a 3-amino-phenyl group, a 4-amino-phenyl group, a 4-diethylamino-phenyl group, a 4-ethoxycarbonyl-phenyl group, a 3-3o methylcarbamoyl-phenyl group, a 4-methylsulfamoyl-phenyl group, a 3,4-ethylenedioxy-phenyl group, a 4-acetoxy-phenyl group, a 4-methylsulfonyl-phenyl group, a 4-sulfamoyl-phenyl group, a 4-dibenzylsulfamoyl-phenyl group, a 3-acetylamino-phenyl group, ' CA 02431171 2003-06-06 a 4-methylsulfonylamino-phenyl group, a 4-carboxy-phenyl group, a 4-carbamoyl-phenyl group, a 2-naphthyl group and the like are preferable.
As A3, a hydrogen atom, a halogen atom (e. g., fluorine s atom, chlorine atom, bromine atom), a C1_4 alkyl group (e. g., methyl, ethyl) or a C1_4 ethoxycarbonyl group (e. g., methoxycarbonyl, ethoxycarbonyl) and the like are preferable.
As the sulfamoyl group optionally having substituents represented by R1° in the aforementioned formulas (Ia) and io (Ial), for example, a sulfamoyl, a C1_6 alkylsulfamoyl group (e. g., methylsulfamoyl etc.), a C,_15 aralkylsulfamoyl group (e.g., benzylsulfamoyl etc.) can be mentioned, and as the alkylsulfonyl group optionally having substituents, for example, unsubstituted methylsulfonyl, ethylsulfonyl and the is like, as well as an alkylsulfonyl substituted by halogen (e. g., chloromethylsulfonyl, 1,1-difluoroethylsulfonyl etc.) and the like can be mentioned. As the C1_Z alkylenedioxy group designated by the two bonded R1~ substituting adjacent carbon atoms, methylenedioxy and ethylenedioxy can be mentioned.
ao As the carbamoyl group optionally having substituents represented by R1~ in the aforementioned formulas (Ib) and (Ibl), for example, an unsubstituted carbamoyl, as well as a mono-C1_6 alkyl-carbamoyl (e. g., methylcarbamoyl, ethylcarbamoyl etc.), a di-C1_6 alkyl-carbamoyl (e. g., dimethylcarbamoyl, 25 diethylcarbamoyl, ethylmethylcarbamoyl etc.), a C6_14 aryl-carbamoyl (e.g., phenylcarbamoyl, 1-naphthylcarbamoyl, 2-naphthylcarbamoyl etc.), a 5 or 6-membered heterocyclic carbamoyl (e.g., 2-pyridylcarbamoyl, 3-pyridylcarbamoyl, 4-pyridylcarbamoyl, 2-thienylcarbamoyl, 3-thienylcarbamoyl etc.) 3o and the like can be mentioned.
As the alkylsulfonyl group optionally having substituents represented by R1~, those mentioned as the alkylsulfonyl group optionally having substituents, which is represented by R1° can be mentioned.
As the C1_2 alkylenedioxy group designated by the two bonded R1~ substituting adjacent carbon atoms, methylenedioxy and ethylenedioxy can be mentioned.
s As the sulfamoyl group optionally having substituents, which is represented by Rlb in the .aforementioned formulas (Ia2), (Ib2), (Icl) and (Ic2), those mentioned as the sulfamoyl group optionally having substituents, which is represented by R1° can be mentioned, and as the carbamoyl group io optionally having substituents, which is represented by Rlb, those mentioned as the carbamoyl group optionally having substituents, which is represented by R1°, can be mentioned.
As the alkyl group optionally having substituents, which is represented by Rlb, an optionally halogenated Cl_6 alkyl is [e. g., Cl_6 alkyl (e. g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl etc.) optionally having 1 to 5, preferably 1 to 3, halogen atoms (e.g., fluorine, chlorine, bromine, iodine etc.), such as methyl, chloromethyl, difluoromethyl, trichloromethyl, ao trifluoromethyl, ethyl, 2-bromomethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, propyl, 3,3,3-trifluoropropyl, isopropyl, butyl, 4,4,4-trifluorobutyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 5,5,5-trifluoropentyl, hexyl, 6,6,6-trifluorohexyl and the like], and a hydroxy-C1_6 alkyl Zs (e. g., hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxy-isopropyl etc.) can be mentioned.
As the optionally esterified carboxyl group, which is represented by Rlb, for example, an unsubstituted carboxyl group, as well as a C,_6 alkoxy-carbonyl (e. g., methoxycarbonyl, 3o ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl etc.) can be mentioned.
As the halogen atom represented by Rlb, for example, fluorine, chlorine, bromine, iodine and the like can be ' CA 02431171 2003-06-06 mentioned.
As the amino group optionally having substituents, which is represented by Rlb, unsubstituted amino, as well as mono-C1_6 alkylamino (e. g., methylamino, ethylamino etc.), mono-C6_14 s arylamino (e. g., phenylamino, 1-naphthylamino, 2-naphthylamino etc.), di-C1_6 alkylamino (e. g., dimethylamino, diethylamino, ethylmethylamino etc.), di-C6_14 arylamino (e. g., diphenylamino etc.), formylamino, C1_6 alkyl-carbonylamino (e. g., acetylamino etc.), C6_14 aryl-carbonylamino (e. g., benzoylamino, io naphthoylamirio etc.), C1_6 alkoxy-carbonylamino (e. g., methoxycarbonylamino, ethoxycarbonylamino, propoxycarbonylamino, butoxycarbonylamino etc.), C1_s alkylsulfonylamino (e. g., methylsulfonylamino, ethylsulfonylamino etc.), C6_14 arylsulfonylamino (e. g., is phenylsulfonylamino, 2-naphthylsulfonylamino, 1-naphthylsulfonylamino etc.) and the like can be mentioned.
As the hydroxy group optionally having substituents, which is represented by Rlb, an unsubstituted hydroxy, as well as an alkoxy optionally having substituents [e. g., optionally ao halogenated C1_e alkoxy (e. g., C1_e alkoxy (e. g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxy etc.) optionally having 1 to 5, preferably 1 to 3, halogen atoms (e. g., fluorine, chlorine, bromine, iodine etc.), such as methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, Zs 2,2,2-trifluoroethoxy, propoxy, isopropoxy, butoxy, 4,4,4-trifluorobutoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxy etc . , and the like ) , a Cl_6 alkoxy-carbonyl-Cl_6 alkoxy ( a . g . , ethoxycarbonylmethyloxy etc.)], a C6_14 aryloxy (e. g., phenyloxy, 1-naphthyloxy, 2-naphthyloxy etc.), a C~_16 aralkyloxy (e. g., 3o benzyloxy, phenethyloxy etc.), a Cl_6 alkyl-carbonyloxy (e. g., acetoxy, propionyloxy etc.), a C6_14 aryl-carbonyloxy (e. g., benzoyloxy, naphthylcarbonyloxy etc.), a C1_6 alkoxy-carbonyloxy (e. g., methoxycarbonyloxy, ethoxycarbonyloxy, ' CA 02431171 2003-06-06 propoxycarbonyloxy, butoxycarbonyloxy etc:), a mono-C1_s alkyl-carbamoyloxy (e. g., methylcarbamoyloxy, ethyicarbamoyloxy etc.), a di-C1_s alkyl-carbamoyloxy (e. g., dimethylcarbamoyloxy, diethylcarbamoyloxy etc.), a Cs_14 aryl-carbamoyloxy (e. g., s phenylcarbamoyloxy, naphthylcarbamoyloxy etc.), a nicotinoyloxy and the like can be mentioned.
As the alkylsulfonyl group optionally having substituents, which is represented by Rlb, those mentioned as the alkylsulfonyl group optionally having substituents, which is io represented by R1°, can be mentioned.
As the C1_2 alkylenedioxy group designated by the two bonded Rlb substituting adjacent carbon atoms, methylenedioxy and ethylenedioxy can be mentioned.
As the C1_4 aliphatic hydrocarbon group optionally having is substituents, which is represented by RZ in the aforementioned formulas (Ia), (Ia3), (Ib) and (Ib3), an optionally halogenated Cl_4 alkyl [ a . g . , a Cl_4 alkyl ( a . g . , methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl etc.) optionally having 1 to 5, preferably 1 to 3, halogen zo atoms (e. g., fluorine, chlorine, bromine, iodine etc:), such as methyl, chloromethyl, difluoromethyl, trichloromethyl, trifluoromethyl, ethyl, 2-bromomethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, propyl, 3,3,3-trifluqropropyl, isopropyl, butyl, 4,4,4-trifluorobutyl, isobutyl, sec-butyl, tert-butyl Zs etc.], a hydroxy-C1_4 alkyl (e. g., hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxy-isopropyl etc.), an optionally halogenated C2_4 alkenyl (e. g., Cz_4 alkenyl (e. g., vinyl, propenyl, isopropenyl, 2-buten-1-yl etc.) optionally having 1 to 5, preferably 1 to 3, halogen atoms (e. g., fluorine, 3o chlorine, bromine, iodine etc.)), carboxy C2_4 alkenyl (e. g., 2-carboxyethenyl, 2-carboxy-2-methylethenyl etc.), optionally halogenated Cz_4 alkynyl [e.g., a CZ_4 alkynyl (e.g., 1-fluoroethyne, 2-fluoroethyne, 2-butyn-1-yl etc.) optionally '~ CA 02431171 2003-06-06 having 1 to 5, preferably 1 to 3, halogen atoms (e. g., fluorine, chlorine, bromine, iodine etc.)], an optionally halogenated C3_4 cycloalkyl [e. g., a C3_4 cycloalkyl (e. g., cyclopropyl, cyclobutyl etc.) optionally having 1 to 5, s preferably 1 to 3, halogen atoms (e. g., fluorine, chlorine, bromine, iodine etc.), such as cyclopropyl, cyclobutyl etc.]
and the like can be mentioned.
As the optionally esterified carboxyl group, which is represented by R2, those mentioned as the optionally esterified io carboxyl group, which is represented by Rlb, can be mentioned.
As the carbamoyl group optionally having substituents, which is represented by R2, those mentioned as the carbamoyl group optionally having substituents, which is represented by R1° can be mentioned.
is As the amino group optionally having substituents, which is represented by R2, those mentioned as the amino group optionally having substituents, which is represented by Rlb, can be mentioned.
As the cyclic amino group represented by RZ, a 5 to 7-ao membered saturated cyclic amino optionally having, besides one nitrogen atom and carbon atoms, 1 to 4 of 1 or 2 kinds of hetero atoms selected from nitrogen atom, sulfur atom and oxygen atom. Specifically, pyrrolidin-1-yl, piperidino, piperazin-1-yl, morpholino, thiomorpholino, hexahydroazepin-1-zs y1 and the like are used.
As the alkylthio group optionally having substituents, which is represented by R2, for example, an unsubstituted C1_6 alkylthio (e. g., methylthio, ethylthio, propylthio, butylthio, pentylthio etc.), an optionally halogenated C1_6 alkylthio, a 3o C~_16 aralkylthio (e.g., benzylthio, phenethylthio etc.) and the like can be mentioned.
As the alkoxy group optionally having substituents, which is represented by R2, for example, an optionally halogenated ' CA 02431171 2003-06-06 C1_e alkoxy [e. g., a C1_8 alkoxy (e. g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxy etc.) optionally having 1 to 5, preferably 1 to 3, halogen atoms (e. g., fluorine, chlorine, bromine, iodine etc.), such s as methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, 2,2,2-trifluoroethoxy, propoxy, isopropoxy, butoxy, 4,4,4-trifluorobutoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxy etc.], a C1_6 alkoxy-carbonyl-Cl_6 alkoxy (e. g., ethoxycarbonylmethyloxy etc.) and the like can be mentioned.
io As the~saturated or unsaturated divalent C3_5 carbon chain designated by the two bonded Rz'substituting adjacent carbon atoms, for example, trimethylene, tetramethylene, butadienylene and the like can be mentioned.
The C1_4 aliphatic hydrocarbon group optionally having i5 substituents, an optionally esterified carboxyl group, a carbamoyl group optionally having substituents, an amino group optionally having substituents, a cyclic amino group, an alkylthio group optionally having substituents and an alkoxy group optionally having substituents, which is represented by ao RZ° and R2b in the aforementioned formulas (Ial) and (Ibl), are the same as those exemplified for R2, and examples of the saturated or unsaturated divalent Cj_5 carbon chain, which is designated by R2a and R2b bonded to each other, are the same as those exemplified for the saturated or unsaturated divalent C3_s 2s carbon chain, which is designated by two R2 bonded to each other.
As the C1_4 aliphatic hydrocarbon group optionally having substituents, which is represented by Rld in the aforementioned formulas (Ia4) and (Ib4), those mentioned as the C1_4 aliphatic ao hydrocarbon group optionally having substituents, which is represented by R2 can be mentioned.
As the sulfamoyl group optionally having substituents, which is represented by Rld, those mentioned as the sulfamoyl ~

group optionally having substituents, which is represented by R1°, can be mentioned.
As the carbamoyl group optionally having substituents, which is represented by Rla, those mentioned as the carbamoyl s group optionally having substituents, which is represented by R1°, can be mentioned.
As the optionally esterified carboxyl group, which is represented by Rla, those mentioned as the optionally esterified carboxyl group, which is represented by Rib, can be io mentioned.
As the halogen atom represented by Ria, for example, fluorine, chlorine, bromine, iodine and the like can be mentioned.
As the amino group optionally having substituents, which i5 is represented by Rla, those mentioned as the amino group optionally having substituents, which is represented by Rib, can be mentioned.
As the cyclic amino group, which is represented by Ria, those mentioned as the cyclic amino group, which is zo represented by R2, can be mentioned.
As the hydroxy group optionally having substituents, which is represented by Rla, those mentioned as the hydroxy group optionally having substituents, which is represented by Rlb, can be mentioned.
Zs As the alkylthio optionally having substituents group, which is represented by Rla, those mentioned as the alkylthio optionally having substituents group, which is represented by RZ, can be mentioned.
As the alkylsulfonyl group optionally having substituents, 3o which is represented by Rla, those mentioned as the alkylsulfonyl group optionally having substituents, which is represented by R1°, can be mentioned.
As the C1_2 alkylenedioxy group designated by the two ' CA 02431171 2003-06-06 bonded Rid substituting adjacent carbon atoms, methylenedioxy and ethylenedioxy can be mentioned.
As the saturated or unsaturated divalent Ca_5 carbon chain designated by the two bonded Rld substituting adjacent carbon atoms, those mentioned as the saturated or unsaturated divalent C3_5 carbon chain designated by bonded RZ, can be mentioned.
As the C1_6 lower alkyl group represented by R° and Rb in the aforementioned formulas (Ia4) and (Ib4), methyl, ethyl, so propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl and the like can be mentioned.
As the ring formed by Ra and Rb bonded together with the nitrogen atom, azetidin-1-yl, pyrrolidin-1-yl, piperidino, morpholino and the like can be mentioned.
is As the halogen atom represented by R3 in the aforementioned formulas (Ia), (Ial), (Ia2), (Ia3), (Ia4), (Ib), (Ibl), (Ib2), (Ib3), (Ib4), (Icl) and (Ic2), fluorine atom, chlorine atom, bromine atom, iodine atom and the like can be mentioned.
2o As the C1_4 aliphatic hydrocarbon group optionally having substituents designated by R3, those mentioned as the C1_4 aliphatic hydrocarbon group optionally having substituents represented by RZ can be mentioned.
As the optionally esterified carboxyl group represented 2s by R3, those mentioned as the optionally esterified carboxyl group represented by Rlb can be mentioned.
The compounds represented by the aforementioned formulas (Ia), (Ial), (Ia2), (Ia3), (Ia4), (Ib), (Ibl), (Ib2), (Ib3), (Ib4), (Icl) and (Ic2) are all encompassed in the compound 3o represented by the formula (I).
More specifically, for example, the compounds produced by Examples 1-83 to be mentioned below are used as compound (I), of which 3-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-4-methylpyridine (compound No. 74), 3-[4-(4-fluorophenyl)-1,3-thiazol-2-yl]-4-methylpyridine (compound No. 78), 4-[2-(4-methyl-pyridin-3-yl)-1,3-thiazol-4-yl]benzenesulfonamide (compound No. 154), 3-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]-4-s methylpyridine (compound No. 137), 4-[4-(4-methyl-pyridin-3-yl)-1,3-thiazol-2-yl]benzenesulfonamide (compound No. 135) and the like are preferable.
As the salts of the compounds represented by the formula (I), for example, a metal salt, an ammonium salt, a salt with io an organic base, a salt with an inorganic acid, a salt with an organic acid, a salt with a basic or acidic amino acid and the like can be mentioned. Preferable examples of the metal salt are, for example, alkali metal salts such as sodium salt, potassium salt and the like; alkaline earth metal salts such is as calcium salt, magnesium salt, barium salt and the like;
aluminum salt and the like can be mentioned. Preferable examples of the salt with an organic base are, for example, salts with trimethylamine, triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, ao cyclohexylamine, dicyclohexylamine, N,N'-dibenzylethylenediamine and the like can be mentioned.
Preferable examples of the salt with an inorganic acid are, for example, salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like can 2s be mentioned. Preferable examples of the salt with an organic acid are, for example, salts with formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, malefic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-3o toluenesulfonic acid and the like can be mentioned. Preferable examples of the salt with a basic amino acid are, for example, salts with arginine, lysine, ornithine and the like can be mentioned and preferable examples of the salt with an acidic ' CA 02431171 2003-06-06 amino acid are, for example, salts with aspartic acid, glutamic acid and the like can be mentioned.
Of these, a pharmacologically acceptable salt is preferable. For example, when the compound has an acidic s functional group therein, an inorganic salt such as an alkali metal salt (e.g., sodium salt, potassium salt etc.), an alkaline earth metal salt (e. g., calcium salt, magnesium salt, barium salt etc.) and the like, an ammonium salt and the like can be mentioned. When the compound has a basic functional io group therein, for example, a salt with an inorganic acid such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like, or a salt with an organic acid such as acetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, malefic acid, citric acid, succinic acid, i5 methanesulfonic acid, p-toluenesulfonic acid and the like can be mentioned.
Now the production method of the compound represented by the formula (I) is described. Throughout the present specification, the starting compounds and synthetic ao intermediates may be used as a free form or a salt similar to the salts of compound (I), or may be subjected to a reaction in the form of a reaction mixture, or after isolation according to a known means. In the following, a compaund represented by the formula (symbol accorded to the formula) or Zs a salt thereof is simply referred to as compound (symbol accorded to the formula).
Production Method 1 The compound (I-1j can be produced by the reaction shown by the following formulas.

H a2 CN Q2 CONH2 Q ~ (III-1) (IV-1) (I I-1 ) a X ..~ Q ~ C S N H 2 -,. I \~-- Q 2 (VI 1) Q3 S
. Q2 M (I-1 ) (XI-1) S-C N Q N
Q ~ --~- I \>- B r (VII-1) 0 Q3 S
(VIII-1) a H Q1 N
N I \
~o ~. \ i Q3 S a3 S N
(IX_1) (X-1) wherein Q1 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, QZ is a 3-pyridyl group optionally having s substituents, Q3 is a hydrogen atom, a halogen atom, a C1_4 aliphatic hydrocarbon group optionally having substituents or an optionally esterified carboxyl group, X is a halogen atom such as chlorine atom, a bromine atom and the like, M is an alkali metal atom such as potassium, sodium, lithium and the io like.
The compound (V-1) can be obtained by halogenating compound (II-1) according to a method known per se or a method analogous thereto. This reaction can be performed according to a method known per se, such as the method described in Shin Jikken Kagaku Koza (New Courses in Experimental Chemistry), vol. 14, p. 331 (Maruzen) or a method analogous thereto. As the halogenating agent used for this reaction, chlorine, s bromine, NCS, NBS, phosphorus pentachloride, cupric bromide and the like are mentioned. Particularly, bromine and cupric bromide are preferable. In this reaction, the halogenating agent is used in 1 to 10 equivalents, preferably 1 - 3 equivalents, relative to ketone form (II-1). The reaction so temperature is from 20°C to 100°C, preferably 0°C -50°C. The reaction time is about 5 min. to 20 hrs. This reaction is generally carried out in an organic solvent that does not affect the reaction. As the organic solvent that does not affect the reaction, for example, organic acids such as acetic i5 acid and the like, acetic acid esters such as ethyl acetate, isopropyl acetate and the like, ethers such as diethyl ether, dioxane, tetrahydrofuran and the like, saturated hydrocarbons such as hexane, pentane and the like, halogenated hydrocarbons such as dichloromethane, chloroform and the like, aromatic ao hydrocarbons such as benzene, toluene and the like, and the like are used. These may be used upon mixing one or more kinds thereof at an appropriate ratio.
In addition, compound (VI-1) can be obtained by thioamidating compound (III-1) according to a method known per 2s se or a method analogous thereto. This reaction can be performed by a method known per se, such as the method described in Shin Jikken Kaqaku Koza (New Courses in Experimental Chemistry), vol. 14, p. 1827 (Maruzen) or a method analogous thereto. In this reaction, hydrogen sulfide 3o is mainly used as a thioamidating agent. The reaction temperature is from 20°C to 100°C, preferably 20°C -50°C . The reaction time is about 5 min. to 20 hrs. This reaction is generally carried out in an organic solvent that does not ' CA 02431171 2003-06-06 affect the reaction. As the organic solvent that does not affect the reaction, for example, basic solvents such as D1~, DMSO and the like, ethers such as diethyl ether, dioxane, tetrahydrofuran and the like, saturated hydrocarbons such as s hexane, pentane and the like, halogenated hydrocarbons such as dichloromethane, chloroform and the like, aromatic .hydrocarbons such as benzene, toluene and the like, and the like are used. These may be used upon mixing one or more kinds thereof at an appropriate ratio. In addition, compound (VI-1) io can be also synthesized from the corresponding carboxamide compound (IV-1) according to a method described in, for example, Shin Jikken Kagaku Koza (New Courses in Experimental Chemistry), vol. 14, p. 1827 (Maruzen).
The thiazole compound (I-1) can be obtained by subjecting z5 compound (V-1) and compound (VI-1) to a reaction known per se, such as reaction according to, for example, Shin Jikken Kagaku Koza (New Courses in Experimental Chemistry), vol. 14, p. 2191 (Maruzen) or a method analogous thereto. In this reaction, a solvent inert to the reaction, such as THF, alcohols, 2o dichloromethane and the like are used. The compound (V-1) is used in a 0.2 to 2 equivalents, preferably 1.0 to 1.5 equivalents, relative to compound (VI-1). The reaction temperature is 0°C - 150°C, preferably 20°C -120°C.
The compound (I-1) can be also synthesized by a method as that goes through compound (VII-1) and compound (VIII-1) or compound (VII-1) and compounds (IX-1) and (X-1). That is, compound (I-1) can be obtained by converting compound (V-1) to thiocyanate compound (VII-1), and then to bromothiazole (VIII-1) according to a method known per se, such as a method of 3o Journal of Indian Chemical Society, vol. 37, pp. 773-774 (1960) or Tetrahedron, vol. 56, pp. 3161-3165 (2000), and coupling the compound with compound (XI-1)(M is metal) prepared separately, by a reaction known per se, such as a ' CA 02431171 2003-06-06 method described in, for example, Tetrahedron Letters, vol. 41, pp. 1707-1710 (2000) or a method analogous thereto.
In addition, compound (I-1) can be also obtained from compound (VII-1) by a reaction known per se, such as the s method described in Journal of Indian Chemical Society, vol.
32, pp. 427-430 (1955) or a method analogous thereto via compounds (IX-1) and (X-1). In compound (I-1), moreover, the functional group of Q1, Qz and Q3 can be converted by a reaction known per se, such as the method described in Tetrahedron io Letters, vol: 41, pp. 1707-1710 (2000) or a method analogous thereto. Specifically, acylation and alkylation of Q1 and Q3, and halogenation of Qz and the like are included.
Production Method 2 The compound (I-2) can be produced by the reaction shown i5 by the following formula.

'~ CA 02431171 2003-06-06 Q ~ (III-2) (IV-2) (II-2) Q

N
Q 2 X + Q 1 C S N H 2 -~.- I ~~--Q' (V-2) Q3 , (VI-2) Q3 S
(I-2) Q
(XI_2~

S-C N Q N
Q ~ ---~. ( ~~--E
(VII-2) Q Qs S
(VI I I-2) N
~0 Q3 '' S
(IX-2) wherein each symbol is as defined above.
The compound (V-2) can be obtained by halogenating compound (II-2) according to a method known per se or a method s analogous thereto. This reaction can be performed according to a method known per se, such as the method described in Shin Jikken Kagaku Koza-New Courses in Experimental Chemistry), vol. 14, p. 331 (Maruzen) or a method analogous thereto. As the halogenating agent used for this reaction, chlorine, io bromine, NCS, NBS, phosphorus pentachloride, cupric bromide and the like are mentioned. Particularly, bromine and cupric bromide are preferable. In this reaction, the halogenating ' CA 02431171 2003-06-06 agent is used in 1 to 10 equivalents, preferably 1 - 3 equivalents, relative to ketone form (II-2). The reaction temperature is from 20°C to 100°C, preferably 0°C -50°C. The reaction time is about 5 min. to 20 hrs. This reaction is s generally carried out in an organic solvent that does not affect the reaction. As the organic solvent that does not affect the reaction, for example, organic acids such as acetic acid and the like, acetic acid esters such as ethyl acetate, isopropyl acetate and the like, ethers such as diethyl ether, io dioxane, tetrahydrofuran and the like, saturated hydrocarbons such as hexane, pentane and the like, halogenated hydrocarbons such as dichloromethane, chloroform and the like, aromatic hydrocarbons such as benzene, toluene and the like, and the like are used. These may be used upon mixing one or more kinds i5 thereof at an appropriate ratio.
In addition, compound (VI-2) can be obtained by thioamidating compound (III-2) according to a method known per se or a method analogous thereto. This reaction can be performed by a method known per se, such as the method 2o described in Shin Jikken Kagaku Koza (New Courses in Experimental Chemistry), vol. 14, p. 1827 (Maruzen) or a method analogous thereto. In this reaction, hydrogen sulfide is mainly used as a thioamidating agent. The reaction temperature is from 20°C to 100°C, preferably 20°C -50°C. The 2s reaction time is about 5 min. to 20 hrs. This reaction is generally carried out in an organic solvent that does not affect the reaction. As the organic solvent that does not affect the reaction, for example, basic solvents such as DMF, DMSO and the like, ethers such as diethyl ether, dioxane, 3o tetrahydrofuran and the like, saturated hydrocarbons such as hexane, pentane and the like, halogenated hydrocarbons such as dichloromethane, chloroform and the like, aromatic hydrocarbons such as benzene, toluene and the like, and the ' CA 02431171 2003-06-06 like are used. These may be used upon mixing one or more kinds thereof at an appropriate ratio. In addition, compound (VI-2) can be also synthesized from the corresponding carboxamide compound (IV-2) according to a method described in, for s example, Shin Jikken Kagaku Koza (New Courses in Experimental Chemistry), vol. 14, p. 1827 (Maruzen).
The thiazole compound (I-2) can be obtained by subjecting compound (V-2) and compound (VI-2) to a reaction known per se, such as reaction according to, for example, Shin Jikken Kagaku io Koza (New Courses in Experimental Chemistry), vol. 14, p. 2191 (Maruzen) or a method analogous thereto. In this reaction, a solvent inert to the reaction, such as THF; alcohols, dichloromethane and the like are used. The compound (V-2) is used in a 0.2 to 2 equivalents, preferably 1.0 to 1.5 is equivalents, relative to compound (VI-2). The reaction temperature is 0°C - 150°C, preferably 20°C -120°C.
The compound (I-2) can be also synthesized by a method that goes through compound (VII-2) and compound (VIII-2) or compound (VII-2) and compound (IX-2). That is, compound (I-2) Zo can be obtained by converting compound (V-2) to thiocyanate compound (VII-2), and then to bromothiazole (VIII-2) according to a method known per se, such as a method of Journal of Indian Chemical Society, vol. 37, pp. 773-774 (1960) or Tetrahedron, vol. 56, pp. 3161-3165 (2000), and coupling the 2s compound with compound (XI-2)(M is metal) prepared separately, by a reaction known per se, such as a method described in, for example, Tetrahedron Letters, vol. 41, pp. 1707-1710 (2000) or a method analogous thereto.
In addition, compound (I-2) can be also obtained from 3o compound (VII-2) by a reaction known per se, such as the method described in Journal of Indian Chemical Society, vol.
32, pp. 427-430 (1955) or a method analogous thereto via compound (IX-2). In compound (I-2), moreover, the functional group of Q1, QZ and Q3 can be converted by a reaction known per se, such as the method described in Tetrahedron Letters, vol.
41, pp. 1707-1710 (2000) or a method analogous thereto.
Specifically, acylation and alkylation of Q1 and Q3, and s halogenation of Q2 and the like are included.
Production Method 3 The compound (I-3) can be produced by the reaction shown by the following formula.
X
CSNH
- a ~ q VI-1 2 ( ) (XII-1) ~ (XIII-1) ~ Qs N
Q, ~.s (I-3) N Q3 ~ M
I ~ 02 --~,- ~ 2 (XI-2) -o s X s (I_5) (I_6) so wherein each symbol is as defined above.
The compound (I-3) can be also obtained by condensation of compound (XIII-1) obtained from compound (XII-1) as a starting material with compound (VI-1) obtained by the aforementioned method. The compound (XII-1) can be synthesized i5 according to the method of Synthesis, pp. 705-706 (1975) or Journal of Chemical and Engineering Data, vol. 19, pp. 392-393 (1974) or JP-A-5-345772. The compound (XIII-1) can be obtained from compound (XII-1) as a starting material according to the aforementioned method for obtaining compound (V-1) from zo compound (II-1). In addition, condensation of compound (XIII-1) and compound (VI-1) can be carried out according to condensation of compound (V-1) and compound (VI-1).

' CA 02431171 2003-06-06 In addition, compound (I-3) can be also obtained by halogenation using compound (I-5), wherein the 5-position of thiazole ring is unsubstituted, which is obtained by the aforementioned method, as a starting material according to the s method described in Shin Jikken Kagaku Koza (New Courses in Experimental Chemistry), vol. 14, p. 331 (Maruzen) to give compound (I-6), wherein the 5-position is halogenated, and substitution using compound (XI-2) according to the method used to give compound (I-1) from compound (VIII-1).
io Production Method 4 The compound (I-4) can be produced by the reaction shown by the following formula.
X

Q - , Q2 ~ D' CSNH2 ( ) (XII-2) ~ (XIII-2) 0 N
yQ, a2 ~s (I-4) N a3 ~ M
I ~ Q' ~ \ ~ (XI-1 ) ~--Q
s X s (I-7) (I-8) wherein each symbol is as defined above.
is The compound (I-4) can be also obtained by condensation of compound (XIII-2) obtained from compound (XII-2) as a starting material with compound (VI-2) obtained by the aforementioned method. The compound (XII-2) can be synthesized according to the method of Synthesis, pp. 705-706 (1975) or 2o Journal of Chemical and Engineering Data, vol. 19, pp. 392-393 (1974) or JP-A-5-345772. The compound (XIII-2) can be obtained from compound (XII-2) as a starting material according to the ' CA 02431171 2003-06-06 c aforementioned method for obtaining compound (V-1) from compound (II-1). In addition, condensation of compound (XIII-2) and compound (VI-2) can be carried out according to condensation of compound (V-1) and compound (VI-1).
s In addition, compound (I-4) can be also obtained by halogenation using compound (I-7), wherein the 5-position of thiazole ring is unsubstituted, which is obtained by the aforementioned method, as a starting material according to the method described in Shin ,7ikken Kagaku Koza (New Courses in io Experimental~Chemistry), vol. 14, p. 331 (Maruzen) to give compound (I-8), wherein the 5-position is halogenated, and substitution using compound (XI-1) according to the method used to give compound (I-1) from compound (VIII-1).
When the objective product obtained by the above-is mentioned reaction is a free form, it may be converted to a salt according to a conventional method, and when it is obtained as a salt, it may be converted to a free form or a different salt according to a conventional method. The compound (I) thus obtained can be isolated and purified from a 2o reaction solution by a known means such as phase transfer, concentration, solvent extraction, fractional distillation, crystallization, recrystallization, chromatography and the like.
In each of the aforementioned reactions, when a starting 2s compound contains amino, carboxy or hydroxy as a substituent, it may be protected by a group generally used in peptide chemistry and the like. The protecting group is removed as necessary after the reaction to give the object compound.
As the protecting group of amino, there are exemplified 3o formyl, and Cl_s alkyl-carbonyl (e. g., acetyl, propionyl etc.), phenylcarbonyl, C1_s alkyloxy-carbonyl (e. g., methoxycarbonyl, ethoxycarbonyl etc.), phenyloxycarbonyl, C~_lo aralkyloxy-carbonyl (e.g., benzyloxycarbonyl etc.), trityl, phthaloyl and ' CA 02431171 2003-06-06 the like, all of which are optionally substituted. Examples of these substituents include halogen atom (e. g., fluorine, chlorine, bromine, iodine etc.), C1_6 alkyl-carbonyl (e. g., acetyl, propionyl, valeryl etc.), nitro and the like, wherein s the number of substituents is approximately 1 to 3.
As the protecting group of carboxy, there are exemplified C1_6 alkyl (e. g., methyl, ethyl, propyl, isopropyl, butyl, tert-butyl etc.), phenyl, trityl, silyl and the like, all of which are optionally substituted. Examples of these substituents io include halogen atom (e. g., fluorine, chlorine etc.), formyl, C1_6 alkyl-carbonyl (e. g., acetyl, propionyl, butylcarbonyl etc.), nitro, C1_6 alkyl (e. g., methyl, ethyl, tert-butyl etc.), Cs-io ar'Y1 (e. g., phenyl, naphthyl etc.) and the like, wherein the number of substituents is approximately 1 to 3.
is As the protecting group of hydroxy, there are exemplified C1_6 alkyl (e. g., methyl, ethyl, propyl, isopropyl, butyl, tert-butyl etc.), phenyl, C~_il aralkyl (e. g., benzyl etc.), formyl, C1_6 alkyl-carbonyl (e. g., acetyl, propionyl etc.), phenyloxycarbonyl, C~_il aralkyloxy-carbonyl (e. g., zo benzyloxycarbonyl etc.), tetrahydropyranyl, tetrahydrofuranyl or silyl and the like, all of which are optionally substituted.
Examples of these substituents include halogen atom (e. g., fluorine, chlorine, bromine, iodine etc.), C1_6 alkyl (e. g., methyl, ethyl, tert-butyl etc.), C~_11 aralkyl (e. g., benzyl 2s etc.), C6_lo aryl (e.g., phenyl, naphthyl etc.), vitro and the like, wherein the number of substituents is approximately 1 to 4.
For removing the protecting group, a method known per se or a method analogous thereto is used. For example, a method 3o comprising treatment with an acid, a base, ultraviolet radiation, hydrazine, phenylhydrazine, sodium N-methyldithiocarbamate, tetrabutyl ammonium fluoride, palladium acetate and the like or reduction reaction is used.

In any case, compound (I) can be synthesized by each of known deprotection, acylation reaction, alkylation reaction, hydrogenation reaction, oxidization reaction, reduction reaction, carbon chain extension reaction and substituent s exchange reaction, where desired, alone or two or more thereof in combination. For these reactions, for example, the methods described in Shin Jikken Kagaku Koza (New Courses in Experimental Chemistry), vol. 15 (1977), (Maruzen) are employed.
io When the objective product obtained by the above-mentioned reaction is a free form, it may be converted to a salt according to a conventional method, and when it is obtained as a salt, it may be converted to a free form or a different salt according to a conventional method. The is compound (I) thus obtained can be isolated and purified from a reaction solution by a known means such as phase transfer, concentration, solvent extraction, fractional distillation, crystallization, recrystallization, chromatography and the like.
ao When compound (I) is present as a configuration isomer, diastereomer, conformer and the like, it can be isolated as desired by the aforementioned separation and purification means. When compound (I) is a racemate, it can be separated into an S form and an R form by a general means for optical zs resolution.
When compound (I) has a steric isomer, such isomer alone and a mixture thereof are encompassed in the present invention.
The compound (I) may be a hydrate or a non-hydrate.
The compound (I) may be labeled with an isotope (e.g., 3H, 30 14C, 35S ) and the like .
A prodrug of compound (I) is a compound which is converted into compound (I) as a result of a reaction with an enzyme, gastric acid etc. under physiological conditions in ' CA 02431171 2003-06-06 vivo. Thus, the compound is converted into compound (I) by enzymatical oxidation, reduction, hydrolysis etc., or by hydrolysis due to gastric acid etc. A prodrug of compound (I) may be a compound obtained by subjecting an amino group of compound (I) to an acylation, alkylation or phosphorylation (e.g., a compound obtained by subjecting an amino group of compound (I) to an eicosanoylation, alanylation, pentylaminocarbonylation, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxycarbonylation, tetrahydrofuranylation, Io pivaloylmethylation, pivaloyloxymethylation, tert-butylation, etc.); a compound obtained by subjecting a hydroxy group in compound (I) to an acylation, alkylation, phosphorylation and boration (e. g., a compound obtained by subjecting a hydroxy group of compound (I) to an acetylation, palmitoylation, propanoylation, pivaloylation, succinylation, fumarylation, alanylation, dimethylaminomethylcarbonylation, etc.); a compound obtained by subjecting a carboxyl group of compound (I) to an esterification or amidation (e. g., a compound obtained by subjecting a carboxyl group of compound (I) to an Zo ethyl-esterification, phenyl-esterification, carboxymethyl-esterification, dimethylaminomethyl-esterification, pivaloyloxymethyl-esterification, ethoxycarbonyloxyethyl-esterification, phthalidyl-esterification, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl-esterification, cyclohexyloxycarbonylethyl-esterification and methylamidation, etc.) and the like. Any of these compounds can be produced from compound (I) by a method known per se.
A prodrug of compound (I) may also be one which is converted to compound (I) under physiological conditions, such ao as those described in "IYAKUHIN no KAIHATSU (Development of Pharmaceuticals)", Vol. 7, Design of Molecules, p. 163-198, Published by HIROKAWA SHOTEN (1990).
The compounds (I), (I-1), (I-2), (I-3), (I-4), (I-5), (I-' CA 02431171 2003-06-06 6), (I-7), (I-8), (Ia), (Ial), (Ia2), (Ia3), (Ia4), (Ib), (Ibl), (Ib2), (Ib3), (Ib4), (Icl) and (Ic2) (hereinafter the both are also referred to as the compound of the present invention) provide a superior effect as a medicine and show a s particularly superior steroid Cl~,ZO-lyase-inhibitory activity.
The compound of the present invention shows low toxicity and lower side effects. Therefore, they can be used for mammals (e.g., human, calf, horse, pig, dog, cat, monkey, mouse, rat etc., particularly human), are useful as, for example, (i) an io androgen or estrogen reducing agent or (ii) an agent for the treatment or prevention of various diseases such as diseases related to androgen or estrogen, such as (1) primary cancer, metastasis or recurrence of malignant tumor (e. g., prostate cancer, breast cancer, uterine cancer, ovarian cancer etc.), ~s (2j various symptoms accompanying the cancers (e. g., pain, cachexia etc.), and (3) sex hormone dependent diseases (e. g., prostatic hypertrophy, masculinism, hypertrichosis, male pattern baldness, male infant-type prematurity, endometriosis, hysteromyoma, adenomyosis of uterus, mastopathy, polycystic ao ovary syndrome etc.) and the like.
The compound of the present invention shows a superior effect even when used alone. When combined with a different pharmaceutical prep~.ration or therapy, the effect can be reinforced furthermore. As the combination drug and therapy, 25 for example, there are mentioned, but not limited to, "sex hormone agents (hormone preparation)", "alkylating agents", "antimetabolites", "carcinostatic antibiotics", "plant alkaloids", "immunotherapeutic agents", "pharmaceutical agents inhibiting action of cell growth factor and its receptor" and 3o the like (hereinafter to be briefly referred to as a combination drug). Besides the combined use, the compound of the present invention and a different compound that provides preferable efficacy (specifically, various efficacies to be " CA 02431171 2003-06-06 mentioned below) when combined with the compound may be contained in a single preparation to give a mixture.
Examples of the "hormone preparation" include fosfestrol, diethylstilbestrol, chlorotrianisene, medroxyprogesterone s acetate, megesterol acetate, chlormadinone acetate, cyproterone acetate, danazol, allylestrenol, gestrinone, mepartricine, raloxifene, ormeloxifene, levormeloxifene, antiestrogen (e. g., tamoxifen citrate, toremifene citrate etc.), contraceptive pill, mepitiostane, testolactone, so aminoglutethimide, LHRH receptor modulator [LH-RH receptor agonist (e. g:, goserelin acetate, buserelin acetate, leuprorelin acetate etc.), LH-RH receptor antagonist (e. g., ganirelix, cetrorelix, abarelix etc.)), droloxifene, epitiostanol, ethinylestradiol sulfonate, aromatase inhibitor is (e. g., fadrozole hydrochloride, anastrozole, letrozole, exemestane, vorozole, formestane etc.), antiandrogen (e. g., flutamide, bicalutamide, nilutamide etc.), 5a-reductase inhibitor (e. g., finasteride, epristeride etc.), adrenocortical hormone preparation(e.g., cortisol, 2o dexamethasone, prednisolone, betamethasone, triamcinolone etc.), androgen synthesis inhibitor (e. g., abiraterone etc.), retinoid and an agent to delay metabolism of retinoid (e. g., liarozole etc.) and the like.
Examples of the "alkylating agents" include nitrogen 2s mustard, nitrogen mustard-n-oxide hydrochloride, chlorambucil, cyclophosphamide, ifosfamide, thiotepa, carboquone, improsulfan tosilate, busulfan, nimustine hydrochloride, mitobronitol, melphalan, dacarbazine, ranimustine, estramustine phosphate sodium, triethylene melamine, 3o carmustine, lomustine, streptozocin, pipobroman, etoglucide, carboplatin, cisplatin, miboplatin, nedaplatin, oxaliplatin, altretamin, ambamustine, dibrospidium hydrochloride, fotemustine, prednimustine, pumitepa, ribomustin, temozolomide, treosulfan, trophosphamide, zinostatin stimalamer, adozelesin, cystemstin, bizelesin and the like.
Examples of the "antimetabolites" include mercaptopurine, 6-mercaptopurine riboside, thioinosine, methotrexate, s enocitabine, cytarabine, cytarabine ocphosphate, ancitabine hydrochloride, 5-FU pharmaceutical agents (e. g., fluorouracil, tegafur, UFT, doxifluridine, carmofur, galocitabine, emitefur etc.), aminopterin, calcium leucovorin, tabloid, butocin, calcium folinate, calcium levofolinate, cladribine, io fludarabine, gemcitabine, hydroxycarbamide, pentostatin, piritrexim, idoxuridine, mitoguazone, tiazofurin and the like.
Examples of the "carcinostatic antibiotics" include actinomycin D, actinomycin C, mitomycin C, chromomycin A3, bleomycin hydrochloride, bleomycin sulfate, peplomycin sulfate, I5 daunorubicin hydrochloride, doxorubicin hydrochloride, aclarubicin hydrochloride, pirarubicin hydrochloride, epirubicin hydrochloride, neocarzinostatin, mithramycin, sarcomycin, carzinophilin, mitotane, zorubicin hydrochloride, mitoxantrone hydrochloride, idarubicin hydrochloride and the Zo like .
Examples of the "plant alkaloids" include etoposide, etoposide phosphate, vinblastine sulfate, vincristine sulfate, vindesine sulfate, teniposide, paclitaxel, vinorelbine and the like.
Zs Examples of the "immunotherapeutic agents" (BRM) include picibanil, krestin, sizofiran, lentinan, ubenimex, interferon, interleukin, macrophage colony stimulating factor, granulocyte-colony stimulating factor, erythropoietin, lymphotoxin, BCG vaccine, Corynebacterium parvum, levamisole, 3o polysaccharide K, procodazol and the like.
As the "cell growth factor" in the "pharmaceutical agents inhibiting action of the cell growth factor and its receptor", any substance can be used as long as it enhances proliferation of cells. In general, a factor which is a peptide having a molecular weight of not more than 20,000, and which can show effect upon binding with receptor at a low concentration is exemplified. Specific examples include (1) EGF (epidermal s growth factor) or a substance having substantially the same activity therewith [e.g., EGF, heregulin (HER2 ligand) etc.], (2) insulin or a substance having substantially the same activity therewith [e. g., insulin, IGF (insulin-like growth factor)-1, IGF-2 etc.], (3) FGF (fibroblast growth factor) or io a substance having substantially the same activity therewith [e. g., acidic FGF, basic FGF, KGF (keratinocyte growth factor), FGF-10 etc.], (4) other cell growth factors [e. g., CSF (colony stimulating factor), EPO (erythropoietin), IL-2(interleukin-2), NGF (nerve growth factor), PDGF (platelet-derived growth i5 factor), TGF~ (transforming growth factor ~), HGF (hepatocyte growth factor), VEGF (vascular endothelial growth factor) etc.] and the like.
The "receptor of the cell growth factor" may be any receptor as long as it has a binding ability with the above-Zo mentioned cell growth factor. Specific examples include EGF
receptor, HER2 (heregulin receptor), insulin receptor, IGF
receptor, FGF receptor-1, FGF receptor-2 and the like.
Examples of the "pharmaceutical agents inhibiting action of the cell growth factor" include antibodies against cell 2s growth factor and receptor thereof, such as EGF receptor antibody (e. g., cetuximab) and HER2 antibody (e. g., herceptin); tyrosine kinase inhibitors such as Iressa (EGF
receptor tyrosine kinase inhibitor), TAK-165 (HER2 tyrosine kinase inhibitor), GW2016 (EGF receptor/HER2 tyrosine kinase 3o inhibitor) and the like; ribozyme that inhibits expression of cell growth factor and receptor thereof; anti-sense medicaments and the like.
In addition to the aforementioned pharmaceutical agents, L-asparaginase, aceglatone, procarbazine hydrochloride, cobalt protoporphyriw complex, mercurial hematoporphyrin-sodium, topoisomerase I inhibitor (e. g., irinotecan, topotecan etc.), topoisomerase II inhibitor (e. g., sobuzoxane etc.), s differentiation inducing agent (e.g., retinoid, vitamine D
etc.), angiogenesis inhibitor, a-blocker (e. g., tamsulosin hydrochloride etc.) and the like can be also used.
Along with a chemical therapy to administer the compound of the present invention, for example, a therapy other than so the chemical~therapy such as an operation including orchiectomy, thermotherapy, radiation therapy and the like can be applied in combination.
Particularly, the compound of the present invention can more effectively remove androgen or estrogen in blood when is used in combination with an LHRH receptor modulator (LHRH
modulator) such as LHRH receptor agonist (e. g., goserelin acetate, buserelin acetate, leuprorelin acetate etc.) and LHRH
receptor antagonist (e. g., ganirelix, cetrorelix, abarelix etc.).
ao The compound of the present invention has high selectivity to steroid Cl~,2o-lyase and shows less influence on drug metabolizing enzymes, such as CYP3A4. Since influence on drug metabolizing enzymes (e. g., CYP3A4) is small, it serves well as a safe pharmaceutical agent with less limitation on as combined drug.
For combined use of compound (I) and combination drug, the administration time of compound (I) and combination drug is not limited, and compound (I) and combination drug may be simultaneously administered to the administration objects or 3o administered with time lag. The dose of the combination drug may be similar to that clinically employed, which can be determined as appropriate depending on the administration objects, administration route, disease, combination and the like.
The mode of administration of compound (I) and combination drug.is not particularly limited, and compound (I) and combination drug only need to be combined on s administration. Such administration mode is exemplified by (1) administration of a single pharmaceutical preparation obtained by simultaneous formulation of compound (I) and combination drug, (2) simultaneous administration of two kinds of pharmaceutical preparations obtained by separate formulation io of compound (I) and combination drug by the same administration route, (3) time lag administration of two kinds of pharmaceutical preparations obtained by separate formulation of compound (I) and combination drug by the same administration route, (4) simultaneous administration of two 15 kinds of pharmaceutical preparations obtained by separate formulation of compound (I) and combination drug by different administration routes, (5) time lag administration of two kinds of pharmaceutical preparations obtained by separate formulation of compound (I) and combination drug by different zo administration routes (e.g., administration of compound (I) ->
combination drug and administration in reverse order) and the like.
As the pharmaceutically acceptable carrier, various organic and inorganic carrier substances for conventional zs production material are used and appropriately added as an excipient, a lubricant, a binder, a disintegrating agent and a thickener to solid preparations; as a solvent, a dispersing agent, a solubilizer, a suspending agent, an isotonicity agent, a buffer and a soothing agent to liquid preparations, and the 30 like. Where necessary, additives such as an antiseptic, an antioxidant, a coloring agent, a sweetener and the like can be used according to a conventional method. Preferable examples of the excipient include lactose, sucrose, D-mannitol, starch, ' CA 02431171 2003-06-06 crystalline cellulose, light anhydrous silicic acid and the like. Preferable examples of the lubricant include magnesium stearate, calcium stearate, talc, colloidal silica and the like. Preferable examples of the binder include crystalline s cellulose, sucrose, D-mannitol, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone and the like. Preferable examples of the disintegrating agent include starch, carboxymethyl cellulose, carboxymethyl cellulose calcium, crosscarmellose sodium, io sodium carboxymethyl starch and the like. Preferable examples of the thickener include natural gums, cellulose derivative, acrylate polymer and the like. Preferable examples of the solvent include water for injection, alcohol, propylene glycol, Macrogol, sesame oil, corn oil and the like. Preferable 15 examples of the dispersing agent include Tween 80, HCO 60, polyethylene glycol, carboxymethyl cellulose, alginate sodium and the like. Preferable examples of the solubilizer include polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, tris-aminomethane, cholesterol, zo triethanolamine, sodium carbonate, sodium citrate and the like.
Preferable examples of the suspending agent include surfactants such as stearyl triethanolamine, sodium lauryl sulfate, lauryl aminopropionate, lecithin, benzalkonium chloride, benzethonium chloride, glyceryl monostearate and the 2s like; hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, carboxymethylcellulose sodium, methylcellulose, hydroxymethylcellulose, hydroxyethyl cellulose, hydroxypropylcellulose etc., and the like.
Preferable examples of the isotonicity agent include sodium 3o chloride, glycerine, D-mannitol and the like. Preferable examples of the buffer include buffer solutions of phosphate, acetate, carbonate, citrate and the like. Preferable examples of the soothing agent include benzyl alcohol and the like.

Preferable examples of the antiseptic include p-hydroxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like. Preferable examples of the antioxidant include sulfite, ascorbic acid and s the like.
The pharmaceutical preparation of the present invention can be produced according to a conventional method, wherein the content of the compound of the present invention in the preparation is generally 0.1 - 100% (w/w). Specific examples io are shown in the following.
(1) Tablet, powder, granule, capsule:
These can be produced by adding, for example, an excipient, a disintegrating agent, a binder, a lubricant and the like to the compound of the present invention, and is subjecting the mixture to compression molding, and where necessary, coating for masking of taste, enteric coating or coating for sustained release.
(2) Injection:
An injection can be produced by preparing the compound of zo the present invention into an aqueous injection together with, for example, a dispersing agent, a preservative, an isotonicity agent and the like, or dissolving, suspending or emulsifying in vegetable oil, such as olive oil, sesame oil, cottonseed oil, corn oil etc., propylene glycol and the like, Zs to give an oily injection.
(3) Suppository:
A suppository can be produced by making the compound of the present invention into an oily or aqueous solid, semisolid or liquid composition. Examples of the oily base to be used 3o for such a composition include glyceride of higher fatty acid (e. g., cacao butter, Witepsol etc.), medium fatty acid (e. g., migliol etc.), vegetable oil (e. g., sesame oil, soybean oil, cottonseed oil etc.) and the like. Examples of the aqueous gel ' CA 02431171 2003-06-06 base include natural gums, cellulose derivative, vinyl polymer, acrylate polymer and the like.
While the content of the compound of the present invention in these preparations varies depending on the kind s of preparation, it is generally 0.01 - 50%.
The amount of the compound of the present invention to be used in the aforementioned pharmaceutical preparation varies depending on the compound to be selected, animal species selected to be the administration object, frequency of io administration and the like. The compound exerts effectiveness over a wide range of dosages. For example, the daily dose of a pharmaceutical preparation of the present invention when orally administered to an adult patient with solid tumor (e. g., patient with prostate cancer), as expressed in the effective is amount of the compound of the present invention, is generally about 0.001 to about 500 mg/kg body weight, preferably about 0.1 to about 40 mg/kg body weight, more preferably abaut 0.5 to about 20 mg/kg body weight. When it is used for parenteral administration in combination with a different anticancer ao agent, the dose is generally smaller than the doses mentioned above. However, the amount of the compound actually administered is determined based on the selection of the compound, various dosage forms, age, body weight and sex of the patient, level of disease state, administration route, the as period and intervals of the administration and the like, and can be modified at any time according to the judgment of doctors.
While the administration route of the aforementioned pharmaceutical preparation is not particularly limited by 3o various conditions, for example, it can be administered orally or parenterally. As used herein, by the "parenteral" is meant intravenous, intramuscular, subcutaneous, intranasal, intracutaneous, instillation, intracranial, endorectal, intravaginal and intraperitoneal administrations.
The period and intervals of the administration of the aforementioned pharmaceutical preparation are modified according to various conditions and determined according to s the judgment of doctors at any time. The administration method includes, for example, divisional administration, consecutive daily administration, intermittent administration, administration in large amounts in a short term, repeat administration and the like. In the case of oral io administration, for example, the preparation is desirably administered once a day to several times a day (particularly 2 or 3 times a day) by dividing the dose. It is also possible to administer as a sustained release preparation or intravenous infusion over a long time.
i5 The present invention is explained in more detail by way of the following Reference Examples and Examples. These Examples are mere embodiments and do not limit the present invention in any way and can be modified as long as they do not deviate from the scope of the present invention. In the Zo following Reference Examples and Examples, silica gel 60 (70-230 or 230-400 mesh) manufactured by Merck was used as the filler for column chromatography. The melting point was measured using Yanaco MP-J3. 1H NMR spectrum was measured in Varian Gemini-200 (200 MHz) or MERCURY (300 MHz) using zs tetramethylsilane as the internal standard. The symbols in the Examples mean the following and abbreviations in the Examples mean the following.
s: singlet, d: doublet, t: triplet, q: quartet, dd: double doublet, dt: double triplet, m: multiplet, br: broad, J:
3o coupling constant, room temperature:20 - 30°C, DMF:
dimethylformamide, THF: tetrahydrofuran.
Reference Example 1 (2',4'-dimethyl)phenyl-2-bromoacetophenone (1) (2~,4~-Dimethyl)-2-acetophenone (14.8 g, 100 mmol) was dissolved in ethyl acetate (200 ml) and copper bromide (45.0 g, 200 mmol) was added. The mixture was heated under reflux for 3 hrs. After cooling, solid was filtered off. The filtrate was s concentrated under reduced pressure and the residue was purified by silica gel column chromatography, which was then converted to a powder from isopropyl ether to give the title compound (11.9 g, 52%).
elemental analysis for CloHll~Br io ~C(%) H(%) Calculated: 52.89; 4.88 Found: 52.69; 4.90 1H-Nl~t (200Hz, CDC13) S: 2.37(3H, s), 2.52 (3H, s), 4.42 (2H, s), 7.09 (1H, d, J = 7.0 Hz), 7.11(1H, s), 7.62 (1H, d, J =
15 7.0 Hz) .
Reference Example 2 Examples of the compounds produced according to the method described in Reference Example 1 using commercially available acetylbenzene derivative or acetylpyridine ao derivative as a starting material are shown in Table 1.
[Table 1]

i Br i ~ Q3 Y
Com 1 3 yield meltin . ( Z ) P Q Y % int : ~C
Nop 1 _ hydrogen C 52 36-38 2,4-dimethyl 2 2-hydroxy hydrogen C 65 40-42 3 4-hydroxy hydrogen C 100 124-126 4 3,4-dimethyl hydrogen C 59 56 2,4-difluoro hydrogen C 90 oil 6 2,4-bistrifluoromethylhydrogen C 94 50-52 7 4-trifluoromethyl hydrogen C 86 56-57 8 hydrogen methyl C 93 liq.

9 4-fluoro methyl C 76 liq.

2-fluoro methyl C 88 liq.

Reference Example 3 4'-(dibenzylsulfamoyl)-2-bromoacetophenone (11) 4.-(Dibenzylsulfamoyl)acetophenone (1.89 g, 5.0 mmol) prepared from 4-acetylbenzenesulfonic acid according to the method described in J. Med. Chem., 43, 214-223 (2000) was dissolved in chloroform (10 ml) and a solution of bromine (0.80 g, 5.0 mmol) dissolved in chloroform (5 ml) was added dropwise at room temperature over 10 min., and the mixture was io stirred for 40 min. Chloroform was concentrated under reduced pressure, and recrystallized from a small amount of diethyl ether to give the title compound (1.92 g, 86%).
elemental analysis for CZ1HZ1N03SBr C(%) H(%) N(%) i5 Calculated: 56.38; 4.73; 3.13 Found: 56.61; 4.85; 3.40 1H-NMR (200Hz, CDC13) b: 4.38 (4H, s), 4.46 (2H, s), 7.03- 7.27 (10H, m).
Reference Example 4 2o Examples of the compounds produced according to the method described in Reference Example 3 using commercially available acetylbenzene derivative or acetylpyridine derivative as a starting material are shown in Table 2.
[Table 2]

~Z ~a .,,~ Br ~ J Q3 Comp.(Z1)P Q3 Y yield melting No. ~ oint: C
%~

11 4-dibenz lsulfamo h dro en C .",.. "
1 , 89 12 4-meth lsulfon 1 h dro en C 90 126 13 4-meth lsulfamo 1 h dro en C 74 140 ' CA 02431171 2003-06-06 Reference Example 5 4-methylnicotinonitrile (14) Referring to JP-A-7-10841, 2,6-dichloro-4-methylnicotinonitrile (manufactured by Mabridge) (17.0 g, 90.9 s mmol) was dissolved in methanol (450 ml), and 10% Pd-C (1.7 g, wt.%) and sodium acetate (15.2 g, 186 mmol) were added. The mixture was stirred at room temperature under hydrogen pressure for 16 hrs. and the catalyst and the like were filtered off. The solvent was concentrated under reduced to pressure, and the resulting mixture was partitioned between dichloromethane (300 ml) - 5% aqueous sodium hydrogen carbonate (200 ml). The organic layer was dried and the resulting mixture was concentrated under reduced pressure.
Recrystallization from a small amount of isopropyl ether gave the title compound (9.2 g, 86%).
sublimability elemental analysis for C,H6N2 C(%) H(%) N(%) Calculated: 71.17; 5.12; 23.71 2o Found: 71.19; 5.40; 23.88 1H-NMR (200Hz, CDC13) 8: 2.58 (3H, s), 7.31 (1H, d, J =5.8 Hz), 8.66 (1H, d, J =5.8 Hz), 8.80 (1H, s).
Reference Example 6 3-acetyl-4-methylpyridine (15) 2s To a solution of compound (14)(2.0 g, 16.9 mmolj in ether (13 ml) was added a methylmagnesium iodide-ether solution (18.2 ml, 27.4 mmol) under ice-cooling. The reaction mixture was heated to 50°C and stirred overnight. The reaction mixture was again ice-cooled and 5% hydrochloric acid (400 ml) was 3o added. The reaction mixture was neutralized with a 1N aqueous sodium hydroxide solution and extracted with ethyl acetate.
The extract was combined and dried (MgS04) and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography to give a yellow oil (1.26 g, 55%).
1H-NMR (200Hz, CDC13) S: 2.57 (3H, s), 2.65 (3H, s), 7.20 (1H, d, J = 5.2 Hz), 8.55 (1H, d, J = 5.2 Hz), 8.95 (1H, s).
s Reference Example 7 3-(2-bromoacetyl)pyridine hydrobromate (16) To a solution of 3-acetylpyridine (5.00 g, 41.3 mmol) in acetic acid (100 ml) was added 47$ hydrobromic acid (7.10 ml, 41.3 mmol), and a solution of bromine (2.12 ml, 41.3 mmol) in io acetic acid (50 ml) was added dropwise under ice-cooling.
After the completion of the dropwise addition, the reaction mixture was heated to 80°C and the mixture was stirred for one hr. After cooling, the precipitated crystals were collected by filtration, washed with ethanol-ethyl acetate and dried under is reduced pressure to give white crystals.
melting point: 228°C
1H-NNBt. (200Hz, DMSO-d6) 8: 5.08 (2H, s), 7.93 (1H, dd, J = 8.0 Hz, 5.6 Hz), 8.69 (1H, d, J = 8.0 Hz), 8.99 (1H, d, J = 5.6 Hz), 9.33 (1H, s).
2o Reference Example 8 Examples of the compounds produced according to the method described in Reference Example 7 using compound (15) and 3-propionylpyridine as starting materials are shown in Table 3.
2s [Table 3]

Q2 Br C - Q _ -Q3 yield ( tin c p ~ ~ ) ho _ int Po ( ) 17 3-(4-methylpyridyl) hydrogen 70 amorphous 18 3-pyridyl methyl 80 148-150 ' CA 02431171 2003-06-06 Reference Example 9 4-chloronicotinaldehyde (19) A solution (50 ml) of 4-chloropyridine (25.0 g, 0.22 mol) in tetrahydrofuran was added dropwise to a tetrahydrofuran s solution (300 ml) of lithium diisopropylamide prepared from a solution (179 ml, 0.29 mol) of 1.6 M n-butyllithium in hexane and diisopropylamine (33.4 g, 0.33 mol) under an argon atmosphere at -78°C. After stirring for 30 min., DMF (19.3 g, 0.26 molj was added and the mixture was gradually heated to io room temperature. The reaction mixture was extracted with ethyl acetate (200 ml) - 5% NH4C1 aq. (300 ml). The organic layer was dried (MgS04) and the solvent was evaporated under reduced pressure to give a crude title compound (27 g, 86%) as an oil.
15 1H-NMR (200Hz, CDC13) b: 7.45 (1H, d, J = 5.0 Hz), 8.69 (1H, d, J = 5.OHzj, 9.05 (1H, sj, 10.51 (1H, s).
Reference Example 10 4-chloronicotinonitrile (20) The compound (19) (27.0 g, 0.19 mol), hydroxylamine Zo hydrochloride (13.01 8, 0.19 mol) and sodium acetate (15.6 g, 0.19 mol) were suspended in methanol (100 ml) and the mixture was stirred at room temperature for 2 hrs. The solvent was evaporated and the residue was dissolved in chloroform (100 ml). Phosphorus oxychloride (125 g) was added and the mixture as was heated under reflux for 3 hrs. The solvent was evaporated and the residue was added to water (200 ml), which was adjusted to pH=7 with sodium carbonate. The mixture was extracted with ethyl acetate (200 ml x 2) and the organic layer was dried (MgS04). The solvent was evaporated under 3o reduced pressure to give the title compound (18 g, 68%).
1H-NMR (200Hz, CDC13) b: 7.52 (1H, d, J = 5.0 Hz), 8.72 (1H, d, J = 5.OHz), 8.87 (1H, s).

' CA 02431171 2003-06-06 Reference Example 11 4-methoxynicotinonitrile (21) To a solution of compound (20)(2.77 g, 20.0 mmol) in methanol (5 ml) was added a 28% sodium methylate-methanol s solution (5.0 g, 24.0 mmol) at room temperature and the mixture was stirred for one hr. The solvent was concentrated and the obtained residue was partitioned between ethyl acetate and iced-brine. The organic layer was dried over anhydrous magnesium sulfate and the solvent was evaporated under reduced io pressure. The obtained residue was recrystallized from a small amount of isopropyl ether to give the title compound (2.3 g, 86%).
elemental analysis for C,HeN2o C(%) H($) N(%) I5 Calculated: 62.68; 4.51; 20.88 Found: 62.74; 4.69; 20.59 1H-Nl~t (200Hz, CDC13) b: 4.02 (3H, s), 6.93 (1H, d, J = 5.8 Hz), 8.65 (1H, d, J =5.8Hz), 8.69 (1H, s).
Reference Example 12 2o Examples of the compounds produced according to the method described in Reference Example 11 using compound (20) as a starting material are shown in Table 4.
[Table 4]
NC
Y
Comp. ( Z~ )p y yield ( melting No $ ) oint : C
.
~

21 4-metho N 86 110-112 22 4-iso ro N 90 48 23 4-dimeth lamino N 90 82-83 24 4-methylthio N 90 amor hous Reference Example 13 4-vinylnicotinonitrile (25) s7 To a solution of compound (20)(1.00 g, 7.21 mmol) in dimethylformamide (15 ml) were added tributyl(vinyl)tin (2.50 ml, 8.65 mmol) and dichlorobis(triphenylphosphine)palladium (0.40 g, 0.58 mmol), and the mixture was stirred at 120°C under an argon atmosphere for one hr. The reaction mixture was poured into ice water and extracted with ethyl acetate. The extract was combined and washed with brine and dried (MgS04).
The solvent was evaporated under reduced pressure and the obtained residue was purified by silica gel column io chromatography to give a white powder (0.93 g, 99%).
melting point: 56-57°C
1H-NMR (200Hz, CDC13) b: 5.80 (1H, d, J = 11.0 Hz), 6.21 (1H, d, J = 17.6 Hz), 7.02 (1H, dd, J = 11.0 Hz, 17.6 Hz), 7.54 (1H, d, J = 5.6 Hz), 8.73 (1H, d, J = 5.6 Hz), 8.85 (1H, s).
is Reference Example l4 4-ethylnicotinonitrile (26) The compound (25) (0.73 g, 5.61 mmol) was dissolved in ethyl acetate (15 ml) and 10% palladium carbon (20 mg) was added. The mixture was stirred at normal temperature and 2o normal pressure under a hydrogen atmosphere for 2 hrs. for hydrogenation. The reaction mixture was passed through celite and the filtrate was partitioned between ethyl acetate and brine. The aqueous layer was extracted with ethyl acetate, and the extract was combined and dried (MgS04). The solvent was zs evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography to give a colorless oil (0.62 g, 84%).
1H-NMR (200Hz, CDC13) b: 1.34 (3H, t, J = 7.6 Hz), 2.89 (2H, q, J = 7.6 Hz), 7.30 (1H, d, J = 5.6 Hz), 8.68 (1H, d, J = 5.6 3o Hz), 8.80 (1H, s).
Reference Exaiaple 15 4-methylpyridine-3-carbothioamide (27) To a solution of compound (14)(9.2 g, 77.9 mmol) in dimethylformamide (500 ml) was added triethylamine (800 mg, 7.79 mmol; 10 mol%), and the mixture was stirred at room temperature for 16 hrs. while introducing hydrogen sulfide gas.
The solvent was concentrated and the obtained residue was s partitioned between dichloromethane and brine. The aqueous layer was extracted with dichloromethane. The extracts were combined and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure and the obtained residue was recrystallized from a small amount of ethyl so acetate to give the title compound (10.2 g, 86%).
elemental analysis for C~HBNZS
c(%) H(%) N(%) Calculated: 55.24; 5.30; 18.40 Found: 55.38; 5.42; 18.43 1s 1H-NMR (200Hz, CDC13) b: 2.49(3H, s), 7.13 (1H, d, J = 5.2 Hz), 7.28 (1H, brs), 7.86 (1H, brs), 8.39 (1H, d, J =5.2 Hz), 8.49(1H, s).
Reference Example 16 Examples of the compounds produced according to the Zo method described in Reference Example 15 using commercially available or synthesized nicotinonitrile derivative (compounds (21-24) , (26)), or commercially available cyanobenzene derivative as a starting material are shown in Table 5.

[Table 5~

~~Z~)P
Y
Comp. 1 yield melting No . ( Z ) p Y C int : C

27 4-meth 1 N 86 106-108 28 4-metho N 41 155-157 29 4-iso ro N 51 115 30 4-dimeth lamino N 44 140-143 31 4-meth lthio N 69 180-182 32 4-eth 1 N 100 149-150 33 4-h dro _ 53 195-196 C

34 2,4-difluoro C 36 127-129 35 2-chloro C 11 amor hous 36 3,4-butadien lene N 59 205-207 37 3-sulfamo 1 C 36 127-129 38 4-fluoro C 22 151-152 39 I _ C 71 amorphous 4-sulfamoyl Reference Example 17 s 4-chlorophenylacetyl thiocyanate (40) 4-Chlorophenylacetyl bromide (12.2 g, 52.3 mmol) was suspended in ethanol (50 ml) and heated to 60°C - 70°C. An aqueous solution (10 ml) of KSCN (5.59 g, 57.5 mmol) was added by small portions, and after addition, the mixture was stirred io at 80°C for 10 min. The reaction mixture was left standing at room temperature for 4 hrs. Water (150 ml) was added and the precipitated solid was collected by. filtration. The residue was washed twice with water (150 ml) and dried under reduced pressure to give the title compound (10.1 g, 91~).
is Reference Example 18 4-(4-chlorophenyl)-2-bromo-1,3-thiazole (41) The compound (40) (2.1 g, 10.0 mmol) was suspended in acetic acid (10 ml) and 47~ HBr-acetic acid (1 ml) was added.
The mixture was stirred with heating at 80°C for 2 hrs. The 2o reaction mixture was concentrated under reduced pressure to dryness and the residue was partitioned between ethyl acetate and 5% NaHC03 aq. The aqueous layer was extracted with ethyl acetate, and the extracts were combined, washed with saturated brine and dried (MgS04). The solvent was evaporated under s reduced pressure and isopropyl ether was added to the obtained residue, which.was filtrated to give the title compound (1.2 g, 44%).
1H-NMR (200Hz, CDC13) b: 7.39 (2H, d, J = 8.8 Hz), 7.41 (1H, s), 7.80 (1H, d, J = 5.6 Hz).
io Reference Example 19 4-(4-chlorophenyl)-2-oxo-1,3-thiazole(42) The compound (40)(10.9 mg, 52.2 mmol) was suspended in acetic acid (50 ml) and 50% sulfuric acid (15 ml) was added dropwise at 60°C. The mixture was heated under reflux for 2 is hrs. After cooling, the reaction mixture added to ice (200 g).
The precipitated crystals were collected by filtration, washed twice with water (200 ml) and dried under reduced pressure to give the title compound (10.1 g, 91%).
melting point: 230-233°C
20 1H-NMR (200Hz, CDC13) 8: 6.28 (1H, s), 7.37 (2H, d, J=7.OHz), 7.52 (2H, d, J =7.0 Hz), 11.46 (1H, brs).
Reference Example 20 4-(4-chlorophenyl)-[2-(4-chloropyridin-3-yl))-1,3-thiazole (43) 25 According to the synthetic example of compound (19), 4-chloropyridine (1.14 g, 10.0 mmol) and LDA (12 mmol) were reacted and ZnClZ (1.63 g, 12.0 mmol) was added to the obtained the reaction mixture. The mixture was stirred at -78°C for 10 min. and compound (41) (548 mg, 2.0 mmol) and 3o tetrakistriphenylphosphinepalladium (580 mg, 0.5 mmol) were added. The mixture was stirred at room temperature far 30 hrs.
The reaction mixture was partitioned between ethyl acetate and NH4C1 aq., and the ethyl acetate layer was washed once with NH4C1 aq. The extract was dried (MgS04) and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography to give the title compound (250 mg, 40~).
s melting point: 149-150°C
1H-NMR (200Hz, CDC13) b: 7.17 (1H, s), 7.49 (2H, d, J=8.OHz), 7.63 - 7.67 (1H, m), 7.84 (2H, d, J =8.0 Hz), 8.59 (1H, d, J=6.OHz), 9.11 (1H, s).
Example 1 io 4-(2,4-dimethylphenyl)-[2-(4-methylpyridin-3-yl)]-1,3-thiazole monohydrochloride (44) A mixture of compound (1) (227 mg, 1.O mmo1), compound (27) (152 mg, 1.0 mmol) and ethanol (3 ml) was heated under reflux for 6 hrs. After cooling, the solvent was evaporated is under reduced pressure, and the obtained residue was partitioned between ethyl acetate and saturated aqueous sodium hydrogen carbonate. The organic layer was dried (MgS04) and the solvent was evaporated under reduced pressure. The residue was recrystallized from 4N hydrochloric acid/ethyl acetate to Zo give crystals (220 mg, 69~) of monohydrochloride.
melting point: 148-150°C
1H-NMR (200Hz, CDC13) b: 2.33 (3H, s), 2.47 (3H, s), 2.83 (3H, s), 7.10-7.17 (2H, m), 7.59 (1H, d, J=7.6Hz), 7.96 (1H, d, J
=5.8 Hz), 8.10(1H, s), 8.79 (1H, d, J =5.8 Hz), 9.22 (1H, s).
as Example 2 Examples of the compounds produced according to the method described in Reference Example 1 using commercially available or synthesized a-bromoketone derivatives (compounds (1-13), (16-18)) and commercially available or synthesized 3o thioacetamide derivatives (compounds (27-39)) as starting materials are shown in Table 6 to Table 12.
[Table 6]

~(Zt )p N _ ~(Z2)q 3/1$ ~ Y2 Q
[Table 6) Comp. 1 3 z 1 z yield meltin (Z Q (Z ) Y Y salt ) No. p q ($) po t:

C

45 4- hydro hydrogen C N HBr 82 238-241 hen en 46 4-nitro hydrogenhydrogen C N HBr 92 267-271 47 4-bromo h drogenhydrogen C N HBr 71 213-216 48 3-nitro hydrogenhydrogen C N HBr 91 238-241 49 3-metho hydrogenh drogen C N HBr 83 231-233 50 2-metho hydrogenhydro en C N HBr 81 242-243 51 2,4-dimetho hydrogenhydrogen C N HBr 70 224-225 52 4-phenyl hydrogen4- C N 83 94-95 trifluoro-methyl 53 4-bromo hydrogen4- C N 93 69-71 trif luoro-methyl 54 2,5-dimetho hydrogenhydrogen C N HBr 79 223-226 55 4- hydrogenhydrogen C N 65 76-77 diethylamino 56 2,4-dimeth hydro hydrogen C N HCl 78 152 1 en 57 2,4-dimethyl hydrogen4- C N HBr 33 152 trifluoro-methyl 58 4-fluoro hydrogen4- C N 81 52-53 trifluoro-methyl [Table 7) Ch ( Z1 ) Q3 ( Zz ) Y1 Yz salt yiel melting mp i o P po nt:

(~C) 59 4-nitro hydrogen4-trifluoro- C N HBr 80 165-167 meth 1 60 3-vitro hydrogen4-trifluoro- C N HBr 70 178-183 meth 1 61 3-methoxy hydrogen4-trifluoro- C N HBr 70 140-145 meth 1 62 2-methoxy hydrogen4-trifluoro- C N HBr 42 176-180 meth 1 63 4-methyl hydrogen4-trifluoro- C N HBr 58 184 meth 1 64 4-methoxy hydrogen4-trif luoro-C N HCl 40 93-95 meth 1 65 3-chloro hydrogen4-trifluoro- C N HBr 65 140-143 methyl 66 2-chloro hydrogen4-trif luoro-C N HCl 82 87-90 methyl 67 3,4- hydrogen4-trifluoro- C N HBr 47 123 dimeth 1 meth 1 68 4-hydroxy hydrogen4-trifluoro- C N 40 117-119 meth 1 69 4-etho hydrogen4-trifluoro- C N HBr 69 168-170 n carbo meth 1 70 4-diethyl- hydrogen4-trifluoro- C N HC1 91 105-110 amino methyl 71 3-methyl- hydrogen4-trifluoro- C N 89 132-133 carbamoyl methyl [Table 8]
Comp.1 3 2 1 2 yiel melting N (Z ) S2 (Z ) Y Y saltd o. p q point:

(%) ( C) 72 4- hydrogen4-trifluoro- C N HBr 60 144-145 trifluoro- methyl methyl 73 3,4-buts- hydrogen4-trifluoro- C N HBr 77 107 dienylene methyl 74 4-chloro hydrogen4-methyl C N 38 119 75 hydrogen methyl 4-trifluoro- C N 34 75 meth 1 76 2,5- hydrogen4-trifluoro- C N HBr 52 154-157 dimethoxy methyl 77 2t4- hydrogen4-trifluoro- C N HBr 46 157-160 di.methoxy methyl 78 4-fluoro hydrogen4-methyl C N 44 129 79 4-fluoro hydrogen4-trifluoro- C N HCl 67 100-102 meth 1 80 hydrogen methyl 4,5-buta- C N 47 amor-dienylene phous 81 hydrogen methyl hydrogen N N 31 146-147 82 hydrogen hydrogen4-trifluoro- C N HBr 36 150-152 meth 1 83 3,4- hydrogen4-trifluoro- C N HBr 41 146-148 dichloro methyl 84 4-fluoro hydrogen4-methoxy C N 17 184 85 2,4- hydrogen4-methoxy C N HCl 16 154 dimeth 1 86 hydrogen methyl 4-methyl C N 13 65 87 hydrogen methyl hydrogen C N 24 80 88 4-hydroxy hydrogen4-methyl C N 72 218 [Table 9]
Comp. 1 3 2 1 2 yield melting N (Z ) Q (Z ) Y Y salt o. p 9 ~$) point:

('C ) 89 4-methyl- hydrogen4,5-buta- C N 24 amorphous sulfamo ' 1 then lene _ 90 3,4- hydrogen4-trifluoro- C N HBr 54 148-150 ethylene- methyl dioxy 91 4-fluoro methyl 4-trifluoro- C N HC1 16 84 methyl 92 4-fluoro methyl 4-methyl C N 21 82 93 2-fluoro hydrogen4-trifluoro- C N HBr 81 155-158 meth 1 94 3-fluoro hydrogen4-trifluoro- C N HBr 64 160-163 meth 1 95 4-acetoxy hydrogen4-trifluoro- C N 97 116-118 meth 1 96 2,4-bis- hydrogen4-trifluoro- C N HCl 67 102-103 trifluoro- methyl methyl 97 3,4- hydrogen4-methoxy C N 52 152 ethylene-dio 98 hydrogen ethoxy- 4-trifluoro- C N 46 oil carbon meth 1 99 4-fluoro methyl hydrogen C N 31 136 100 4-fluoro hydrogendimethylamino C N 2HC1 78 189-192 101 4-fluoro hydrogen4-methylthio C N HC1 64 195-199 102 hydrogen hydrogen4-trifluoro- N N 2HC1 76 171-173 meth 1 [Table 10]
Comp.1 3 z 1 z yield melting (Z ) Q (Z ) Y Y salt No. p q (%) po C;

103 4-methyl hydrogen4-methyl C N 65 98 104 2-methoxy hydrogen4-methyl C N 28 106 105 3,4- hydrogen4-methyl C N 58 87 ethylene-dioxy 106 2,4- hydroge 4-methyl C N 22 88 dimethoxy 107 3,4- hydrogen4-methyl C N 53 78 dimeth 1 108 2,4- hydrogen4-methyl C N 21 89 dif luoro 109 2,4-bis- hydrogen4-methyl C N HCl 27 155 trifluoro-methyl 110 3-methoxy hydroge 4-methyl C N 35 amor-phous 111 3-nitro hydrogen4-methyl C N 61 149 112 4-ethoxy hydrogen4-methyl C N 62 116 -carbonyl 113 3-fluoro hydrogen4-methyl C N 37 136 114 2-chloro hydrogen4-methyl C N HCl 44 136 115 4- hydrogen4-methyl C N HBr 48 128 trifluoro-meth 1 116 4-fluoro hydrogen4-ethyl C N HBr 74 233-235 117 4-fluoro hydrogen4-(benzyl- C N 2HC1 64 204-205 methyl)-amino [Table 11]
Comp.1 3 2 1 z yield melting N (Z ) Q (Z ) Y Y salt o. p 9 (~) po Cj 118 4-dibenz hydroge 4-trifluoro- C N 74 130 ~

sulfamo meth 1 119 4-dibenz hydroge 4-methyl C N 45 160 sulfamo 120 3- hydroge 4-trifluoro- C N HC1 70 154-155 acet lamino meth 1 121 hydrogen hydroge 4-methyl N N 32 110 122 4-methyl- hydroge 4-trifluoro- C N 63 197 sulfamo 1 meth 1 123 4-methyl- hydroge 4-methyl C N 46 164 sulfamo 1 124 4-fluoro hydroge 4-isopropoxy C N 64 114 125 4-methyl- hydroge 4-methyl C N 51 167 sulfon 1 126 2-fluoro methyl 4-methyl C N 39 95 127 3,4-buta- hydroge 4-methyl C N 63 116 dien lene 128 3-methoxy hydroge 4-isopropoxy C N 55 74-76 129 hydrogen hydroge hydrogen N N HBr 64 195-198 130 4-methyl- hydroge hydrogen C N HCl 58 211-213 sulfamoyl 131 4-methyl- hydroge hydrogen C N HBr 74 220-223 sulfonyl [Table 12]
(Z1)p Q3 (ZZ)q Y1 YZ salt y~$~d ~ nt g ( C) 132 4- hydrogen 4,5-buta- C N 79 142 h dro X then lene 133 4-fluorohydrogen 4, 5-buta- C N 33 95 then lene 134 4-methylhydrogen 2-chloro N C 90 111-112 135 4-methylhydrogen 4-sulfamoyl N C 54 192-195 136 hydrogenhydrogen 4-fluoro N C HBr 84 225-227 137 4-methylhydrogen 4-fluoro N C HC1 93 180-183 138 4-methylmethyl 4-sulfamoyl N C 50 202-204 139 4-methylhydrogen 2,4-difluoroN C HBr 82 225-230 s Example 3 ethyl 5-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]nicotinic acid (140) A solution of compound (41) (0.25 g, 0.91 mmol) in tetrahydrofuran (5 ml) was cooled to -78°C under an argon io atmosphere and 1.6 M n-butyllithium-hexane solution (0.57 ml, ' CA 02431171 2003-06-06 0.91 mmol) was added. After stirring at -78°C for 30 min., a solution of zinc chloride (0.12 g, 0.91 mmol) in tetrahydrofuran (2 ml) was added to the reaction mixture. The reaction mixture was warmed to room temperature and stirred s for 30 min. and ethyl 5-bromonicotinate (0.21 g, 0.91 mmol) and tetrakis(triphenylphosphine)palladium (0.16 g, 0.14 mmol) were added. The mixture was heated to 75°C and stirred for 2 hrs. After cooling, the reaction mixture was poured into ice water and partitioned between ethyl acetate and brine. The io aqueous layer was extracted with ethyl acetate and the extracts were combined and dried (MgS04), and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography, and crystallized from ethyl acetate-n-hexane to give white crystals (0.16 g, m 51%).
melting point: 132-135°C
elemental analysis for C1~H13C1NZOZS
C(%) H(%) N(%) Calculated: 59.21; 3.80; 8.12 2o Found: 59.15; 3.66; 7.97 1H-NMR (200Hz, CDC13) b: (3H, t, = 7.1 Hz),4.49 (2H, 1.50 J q, J = 7.1 Hz), 7.44 (2H, d, 8.6 Hz), 7.59 (1H, s), 7.96 J = (2H, d, J = 8.6 Hz), 8.86 (1H, 9.27 (1H, s), 9.41 (1H, s).
s), Example 4 Zs methyl 3-[4-(4-chlorophenyl)-1,3'-thiazol-2-yl]isonicotinic acid (141) The compound (43) (6.0 g, 20.0 mmol), triethylamine (5.32 g, 52.6 mmol), palladium acetate (930 mg, 4.0 mmol), and dppf (2.22 g, 4.0 mmol) were dissolved in D1~' (80 ml)-methanol (40 3o ml) under an argon atmosphere and the mixture was stirred at 70°C for 40 hrs. under a carbon monoxide atmosphere. The solvent was evaporated and, after cooling, the reaction mixture was partitioned between ethyl acetate and aqueous " CA 02431171 2003-06-06 sodium hydrogen carbonate. The aqueous layer was extracted with ethyl acetate. The extracts were combined, dried (MgS04), and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column s chromatography, and crystallized from ethyl acetate-n-hexane to give white crystals (4.71 g, 69%).
melting point: 92-94°C
elemental analysis for C16H11C1N202S
C(%) H(%) N(%) io Calculated: ,58.09; 3.35; 8.47 Found: 58.23; 3.56; 8.58 1H-NMR (200Hz, CDCl3j S: 3.83 (3H, s), 7.41 (2H, d, J = 8.4 Hz), 7.55 (1H, d, J=4.4Hz), 7.60 {1H, s), 7.87 (2H, d, J = 8.4 Hz), 8.78 (1H, d, J=5.2Hz), 9.05 (1H, s).
is Example 5 4-f3-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]pyridine-4-yl}morpholine (142) Morpholine (5 ml) was added to compound (43) (120 mg, 0.40 mmol) and sodium iodide (156 mg, 0.40 mmol). The reaction 2o mixture was heated to 80°C and stirred for 6 hrs. The solvent was evaporated under reduced pressure, and the obtained residue was partitioned between ethyl acetate and aqueous sodium hydrogen carbonate. The aqueous layer was extracted with ethyl acetate. The extracts were combined, dried (MgS04) Zs and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography, and crystallized from ethyl acetate-n-hexane to give white crystals (100 mg, 67%).
melting point: 169°C
3o elemental analysis for C19H16C1N30S 0.5H20 C{%) H(%) N(%) Calculated: 60.23; 4.52; 11.09 Found: 59.71; 4.58; 11.47 1H-NMR (200Hz, CDC13) 8: 3.06 (4H, m), 3.88 (4H, m), 7.01 (1H, d, J = 5.8 Hz), 7.27 (1H, s), 7.42 (2H, d, J = 8.6 Hz), 7.59 (1H, s), 7.95 (2H, d, J = 8.6 Hz), 8.53 (1H, d, J = 5.8 Hz), 9.14 (1H, s).
s Example 6 Examples of the compounds produced according to the method described in Example 5 using commercially available amine derivative as a starting material are shown in Table 13.
[Table 13]

N
1o S N
Comp. Z1 ~.lyield melting point:
No .. - ($) __~~
.

143 4-(4-chlorophenyl)-4- 30 198 h drox i eridino 144 carbamoylmethylamino 40 202 Ex~ple 7 2-{3-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]pyridin-4-yl}propan-2-0l (145) is The compound (141) (857 mg, 2.5 mmol) was dissolved in anhydrous tetrahydrofuran (5 ml) and a 2M solution (3 ml, 6.0 mmol) of MeMgI in ether was added under ice-cooling. The reaction mixture was stirred at room temperature for one hr.
The reaction mixture was partitioned between ethyl acetate and 2o aqueous ammonium chloride and the aqueous layer was extracted with ethyl acetate. The organic layers were combined and dried (Mgso4). The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give the title compound as white crystals 2s (480 mg, 61$j.
melting point: 146°C

elemental analysis for C1~H15C1NZOS
C(%) H(%) N(%) Calculated: 61.72; 4.57; 8.47 Found: 61.98; 4.58; 8.55 s 1H-Nl~t (200Hz, CDC13) b: 1.55 (3H, s), 1.59 (3H, s), 7.43 (2H, d, J = 8.8 Hz), 7.52 (1H, d, J = 5.0 Hz), 7.64 (1H, s), 7.72 (1H, s), 7.81 (2H, d, J = 8.8 Hz), 8.68 (1H, d, J = 5.0 Hz), 8.93 (1H, s).
Example 8 io 3-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-N,N-dimethylisonicotinamide (146) The compound (141) (170 mg, 0.5 mmol) was dissolved in methanol (10 ml)-1N NaOH aq. (10 ml) and the mixture was stirred at 40°C for one hr. The pH of the reaction mixture was is adjusted to around 6, and the precipitated solid was collected by filtration, which was dried in vacuo and dissolved in dimethylformamide (3 ml) together with WSC (117 mg, 0.6 mmol), HOBt (85 mg, 0.6 mmol) and dimethylamine (27 mg, 0.6 mmol).
The mixture was stirred at 30°C for 2 hrs. The reaction 2o mixture was partitioned between ethyl acetate and aqueous sodium hydrogen carbonate. The aqueous layer was extracted with ethyl acetate, and the organic layers were combined and dried (MgS04). The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column 25 chromatography to give the title compound as white crystals (120 mg, 35%).
melting point: 195°C
elemental analysis for C17H14C1N3OS
C(%) H(%) N(%) 3o Calculated: 59.38; 4.10; 12.22 Found: 59.11; 4.17; 12.23 1H-NMR (200Hz, CDC13) b: 2.80 (3H, s), 3.14 (3H, s), 7.39 (1H, d, J = 5.2 Hz), 7.41 (2H, d, J = 7.0 Hz), 7.57 (1H, s), 7.86 w (2H, d, J = 7.0 Hz), 8.71 (1H, d, J = 5.2 Hz), 9.17 (1H, s).
Example 9 Examples of the compounds produced according to the method described in Example 8 using commercially available s amine derivative as a starting material are shown in Table 14.
[Table 14]

N
S N
Comp. No. Z1 yield melting -. ._... _ ( $1 ant-( C

147 carbamoyl 24 201 148 methylcarbamoyl 30 205 149 (4-benzylpiperidino)carbonyl 18 amorphous Example 10 io 3-(5-chloro-4-(4-chlorophenyl)-1,3-thiazol-2-yl]-4-methylpyridine (150) The compound (74) (286 mg, 1.0 mmol) was dissolved in dimethylformamide (2 ml) and a solution of trichloroisocyanuric acid (100 mg, 0.4 mmol) in is dimethylformamide (1 ml) was added under ice-cooling. The reaction mixture was stirred at room temperature for one hr.
and partitioned between ethyl acetate and aqueous sodium hydrogen carbonate. The aqueous layer was extracted with ethyl acetate, and the organic layers were combined and dried (MgSO4).
2o The solvent was evaporated under reduced pressure to give the title compound as white crystals (190 mg, 59$).
melting point: 146°C
elemental analysis for C15H1oC12NZS
C(~) H(~) N(~) Zs Calculated: 56.09; 3.14; 8.72 Found: 55.95; 3.13; 8.43 1H-NMR (200Hz, CDC13) b: 2.67 (3H, s), 7.25 (1H, d, J = 5.2 Hz), 7.45 (2H, d, J = 8.2 Hz), 8.00 (2H, d, J = 8.2 Hz), 8.53 (1H, d, J = 5.2 Hz), 8.89 (1H, s).
s Example 11 Examples of the compounds produced according to the method described in Example 10 using compounds (104) and (125) as starting materials are shown in Table 15.
[Table 15]
(Z~ )p '~.. I H3C
N

IO
Comp. (Z1)p salt yield melting ($) No . _,_,. -,_ oint :
C

151 2-metho HCl 51 143 152 4-meth lsulfamo 85 138 Example 12 3-[5-fluoro-4-(4-methylphenyl)-1,3-thiazol-2-yl]-4-methylpyridine (153) Is The compound (103) (133 mg, 0.5 mmol) was dissolved in acetonitrile (5 ml) and a solution of Selectfloro~' (236 mg, 0.6 mmol) in acetonitrile (3 ml) was added. The reaction mixture was stirred under heating under reflux for 16 hrs. The reaction mixture was partitioned between ethyl acetate and Zo aqueous sodium hydrogen carbonate. The aqueous layer was extracted with ethyl acetate, and the organic layers were combined and dried (MgS04). The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give the title compound as crystals 2s (30 mg, 21~).
melting point: 96°C

' CA 02431171 2003-06-06 elemental analysis for C1sH13FNZS
C(%) H(%) N(%) Calculated: 67.58; 4.61; 9.85 Found: 67.87; 4.77; 9.88 s 1H-NMR (200Hz, CDC13) b: 2.41 (3H, s), 2.69 (3H, s), 7.23-7.30 (3H, m), 7.87 (2H, d, J = 8.0 Hz), 8.50 (1H, d, J = 5.0 Hz), 8.84 (1H, s).
Example 13 4-[2-(4-methylpyridin-3-yl)-1,3-thiazol-4-io yl]benzenesulfonamide (154) The compound (119) (770 mg, 1.3 mmol) was dissolved in conc. sulfuric acid (3.0 ml) and the mixture was stirred at 10°C for 0.5 hr. The reaction mixture was poured into ice water (50 ml) and neutralized with 5% aqueous sodium hydrogen is carbonate. The reaction mixture was extracted with ethyl acetate-tetrahydrofuran (1:1) and the organic layer was dried (Mgso4). The solvent was evaporated under reduced pressure, and the residue was recrystallized from a small amount of dichloromethane to give the title compound as white crystals 20 (260 mg, 67%).
melting point: 219°C
elemental analysis for C15H13N3~2Sz 0.25H20 C(%) H(%) N(%) Calculated: 53.63; 4.05; 12.51 as Found: 53.81; 3.99; 12.22 1H-NMR (200Hz, CDC13) 8: 2.68 (3H, s), 7.43 (1H, s), 7.47 (1H, d, J = 5.2Hz), 7.93 (2H, d, J = 8.4 Hz), 8.24 (2H, d, J = 8.4 Hz), 8.52 (1H, s), 8.55 (1H, d, J = 5.2 Hz), 9.00 (1H, s.).
Example 14 3o As a compound that can be produced according to a method similar to the method described in Example 13 using compound (118) as a starting material, 4-~2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-' CA 02431171 2003-06-06 yl}benzenesulfonamide (155) can be obtained in a yield of 52%.
melting point: 217°C
elemental analysis for C15H1oF3N30zSz 0.5HZ0 C(%) H(%) N(%) s Calculated: 45.68; 2.81; 10.65 Found: 45.94; 2.59; 10.84 1H-NN~t (200Hz, CDC13) b: 7.43 (1H, s), 7.91-8.23 (5H, m), 8.62(1H, s), 9.03 (1H, d, J = 5.2 Hz), 9.14 (1H, s).
Example 15 io 4-{2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl}aniline (156) The compound (59) (0.61 g, 1.72 mmol) was dissolved in formic acid (10 ml) and Pd-C (0.06 g, 10 wt.%) was added. The mixture was stirred at normal temperature and normal pressure i5 under a hydrogen atmosphere for 2 hrs. The catalyst and the like were filtered off and formic acid was concentrated under reduced pressure. The residue was partitioned between ethyl acetate and saturated aqueous sodium hydrogen carbonate. The organic layer was washed with brine and dried (MgS04). The 2o solvent was evaporated under reduced pressure, and the obtained residue was purified by silica gel column chromatography to give white crystals (0.23 g, 42%).
melting point: 71-72°C
elemental analysis for ClsH1oN302SF3 25 C(%) H(%) N($) Calculated: 56.07; 3.14; 13.08 Found: 56.08; 3.09; 13.12 1H-NI~t (200Hz, CDC13) b: 3.80 (2H, s), 6.76 (2H, d, J = 8.8 Hz), 7.48 (1H, s), 7.70 (1H, d, J = 5.2 Hz), 7.77 (2H, d, J = 8.8 3o Hz), 8.87 (1H, d, J = 5.2 Hz), 9.05 (1H, s).
Example 16 3-f2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl}aniline (157) ' CA 02431171 2003-06-06 In the same manner as in Example 15, a colorless amorphous compound (0.94 g, quant.) was obtained from compound (60) (1.00 g, 2.85 mmol).
elemental analysis for C15H1oN30zSF3 C(%) H(%) N(%) Calculated: 56.07; 3.14; 13.08 Found: 56.00; 3.23; 13.02 1H-NMR (200Hz, CDC13) S: 3.64 (2H, s), 6.71 (1H, d, J = 7.6 Hz), 7.19-7.35 (3H, m), 7.65 (1H, s), 7.70 (1H, d, J = 5.2 Hz), 8.88 (1H, d,~J = 5.2 Hz), 9.04 (1H, s).
Example 17 N-(4-~2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl}phenyl)acetamide (158) To a solution of compound (156) (0.20 g, 0.63 mmol) in is dichloromethane (3 ml) were added pyridine (0.05 ml, 0.63 mmol) and acetyl chloride (0.04 ml, 0.63 mmol) under ice-cooling. The reaction mixture was warmed to room temperature and, after stirring for one hr., partitioned between ethyl acetate and brine. The aqueous layer was extracted with ethyl 2o acetate, and the extracts were combined and dried (Mgs04). The solvent was evaporated under reduced pressure. The obtained residue was crystallized from ethyl acetate to give white crystals (0.17 g, 76%).
melting point: 216-213°C
2s elemental analysis for C1~H12N30SF3 C(%) H(%) N(%) Calculated: 56.19; 3.33; 11.56 Found: 56.10; 3.30; 11.42 1H-NMR (200Hz, DMSO-d6) b: 2.07 (3H, s), 7.68 (2H, d, J = 8.8 3o Hz), 7.95 (2H, d, J = 8.8 Hz), 7.99 (2H, d, J = 5.2 Hz), 8.10 (1H, brs), 8.30 (1H, s), 9.02 (2H, d, J = 5.2 Hz), 9.11 (1H, s) .

' CA 02431171 2003-06-06 Example 18 N-(3-(2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl}phenyl)acetamide (159) In the same manner as in Example 17, a colorless s amorphous compound (0.30 g, 70%) was obtained from compound (157) (0.38 g, 1.18 mmol). To a solution of this amorphous compound in methanol (3 ml) was added 4N ethyl acetate-hydrochloric acid (0.22 ml) under ice-cooling and the mixture was stirred at the same temperature for 10 min. The reaction io mixture was concentrated under reduced pressure and the obtained residue was crystallized from ethyl acetate-methanol to give hydrochloride as yellow needle crystals.
melting point: 154-155°C
elemental analysis for C1~H12N30SF3~HC1~0.1Hzo s5 C(%) H(%) N(%) Calculated: 50.84; 3.31; 10.45 Found: 50.76; 3.54; 10.36 1H-Nit (200Hz, CDC13) S: 2.21 (3H, s), 7.38-7.46 (2H, m), 7.62-7.74 (4H, m), 8.06 (1H, s), 8.90 (1H, d, J = 4.8 Hz), 9.05 (1H, so s ) .
Example 19 N-(4-f2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl}phenyl)methanesulfonamide (160) In the same manner as in Example 17, a colorless 25 amorphous compound (0.25 g, 72%) was obtained from compound (156) (0.28 g, 0.87 mmol) using methanesulfonyl chloride instead of acetyl chloride. To a solution of this amorphous compound in methanol (3 ml) was added 4N ethyl acetate-hydrochloric acid (0.16 ml) under ice-cooling and the mixture 3o was stirred at the same temperature for 10 min. The reaction mixture was concentrated under reduced pressure and the obtained residue was crystallized from ethyl acetate-methanol to give hydrochloride as yellow needle crystals.

melting point: 205-207°C
elemental analysis forCl6H~ZN3O2S2F3'HC1 C($) H($) N($) Calculated: 44.09; 3.01; 9.64 s Found: 44.07; 2.97; 9.69 1H-NI~llt ( 200Hz, CDC13 ) S: 3 . 06 ( 3H, s ) , 6 . 45 ( 1H, s ) , 7 . 31 ( 2H, d, J = 8.8 Hz), 7.67 (1H, s), 7.73 (1H, d, J = 4.8 Hz), 7.98 (2H, d, J = 8.8 Hz), 8.91 (1H, d, J = 4.8 Hz), 9.06 (1H, s).
Example 20 to N-(3-~2-[4-(trifluoromethyl)pyridin-3-yl)-1,3-thiazol-4-yl}phenyl)methanesulfonamide (161) In the same manner as in Example 17, a colorless amorphous compound (0.28 g, 70$) was obtained from compound (157) (0.31 g, 0.96 mmol) using methanesulfonyl chloride is instead of acetyl chloride. To a solution of this amorphous compound in ethyl acetate (2 ml) was added 4N ethyl acetate-hydrochloric acid (0.18 ml) under ice-cooling and the mixture was stirred at the same temperature for 10 min. The reaction mixture was concentrated under reduced pressure and the zo obtained residue was crystallized from ethyl acetate to give hydrochloride as yellow crystals.
melting point: 162-165°C
elemental analysis for C16H1zN30zS2F3~HCl C($) H($) N($) 2s Calculated: 44.09; 3.01; 9.64 Found: 44.02; 2.28; 9.63 1H-NNllt (200Hz, CDC13) 8: 3.06 (3H, s), 6.66 (1H, s), 7.27-7.42 (1H, m), 7.46 (1H, t, J = 7.9,.Hz), 7.72-7.84 (4H, m), 8.91 (1H, d, J = 5.6 Hz), 9.05 (1H, s).
3o Example 21 4-f2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl}benzoic acid (162) To a solution of compound (69) (0.57 g, 1.24 mmol) in ethanol (15 ml) was added 1N sodium hydroxide (7.45 ml, 7.45 mmol), and the mixture was stirred at room temperature for 3 hrs. To the mixture was added 1N hydrochloric acid (7.45 ml, 7.45 mmol) and the ethanol solvent was evaporated under s reduced pressure. The obtained residue was washed with water and ethanol and dried (PZOS) under reduced pressure to give a white powder (0.37 g, 85%).
elemental analysis for C16H9NZO2SF3-0.4HZ0 C(%) H(%) N(%) io Calculated: 53.75; 2.76; 7.84 Found: 53.85; 2.60; 7.79 1H-Nl~t (200Hz, DMSO-d6) b: 8.00-8.18 (6H, m), 8.62 (1H, s), 9.03 (1H, d, J = 5.2 Hz), 9.14 (1H, s).
Example 22 is 4-[2-(4-methylpyridin-3-yl)-1,3-thiazol-4-yl]benzoic acid (163) In the same manner as in Example 21, a white powder (0.31 g, 94%) was obtained from compound (112) (0.37 g, 1.13 mmol).
melting point: >300°C
zo elemental analysis for C16H12N2~2S
C(%) H(%) N(%) Calculated: 65.85; 4.08; 9.45 Found: 64.60; 4.19; 9.66 1H-Nl~t (200Hz, DMSO-d6) 8: 2.68 (3H, s), 7.47 (1H, d, J = 5.4 2s Hz), 8.04 (2H, d, J = 8.2 Hz), 8.17 (2H, d, J = 8.2 Hz), 8.51 (1H, s), 8.56 (1H, d, J = 5.4 Hz), 9.00 (1H, s).
Example 23 4-~2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl}benzamide (164) 3o To a solution of compound (162) (0.45 g, 1.29 mmol) in tetrahydrofuran (12 ml) were added oxalyl chloride (0.17 ml, 2.59 mmol) and dimethylformamide (3 drops) under ice-cooling, and the mixture was stirred at room temperature for one hr. To los this reaction mixture was added 28% aqueous ammonia (1.00 ml, 16.44 mmol) and the mixture was stirred at room temperature for one hr. and partitioned between ethyl acetate and saturated aqueous sodium hydrogen carbonate. The aqueous layer s was extracted with ethyl acetate. The extracts were combined, washed with brine and dried (MgS04). The solvent was evaporated under reduced pressure. The obtained residue was crystallized from ethanol-ethyl acetate to give white crystals (0.45 g, quant.).
so melting point: 192-193°C
elemental analysis for C16H1oN30SF3~0.5AcOEt C(%) H(%) N(%) Calculated: 54.96; 3.59; 10.68 Found: 54.69; 3.47; 10.77 1s 1H-NMR (200Hz, DMSO-d6) b: 7.44 (lH.brs), 7.97-8.13 (6H, m), 8.60 (1H, s), 9.03 (1H, d, J = 4.8 Hz), 9.14 (1H, s).
Example 24 4-[2-(4-methylpyridin-3-yl)-1,3-thiazol-4-yl]benzamide (165) In the same manner as in Example 23, a white powder (0.05 ao g, 17%) was obtained from compound (163) (0.30 g, 1.0:1 mmol).
melting point: 222-225°C
elemental analysis for Cl6HisN30S
C(%) H(%) N(%) Calculated: 65.06; 4.44; 14.22 2s Found: 64.98; 4.56; 14.10 1H-NMR (200Hz, DMSO-d6) b: 2.68 (3H, s), 7.43 (1H, brs), 7.47 (1H, d, J = 5.0 Hz), 7.97-8.16 (5H, m), 8.4$ (1H, S), 8.55 (1H, d, J = 5.0 Hz), 9.00 (1H, s).
Example 25 3o Production of 3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide i) Production of 3-cyanobenzamide A mixture of 28% aqueous ammonia (20 ml) and THF (30 ml) was cooled to 5°C and 3-cyanobenzoyl chloride (1.45 g) was slowly added. The mixture was stirred for one hr. and the reaction mixture was extracted with ethyl acetate. The organic layer was dried and concentrated. The residue was s recrystallized from ethyl acetate to give the title compound (802 mg) as colorless needle crystals.
1H-NMR (CDC13+CD30D)8: 7.61 (1H, t, J= 7.8 Hz), 7.82 (1H, dt, J=
7.8, 1.4 Hz), 8.13 (1H, dt, J= 7.8, 1.4 Hz), 8.21 (1H, t, J=
1.4 Hz).
io IR (KBr): 3420, 3160, 2232, 1705, 1397 c~ 1.
ii) Production of 3-(aminocarbonothionyl)benzamide 3-Cyanobenzamide (4.67 g) was suspended in a mixture of ethanol (500 ml) and triethylamine (1.0 ml), and hydrogen sulfide gas was blown in at room temperature for 30 min. The i5 mixture was stirred at room temperature for 4 days and the solvent was evaporated under reduced pressure. The residue was washed with a mixture of ethanol-ethyl acetate to give the title compound (5.70 g) as a pale-yellow powder.
1H-NI~t (DMSO-d6)8: 7.40-7.56 (2H, m), 7.91-8.08 (3H, m), 8.32 Zo (1H, t, J= 1.8 Hz), 9.58 (1H, brs), 9.98 (1H, brs).
IR (KBr): 3358, 3160, 1659, 1636, 1418 cm 1.
iii) Production of 3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 2-Bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromate zs (435 mg) and 3-(aminocarbonothionyl)benzamide (202 mg) were suspended in ethanol (10 ml) and the mixture was heated under reflux for 3 hrs. The reaction mixture was cooled to room temperature and the precipitated crystals were collected by filtration and washed with a mixture of ethanol-ethyl acetate.
ao The obtained crystals were dissolved in a mixture of aqueous sodium hydrogen carbonate-ethyl acetate-methanol and extracted with ethyl acetate. The organic layer was dried and concentrated and the residue was recrystallized from ethyl ilo acetate-methanol to give the title compound (235 mg) as colorless powder crystals.
1H-NNfft (DMSO-d6) 8: 2.54 (3H, s), 7.38 (1H, d, J=5.2 Hz), 7.57 (1H, brs), 7.63 (1H, t, J=7.7 Hz), 7.96-8.05 (1H, m), 8.09 (1H, s s), 8.14-8.26 (2H, m), 8.43-8.50 (2H, m), 8.86 (1H, s).
IR (KBr): 3266, 3106, 3056, 1713, 1402 cm 1.
Example 26 Production of N-methyl-3-(4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide io i) Production of 3-cyano-N-methylbenzamide A mixture of 40~ aqueous methylamine solution (20 ml) and THF (30 ml) was cooled to 5°C, and 3-cyanobenzoyl chloride (1.89 g) was slowly added. The mixture was stirred for one hr.
The reaction mixture was extracted with ethyl acetate, and the is organic layer was dried and concentrated. The residue was recrystallized from ethyl acetate to give the title compound (1.14 g) as colorless needle crystals.
1H-NI~t (CDC13) 8: 3.06 (3H, d, J= 4.8 Hz), 6.26 (1H, brs), 7.59 (1H, t, J= 7.9 Hz), 7.80 (1H, dt, J= 7.9, 2.6 Hz), 7.95-8.10 20 ( 2 H, m ) .
IR (KBr): 3293, 2232, 1636, 1559 cm 1.
ii) Production of 3-(aminocarbonothionyl)-N-methylbenzamide 3-Cyano-N-methylbenzamide (930 mg) was dissolved in a mixture of ethanol (80 ml) and triethylamine (2.0 ml), and 2s hydrogen sulfide gas was blown in at room temperature for 30 min. The mixture was stirred at room temperature for 36 hrs.
and the solvent was evaporated under reduced pressure. The residue was washed with ethyl acetate to give the title compound (731 mg) as a pale-brown powder.
30 1H-NMR (DMSO-d6)8: 2.79 (3H, d, J= 4.8 Hz), 7.49 (1H, t, J= 7.8 Hz), 7.86-8.04 (2H, m), 8.29 (1H, s), 8.44-8.64 (1H, m), 9.59 (1H, brs), 9.98 (1H, brs).
IR (KBr): 3304, 1630, 1416 cm 1.

iii) Production of N-methyl-3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 2-Bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromate (408 mg) and 3-(aminocarbonothionyl)-N-methylbenzamide (204 s mg) were suspended in ethanol (10 ml) and the mixture was heated under reflux for 3 hrs. The reaction mixture was cooled to room temperature and the precipitated crystals were collected by filtration and washed with ethyl acetate. The obtained crystals were dissolved in a heated mixture of io aqueous sodium hydrogen carbonate-ethyl acetate and, after partitioning, the aqueous layer was extracted with ethyl acetate. The organic layer was dried and concentrated and the residue was recrystallized from ethyl acetate to give the title compound (236 mg) as pale-yellow powder crystals.
is 1H-NMR (DMSO-d6)8: 2.54 (3H, s), 2.82 (3H, d, J=4.4 Hz), 7.38 (1H, d, J=5.0 Hz), 7.63 (1H, t, J=7.6 Hz), 7.96 (1H, d, J=7.6 Hz), 8.09 (1H, s), 8.17 (1H, d, J= 7.6 Hz), 8.44 (1H, s), 8.47 (1H, d, J= 5.0 Hz), 8.60-8.76 (1H, m), 8.86 (1H, s).
IR (KBr): 3268, 3139, 1672, 1553 cm 1.
2o Example 27 Production of N,N-dimethyl-3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide i) Production of 3-cyano-N,N-dimethylbenzamide 3-Cyanobenzoic acid (12.60 g) was dissolved in THF (200 zs ml) and thionyl chloride (13.0 g) and DMF (0.05 ml) were added.
The mixture was stirred at 60°C for 2 hrs. The reaction mixture was concentrated under reduced pressure and re-dissolved in THF (100 ml). The solution was slowly added to 50% aqueous dimethylamine solution (80 ml) cooled to 5°C. The 3o reaction mixture was stirred at room temperature for one hr.
and extracted with ethyl acetate. The extract was dried and concentrated, and the residue was recrystallized from hexane-diisopropyl ether to give the title compound (8.00 g) as colorless powder crystals.
1H-NMR (CDC13) 8: 2.99 (3H, s), 3.13 (3H, s), 7.55 (1H, t, J=8.1 Hz), 7.64 - 7.74 (3H, m).
IR (KBr): 3054, 2228, 1613, 1580 cm 1.
s ii) Production of 3-(aminocarbonothionyl)-N,N-dimethylbenzamide 3-Cyano-N,N-dimethylbenzamide (7.90 g) was dissolved in ethanol (500 ml) and triethylamine (2.0 ml), and hydrogen sulfide gas was blown in at room temperature for 30 min. The io mixture was stirred at room temperature for 4 days and the solvent was evaporated under reduced pressure. The residue was washed with ethyl acetate to give the title compound (8.60 g) as a brown powder.
1H-NMR (DMSO-db)8: 2.91 (3H, s), 3.00 (3H, s), 7.42 - 7.57 (2H, is m), 7.86 - 7.98 (2H, m), 9.59, (1H, brs), 9.97 (1H, brs).
IR (KBr): 3210, 3056, 1615, 1601 cm 1.
iii) Production of N,N-dimethyl-3-(4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 2-Bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromate ao (1.53 g) and 3-(aminocarbonothionyl)-N,N-dimethylbenzamide (1.00 g) were suspended in ethanol (20 ml) and the mixture was heated under reflux for 2 hrs. Aqueous sodium hydrogen carbonate was added to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was dried as and concentrated, and the residue was subjected to silica gel column chromatography (eluent, methanol: ethyl acetate=1:40) for purification. The eluate was recrystallized from ethyl acetate-diisopropyl ether to give the title compound (1.26 g) as pale-yellow powder crystals.
30 1H-NMR (CDC13) 8: 2.54 (3H, s), 3.03 (3H, s), 3.15 (3H, s), 7.22 (1H, d, J=5.2 Hz), 7.38 - 7.41 (1H, m), 7.46 - 7»60 (2H, m), 8.00 - 8.10 (2H, m), 8.48 (1H, d, J=5.2 Hz), 8.81 (1H, s).
IR (KBr): 2930, 1634, 1395 cm 1.

Example 28 Production of 4-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide i) Production of 4-cyanobenzamide s By the reaction in the same manner as in Example 25-i) using 4-cyanobenzoyl chloride (5.30 g) and 28$ aqueous ammonia (20 ml), the title compound (3.62 g) was obtained by pale-brown needle crystals.
1H-NNfft (CDC13+CD30D) b: 7.76 (2H, d, J=8.1 Hzj, 7.96 (2H, d, J=
8.1 Hz) .
IR (KBr): 3443, 3177, 2230, 1701, 1618, 1561, 1414, 1399 cm 1.
ii) Production of 4-(aminocarbonothionyl)benzamide By the reaction in the same manner as in Example 25-ii) using 4-cyanobenzamide (2.66 g), the title compound (3.05 g) i5 was obtained as a yellow powder.
1H-Nl~t ( DMSO-d6 ) 8: 7 . 51 ( 1H, brs ) , 7 . 80-7 . 98 ( 4H, m) , 8 . 08 ( 1H, brs), 9.61 (1H, brs), 10.01 (1H, brsj.
IR (KBr): 3164, 1659, 1632, 1568, 1427 cm 1.
iii) Production of 4-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-2o yl]benzamide By the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromate (503 mg) and 4-(aminocarbonothionyl)benzamide (232 mg), the title compound (300 mg) was obtained as an amorphous compound.
2s 1H-NI~t (DMSO-d6)b: 2.54 (3H, s), 7.38 (1H, d, J= 4.9 Hz), 7.52 (1H, brs), 7.96-8.18 (6H, m), 8.47 (1H, d, J= 4.9 Hz), 8.85 (1H, s).
IR (KBr): 3169, 1703, 1416, 1397 cm 1.
Example 29 3o Production of N-methyl-4-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide i) Production of 4-cyano-N-methylbenzamide By the reaction in the same manner as in Example 26-ij using 4-cyanobenzoyl chloride (5.17 g) and 40% aqueous methylamine solution (20 ml), the title compound (4.13 g) was obtained as colorless powder crystals.
1H-NMR (CDC13) S: 3.04 (3H, d, J= 4.8 Hz), 6.23 (1H, brs), 7.74 s (2H, d, J=8.5 Hz), 7.86 (2H, d, J= 8.5 Hz).
IR (KBr): 3341, 2228, 1644, 1555 cm 1.
ii) Production of 4-(aminocarbonothionyl)-N-methylbenzamide By the reaction in the same manner as in Example 25-ii) using 4-cyano-N-methylbenzamide (2.04 g), the title compound io (2'.26 g) was~obtained as a yellow powder.
1H-NMR (DMSO-d6)8: 2.79 (3H, d, J= 4.4 Hz), 7.83 (2H, d, J= 8.8 Hz), 7.92 (2H, d, J= 8.8 Hz), 8.50-8.64 (1H, m), 9.61 (1H, brs), 10.01 (1H, brs).
IR (KBr): 3113, 1634, 1547 cm 1.
is iii) Production of N-methyl-4-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide By the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromate (482 mg) and 4-(aminocarbonothionyl)-N-methylbenzamide (243 so mg), the title compound (207 mg) was obtained as an amorphous compound.
1H-NMR (DMSO-d6) b: 2.54 (3H, s), 2.81 (3H, d, J= 4.4 Hz), 7.38 (1H, d, J= 5.2 Hz), 7.98 (2H, d, J= 8.6 Hz), 8.11 (2H, d, J=
8.6 Hz), 8.11 (1H, s), 8.47 (1H, d, J= 5.2 Hz), 8.54-8.67 (1H, 2s m), 8.85 (1H, s).
IR (KBr): 3343, 1645, 1563 cm 1.
Example 30 Production of N,4-dimethyl-3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 3o i) Production of 3-iodo-N,4-dimethylbenzamide 3-Iodo-4-methylbenzoic acid (9.84 g) was dissolved in THF
(50 ml) and thionyl chloride (4 ml) and DMF (0.05 ml) were added. The mixture was heated under reflux for 3 hrs. The reaction mixture was concentrated under reduced pressure to give 3-iodo-4-methylbenzoyl chloride (10.18 g) as a brown powder. Then, by the reaction in the same manner as .in Example 26-i), the title compound (3.47 g) was obtained from a s solution of 3-iodo-4-methylbenzoyl chloride (4.00 g) and methylamine in THF (2M, 30 ml) as colorless powder crystals 1H-NMR (CDC13) b: 2.46 (3H, s), 3.00 (3H, d, J=5.2 Hz), 6.1s (1H, brs), 7.28 (1H, d, J=7.6 Hz), 7.64 (1H, dd, J=1.8, 7.6 Hz), 8.19 (1H, d, J=1.8 Hz).
so IR (KBr): 3322, 1638, 1549, 1480, 1410, 1316, 1265, 667 cm'1.
ii) Production of 3-cyano-N,4-dimethylbenzamide 3-Iodo-N,4-dimethylbenzamide (772 mg), tetrakistriphenylphosphinepalladium (30 mg) and zinc cyanide (250 mg) were suspended in DMF (10 ml) under a nitrogen is atmosphere, and the mixture was stirred at 120°C for 12 hrs.
The reaction mixture was diluted with 5$ aqueous ammonia-ethyl acetate and the organic layer was washed with water and saturated brine. The organic layer was dried and concentrated, and the residue was subjected to silica gel column ao chromatography (eluent, hexane:ethyl acetate=2:1-0:1) for purification. The eluate was recrystallized from ethyl acetate-hexane to give the title compound (300 mg) as colorless powder crystals.
1H-NMR (CDC13)S: 2.60 (3H, s), 3.02 (1H, d, J=4.8 Hz), 6.31 (1H, 2s brs), 7.40 (1H, d, J=8.0 Hz), 7.90 (1H, dd, J= 1.8, 8.0 Hz), 8.01 (1H, d, J=1.8 Hz).
IR (KBr): 3349, 2228, 1647, 1561 coil.
iii) Production of 3-(aminocarbonothionyl)-N,4-dimethylbenzamide 3o By the reaction in the same manner as in Example 26-ii) using 3-cyano-N,4-dimethylbenzamide (1.75 g), a crude title compound (2.80 g) was obtained.
1H-NMR (DMSO-d6)8: 2.35 (3H, s), 2.76 (3H, d, J=4.4 Hz), 7.28 (1H, d, J=8.4 Hz), 7.66 - 7.76 (2H, m), 8.38 - 8.51 (1H, m), 9.56 (1H, brsj, 10.09 (1H, brs).
IR (KBr): 3297, 3125, 1622, 1559 cm 1.
iv) Production of N,4-dimethyl-3-[4-(4-methylpyridin-3-yl)-s 1,3-thiazol-2-yl]benzamide By the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromate (76 mg) and 3-(aminocarbonothionyl)-N,4-dimethylbenzamide (50 mg), the title compound (44 mg) was obtained as colorless so powder crystals.
1H-NNBt (DMSO-d6)b: 2.53 (3H, s), 2.66 (3H, s), 2.81 (3H, d, J=4.8 Hz), 7.38 (1H, d, J=5.2 Hz), 7.50 (1H, d, J=7.9 Hz), 7.87 (1H, dd, J=1.8, 7.8 Hz), 8.15 (1H, s), 8.25 (1H, d, J=1.8 Hz), 8.46 (1H, d, J=5.2 Hz), 8.52 - 8.64 (1H, m), 8.84 (1H, s).
is IR (KBr): 3340, 3044, 1663, 1551 cm 1.
Example 31 Production of N,N,4-trimethyl-3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide i) Production of 3-iodo-N, N,4-trimethylbenzamide ao By the reaction in the same manner as in Example 27-i) using 3-iodo-4-methylbenzoyl chloride (2.00 g) and 50$ aqueous dimethylamine solution (20 ml), the title compound (1.72 g) was obtained as a pale-yellow oil.
1H-NI~t (CDC13)8: 2.45 (3H, s), 2.99 (3H, brs), 3.08 (3H, brs), Zs 7.20 - 7.34 (2H, m), 7.87 (1H, d, J=1.4 Hz).
IR (KBr): 2926, 1634, 1395 cm 1.
ii) Production of 3-cyano-N, N,4-trimethylbenzamide By the reaction in the same manner as in Example 30-ii) using 3-iodo-N,N,4-trimethylbenzamide (1.65 g), 3o tetrakistriphenylphosphinepalladium (80 mg) and zinc cyanide (510 mg), the title compound (1.41 g) was obtained as a colorless oil (containing ethyl acetate).
1H-Nl~t (CDC13)8: 2.59 (3H, s), 3.03 (3H, s), 3.17 (3H, s), 7.39 (1H, d, J=7.9 Hz), 7.62 (1H, dd, J=1.8, 8.0 Hz), 7.69 (1H, d, J=1.8 Hz).
IR (KBr): 2936, 2226, 1634, 1404 cm 1.
iii) Production of N,N,4-trimethyl-3-[4-(4-methylpyridin-3-s yl)-1,3-thiazol-2-yl]benzamide By the reaction in the same manner as in Example 27-ii) using 3-iodo-N,N,4-trimethylbenzamide (1.30 g), crude 3-(aminocarbonothionyl)-N,N,4-trimethylbenzamide (871 mg} was obtained. Then, the title compound (19 mg) was obtained as a io pale-yellow amorphous compound from 2-bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromate (750 mg) and 3-(aminocarbonothionyl)-N,N,4-trimethylbenzamide (482 mg) by the reaction in the same manner as in Example 27-iii).
1H-Nl~t (CDC13)8: 2.56 (3H, s), 2.69 (3H, s), 3.04 (3H, brs), is 3.13 (3H, brs), 7.22 (1H, d, J=4.7 Hz), 7.34 - 7.46 (2H, m), 7.46 (1H, s), 7.86 (1H, d, J=1.2 Hz), 8.47 (1H, d, J=4.7 Hz), 8.83 (1H, s).
IR (KBr): 2924, 1632, 1397 cm 1.
Example 32 ao Production of 4-methyl-3-{2-[2-methyl-5-(pyrrolidine-1-ylcarbonyl)phenyl]-1,3-thiazol-4-yl}pyridine i) Production of 1-(3-iodo-4-methylbenzoyl)pyrrolidine By the reaction in the same manner as in Example 26-i) using 3-iodo-4-methylbenzoyl chloride (2.00 g) and pyrrolidine Zs (3.5 ml), the title compound (1.62 g) was obtained as a pale-yellow oil.
1H-Nl~t (CDC13)S: 1.80 - 2.04 (4H, m), 2.45 (3H, s), 3.43 (2H, t, J=6.4 Hz), 3.62 (2H, t, J=6.7 Hz), 7.24 (1H, d, J=7.5 Hz), 7.40 (1H, dd, J=1.8, 7.5 Hz), 7.97 (1H, d, J=1.8 Hz).
3o IR (KBr): 2971, 1624, 1422 cm 1.
ii) Production of 1-(3-cyano-4-methylbenzoyl)pyrrolidine By the reaction in the same manner as in Example 30-ii) using 1-(3-iodo-4-methylbenzoyl)pyrrolidine (1.55 g), tetrakistriphenylphosphinepalladium (80 mg) and zinc cyanide (460 mg), the title compound (1.44 g) was obtained as a colorless oil (containing ethyl acetate).
1H-NI~t (CDC13)8: 1.80 - 2.05 (4H, m), 2.58 (3H, s), 3.46 (2H, t, s J=6.2 Hz), 3.72 (2H, t, J=6.7 Hz), 7.38 (1H, d, J=8.0 Hz), 7.72 (1H, dd, J=1.8, 8.0 Hz), 7.79 (1H, d, J=1.8 Hz).
IR (KBr): 2975, 2228, 1620, 1445 cmil.
iii) Production of 4-methyl-3-{2-[2-methyl-5-(pyrrolidin-1-ylcarbonyl)phenyl]-1,3-thiazol-4-ylypyridine so By the reaction in the same manner as in Example 27-ii) using 1-(3-cyano-4-methylbenzoyl)pyrrolidine (1.24 g), crude 2-methyl-5-(pyrrolidine-1-ylcarbonyl)benzenecarbothioamide (767 mg) was obtained. Then, by the reaction in the same manner as in Example 25-iii), the title compound (44 mg) was is obtained as a pale-yellow amorphous compound from 2-bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromate (750 mg) and 2-methyl-5-(pyrrolidin-1-ylcarbonyl)benzenecarbothioamide (534 mg).
1H-NI~t (CDC13)8: 1.60 - 2.10 (4H, m), 2.55 (3H, s), 2.69 (3H, 2o s), 3.49 (2H, t, J=6.5 Hz), 3.67 (2H, t, J=6.8 Hz), 7.22 (1H, dd, J=0.8, 5.0 Hz), 7.37 (1H, dd, J= 0.8, 7.5 Hz), 7.46 (1H, s), 7.51 (1H, dd, J=1.7, 7.5 Hz), 7.97 (1H, d, J=1.7 Hz), 8.47 (1H, d, J=5.0 Hz), 8.83 (1H, s).
IR (KBr): 2971, 1622, 1429 cm 1.
2s Example 33 Production of 4-fluoro-N-methyl-3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide i) Production of 3-cyano-4-fluoro-N-methylbenzamide By the reaction in the same manner as in Example 30-ii) 3o using 3-bromo-4-fluoro-N-methylbenzamide (777 mg), tetrakistriphenylphosphinepalladium (40 mg) and zinc cyanide (270 mg), the title compound (210 mg) was obtained as colorless needle crystals.

1H-Nl~t (CDC13)b: 3.03 (3H, d, J=4.6 Hz), 6.19 (1H, brs), 7.28 -7.38 (1H, m), 7.99 - 8.12 (2H, m).
IR (KBr): 3328, 3069, 2236, 1638, 1495 cm 1.
ii) Production of 3-(aminocarbonothionyl)-4-fluoro-N-s methylbenzamide By the reaction in the same manner as in Example 27-ii) using 3-cyano-4-fluoro-N-methylbenzamide (180 mg), the title compound (210 mg) was obtained as a colorless powder.
1H-Nl~llt (CDC13+CD30D)8: 2.94 - 3.04 (3H, m) , 7.17 ( 1H, dd, J=8.8, io 11.2 Hz), 7.49 (1H, brs), 7.92 - 8.03 (1H, m), 8.42 (1H, dd, J=2.2, 7.6 Hz).
IR (KBr): 3275, 3131, 1655, 1630 cm 1.
iii) Production of 4-fluoro-N-methyl-3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide is By the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromate (260 mg) and 3-(aminocarbonothionyl)-4-fluoro-N-methylbenzamide (167 mg), the title compound (142 mg) was obtained as pale-yellow powder crystals.
20 1H-NI~llt ( DMSO-d6 ) 8: 2 . 54 ( 3H, s ) , 2 . 82 ( 3H, dd, J= 4 . 4 Hz ) , 7 . 40 (1H, d, J=5.2 Hz), 7.58 (1H, dd, J=8.8, 11.0 Hz), 7.96 - 8.08 (1H, m), 8.22 (1H, s), 8.49 (1H, d, J=5.2 Hz), 8.65 - 8.86 (2H, m), 8.89 (1H, s).
IR (KBr): 3254, 3102, 1653, 1507 cm 1.
zs Example 34 Production of 2-chloro-N-methyl-5-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide i) Production of 2-chloro-5-cyano-N-methylbenzamide By the reaction in the same manner as in Example 30-ii) 3o using 5-bromo-2-chloro-N-methylbenzamide (677 mg), tetrakistriphenylphosphinepalladium (40 mg) and zinc cyanide (206 mg), the title compound (339 mg) was obtained as colorless needle crystals.

' CA 02431171 2003-06-06 1H-NNgt (CDClj)8: 3.05 (3H, d, J=4.8 Hz), 6.23 (1H, brs), 7.54 (1H, d, J=8.0 Hz), 7.65 (1H, dd, J=1.8, 8.0 Hz), 7.97 (1H, d, J=1.8 Hz).
IR (KBr): 3277, 2238, 1653, 1551 cm 1.
s ii) Production of 5-(aminocarbonothionyl)-2-chloro-N-methylbenzamide By the reaction in the same manner as in Example 27-ii) using 2-chloro-5-cyano-N-methylbenzamide (310 mg), the title compound (320 mg) was obtained as a yellow powder.
1H-NMR (DMSO-d6)8: 2.77 (3H, d, J=4.4 Hz), 7.56 (1H, d, J=9.2 Hz), 7.88 - 8.02 (2H, m), 8.38 - 8.54 (1H, m), 9.63 (1H, brs), 10.03 (1H, brs).
IR (KBr): 3289, 3177, 1634, 1549, 1408, 1285 cm 1.
iii) Production of 2-chloro-N-methyl-5-[4-(4-methylpyridin-3-I5 yl)-1,3-thiazol-2-yl]benzamide By the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-methylpyridin-3-yl)ethanone hydrvbromate (180 mg) and 5-(aminocarbonothionyl)-2-chloro-N-methylbenzamide (132 mg), the title compound (138 mg) was zo obtained as pale-yellow powder crystals.
1H-NI~t (DMSO-d6)8: 2.52 (3H, s), 2.79 {3H, d, J=4.4 Hz), 7.38 (1H, d, J=4.9 Hz), 7.66 (1H, d, J=8.3 Hz), 8.01 (1H, d, J=2.2 Hz), 8.07 (1H, dd, J=2.2, 8.3 Hz), 8.11 (1H, s), 8.46 (1H, d, J=4.9 Hz), 8.50 - 8.62 (1H, m), 8.84 (1H, s).
2s IR (KBr): 3277, 1645, 1063 c~ 1.
Example 35 Production of N-{3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]phenyl}acetamide i) Production of N-(3-cyanophenyl)acetamide 30 3-Aminobenzonitrile (5.70 g) and N,N-dimethylaminopyridine (20 mg) were dissolved in pyridine (40 ml) and the mixture was cooled to 5°C. Acetic anhydride (5.8 ml) was added and the mixture was stirred at room temperature for 12 hrs. The reaction mixture was concentrated under reduced pressure. Ethyl acetate and 1N hydrochloric acid were added to the residue, and the organic layer was washed with 1N
hydrochloric acid, saturated aqueous sodium hydrogen carbonate, s and saturated brine. The organic layer was dried, concentrated and recrystallized from hexane-ethyl acetate to give the title compound (5.78 g) as pale-brown powder crystals.
1H-NNgt (CDC13)8: 2.21 (3H, s), 7.34 - 7.48 (2H, m), 7.62 (1H, brs), 7.72 (1H, dt, J=7.0, 2.4 Hz), 7.93 (1H, s).
io IR (KBr): 3303, 3272, 2228, 1667, 1559 c~ 1.
ii) Production of N-[3-(aminocarbonothionyl)phenyl]acetamide By the reaction in the same manner as in Example 27-ii) using N-(3-cyanophenyl)acetamide (2.05 g), the title compound (2.09 g) was obtained as a yellow powder.
15 1H-NMR (DMSO-d6)8: 2.05 (3H,. s), 7.25 - 7.48 (2H, s), 7.78 (1H, d, J=8.0 Hz), 8.05 (1H, s), 9.48 (1H, brs), 9.87 (1H, brs), 10.11 (1H, s).
IR (KBr): 3260, 3152, 1663, 1611, 1586, 1551, 1445 ciril.
iii) Production of N-~3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-ao 2-yl]phenyl}acetamide By the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromate (315 mg) and N-[3-(aminocarbonothionyl)phenyl]acetamide (197 mg), the title compound (142 mg) was obtained as a yellow 25 amorphous compound.
1H-Nl~t ( CDC13+CD30D ) 8: 2 . 21- ( 3H, s ) , 2 . 52 ( 3H, s ) , 7 . 21 ( 1H, d, J=5.2 Hz), 7.34 (1H, s), 7.40 (1H, d, J=8.2 Hz), 7.66 - 7.80 (2H, m), 8.08 - 8.22 (2H, m), 8.46 (1H, d, J=5.2 Hz), 8.81 (1H, s).
3o IR (KBr): 3056, 2988, 1684, 1615, 1561 c~ 1.
Example 36 Production of N-{4-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]phenyl}acetamide i) Production of N-(4-cyanophenyl)acetamide By the reaction in the same manner as in Example 35-i) using 4-aminobenzonitrile (5.51 g) and acetic anhydride (5.7 ml), the title compound (5.88 g) was obtained as colorless s needle crystals.
1H-NMR (CDC13+CD30D)S: 2.20 (3H, s), 7.59 (2H, d, J=8.7 Hz), 7.68 (2H, d, J=8.7 Hz).
IR (KBr): 3304, 3260, 2222, 1667, 1599 cm'1.
ii) Production of N-[4-(aminocarbonothionyl)phenyl]acetamide io By the~reaction in the same manner as in Example 27-ii) using N-(4-cyanophenyl)acetamide (1.92 g), the title compound (2.17 g) was obtained as a pale-yellow powder.
1H-NMIt (DMSO-d6)8: 2.07 (3H, s), 7.60 (2H, d, J=8.8 Hz), 7.90 (2H, d, J=8.8 Hz), 9.36 (1H, brs), 9.71 (1H, brs).
I5 IR (KBr): 3283, 3112, 1667, 1593, 1412 cm 1.
iii) Production of N-.(4-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]phenyl}acetamide By the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-methylpyridin-3-yljethanone hydrobromate ao (313 mg) and N-[4-(aminocarbonothionyl)phenyl]acetamide (194 mg), the title compound (172 mg) was obtained as colorless needle crystals.
1H-NMR (DMSO-d6)8: 2.09 (3H, s), 2.52 (3H, s), 7.36 (1H, d, J=5.0 Hz), 7.74 (2H, d, J=8.8 Hz), 7.95 (2H, d, J=8.8 Hz), 2s 7.96 (1H, s), 8.65 (1H, d, J=5.0 Hz), 8.82 (1H, s).
IR (KBr): 3042, 1690, 1603, 1543 cm 1.
Example 37 Production of 4-methyl-3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]phenylformamide so 4-Methyl-3-[2-(2-methyl-5-nitrophenyl)-1,3-thiazol-4-yl]pyridine (98 mg) and reduced iron (170 mg) were suspended in a mixture of formic acid (3 ml)-ethyl formate (3 ml). 1N
Hydrochloric acid (0.2 ml) was added and the mixture was stirred at 80°C for 12 hrs. The reaction mixture was diluted with ethyl acetate and the insoluble material was filtered off.
The organic layer was neutralized with saturated aqueous sodium hydrogen carbonate. The organic layer was separated and s concentrated by drying. The residue was subjected to silica gel column chromatography (eluent, hexane: ethyl acetate=1:1-0:1) for purification. Recrystallization from ethyl acetate gave the title compound (15 mg) as pale-yellow columnar crystals.
so 1H-NMR (DMSO-d6)8: 2.53 (3H, s), 2.57 (3H, s), 7.30 - 7.42 (2H, m), 7.61 (1H, dd, J=2.2, 8.4 Hz), 8.10 (1H, s), 8.18 (1H, d, J=2.2 Hz), 8.32 (1H, s), 8.46 (1H, d, J=4.8 Hz), 8.83 (1H, s), 10.34 (1H, s).
IR (KBr): 2861, 1686, 1620 cm 1.
i5 Example 38 Production of N-f4-methyl-3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]phenyl}acetamide 4-Methyl-3-[2-(2-methyl-5-nitrophenyl)-1,3-thiazol-4-yl]pyridine (100 mg) and reduced iron (180 mg) were suspended 2o in acetic acid (2 ml)-acetic anhydride (0.04 ml) and the mixture was stirred at 70°C for 4 hrs. The reaction mixture was diluted with ethyl acetate and the insoluble material was filtered off. The organic layer was neutralized with saturated aqueous sodium hydrogen carbonate. The organic layer was as separated and concentrated by drying. The residue was subjected to silica gel column chromatography (eluent, hexane: ethyl acetate=1:1-0:1) for purification.
Recrystallization from ethyl acetate gave the title compound (43 mg) as colorless powder crystals.
30 1H-NMR (CDC13)8: 2.19 (3H, s), 2.54 (3H, s), 2.61 (3H, s), 7.18 - 7.30 (2H, m), 7.42 (1H, s), 7.58 (1H, dd, J=2.2, 8.4 Hz), 7.71 (1H, brs), 7.94 (1H, d, J=2.2 Hzj, 8.46 (1H, d, J=4.8 Hz), 8.82 (1H, s).

IR (KBrj: 1671, 1613, 1541 cm 1.
Example 39 Production of 4-methyl-3-[2-(2-pyridyl)-1,3-thiazol-4-yl]pyridine s i) Production of pyridine-2-carbothioamide By the reaction in the same manner as in Example 25-ii) using 2-cyanopyridine (5.20 g), the title compound (4.73 g) was obtained as a yellow powder.
1H-NNat (DMSO-d6)b: 7.55-7.66 (1H, m), 7.90-8.04 (1H, m), 8.46-8.64 (2H, m), 9.95 (1H, brs), 10.19 (1H, brs).
IR (KBr): 3353, 3154, 1603, 1582 cm'1.
ii) Production of 4-methyl-3-[2-(2-pyridyl)-1,3-thiazol-4-yl]pyridine By the reaction in the same manner as in Example 25-iii) is using 2-bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromate (446 mg) and pyridine-2-carbothioamide (157 mg), the title compound (67 mg) was obtained as pale-red powder crystals.
1H-NMR (CDC13)b: 2.55 (3H, s), 7.23 (1H, d, J= 4.9 Hz), 7.30-7.42 (1H, m), 7.48 (1H, s), 7.83 (1H, dt, J= 1.4, 7.9 Hz), 8.26 (1H, d, J=7.6 Hz), 8.48 (1H, d, J= 4.9 Hz), 8.60-8.70 (1H, m), 8.84 (1H, s).
. IR (KBr): 3100, 1582, 1433 cm 1.
Example 40 Production of 4-methyl-3-[2-(3-pyridyl)-1,3-thiazol-4-Zs yl]pyridine By the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromate (432 mg) and thionicotinamide (152 mg), the title compound (110 mg) was obtained as colorless powder crystals.
1H-NNgt ( CDC13 ) 8 : 2 . 55 ( 3H, s j , 7 . 24 ( 1H, d, J=5 . 0 Hz ) , 7 . 37-7.46 (2H, m), 8.26-8.36 (1H, m), 8.49 (1H, d, J= 5.0 Hz), 8.69 (1H, dd, J= 1.8, 4.8 Hz), 8.82 (1H, s), 9.24 (1H, dd, J= 1.0, 2.2 Hzj.

IR (KBr): 3046, 1597, 1466 c~ 1.
Example 41 Production of 4-methyl-3-[2-(4-pyridyl)-1,3-thiazol-4-yl]pyridine s By the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromate (428 mg) and thioisonicotinamide (153 mg), the title compound (77 mg) was obtained as colorless powder crystals.
1H-NMR (CDC13)S: 2.55 (3H, s), 7.24 (1H, d, J= 5.0 Hz), 7.51 1o (1H, s), 7.88 (2H, dd, J= 1.8, 4.4 Hz), 8.50 (1H, d, J=5.0 Hz), 8.74 (2H, dd, J=1.8, 4.4 Hz), 8.82 (1H, s).
IR (KBr): 3044, 1597, 1468, 820 c~ 1.
Example 42 Production of 5-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-is yl]nicotinamide i) Production of 5-bromonicotinamide 5-Bromonicotinic acid (5.05 g), ammonium chloride (2.10 g), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (7.30 g), 1-hydroxy-1H-benzotriazole monohydrate 20 (3.90 g) and triethylamine (5.5 ml) were suspended in DMF (40 ml) and the mixture was stirred at room temperature for 16 hrs.
Ethyl acetate and water were added to the reaction mixture and the organic layer was washed with saturated aqueous sodium hydrogen carbonate; water and saturated brine. The organic 2s layer was concentrated by drying and recrystallized from ethyl acetate to give the title compound (2.33 g) as colorless needle crystals.
1H-NMR (CDC13+CD30D)8: 8.41 (1H, t, J= 2.2 Hz), 8.77 (1H, d, J=2.2 Hz), 8.94 (1H, d, J=2.2 Hz).
3o IR (KBr): 3389, 3194, 3032, 1657, 1620 cm 1.
ii) Production of 5-cyanonicotinamide 5-Bromonicotinamide (905 mgj and copper cyanide (630 mg) were suspended in D1~' (15 ml) and the mixture was stirred at 140°C for 24 hrs. Aqueous ammonia was added to the reaction mixture at room temperature and the solvent was evaporated under reduced pressure. The residue was subjected to silica gel column chromatography (eluent, methanol: ethyl s acetate=1:10) for purification to give the title compound (110 mg) as a colorless powder.
1H-NMR (DMSO-d6)b: 7.88 (1H, s), 8.31 (1H, s), 8.67 (1H, s), 9.20 (1H, brs), 9.27 (1H, brs).
IR (KBr): 3398, 3198, 2238, 1663 cm 1.
io iii) Production of 5-(aminocarbothionyl)nicotinamide By the reaction in the same manner as in Example 25-ii) using 5-cyanonicotinamide (80 mgj, the title compound (62 mg) was obtained as a yellow powder.
1H-NMR (DMSO-d6)8: 7.73 (1H, s), 8.26 (1H, s), 8.50-8.60 (1H, i5 m), 8.98-9.16 (2H, m), 9.83 (1H, sj,.10.19 (1H, s).
IR (KBr): 3137, 1699, 1630, 1410 cm 1.
iv) Production of 5-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]nicotinamide By the reaction in the same manner as in Example 25-iii) so using 2-bromo-1-{4-methylpyridin-3-yl)ethanone hydrobromate (64 mg) and 5-(aminocarbothionyljnicotinamide (37 mg), the title compound (16 mg) was obtained as colorless powder crystals.
1H-NMR {DMSO-d6jS: 2.54 (3H, s), 7.39 {1H, d, J=5.1 Hz), 7.80 as (1H, s), 8.19 (1H, s), 8.41 {1H, s), 8.48 (1H, d, J=5.1 Hz), 8.75 (1H, t, J=2.3 Hz), 8.87 (1H, s), 9.13 {1H, d, J=2.3 Hzj, 9.34 (1H, d, J=2.3 Hzj.
IR (KBr): 3316, 3131, 1713, 1420 cnil.
Example 43 3o Production of N-methyl-5-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]nicotinamide i) Production of 5-cyano-N-methylnicotinamide By the reaction in the same manner as in Example 30-ii) using 5-bromo-N-methylnicotinamide (3.11 g), tetrakistriphenylphosphinepalladium (160 mg) and zinc cyanide (1.09 g), the title compound (420 mg) was obtained as colorless powder crystals.
s 1H-NMR (CDC13+CD30D)8: 3.00 (3H, s), 8.49 (1H, t, J=2.1 Hz), 8.96 (1H, d, J=2.1 Hz), 9.18 (1H, d, J=2.1 Hz).
IR (KBr): 3310, 2234, 1651, 1559 cm 1.
ii) Production of 5-(aminocarbonothionyl)-N-methylnicotinamide By the reaction in the same manner as in Example 25-ii) so using 5-cyano-N-methylnicotinamide (380 mg), the title compound (436 mg) was obtained as a pale-green powder.
1H-NMR (CDC13+CD30D)8: 3.00 (3H, s), 8.56 (1H, t, J= 2.2 Hz), 9.01 (1H, d, J= 2.2 Hz), 9.16 (1H, d, J= 2.2 Hz).
IR (KBr): 3330, 3127, 1642, 1287 cm'1.
is iii) Production of N-methyl-5-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]nicotinamide By the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromate (470 mg) and 5-(aminocarbonothionyl)-N-methylnicotinamide (238 ao mg), the title compound (193 mg) was obtained as pale-yellow powder crystals.
1H-NMR (DMSO-d6)8: 2.54 (3H, s), 2.85 (3H, d, J= 4.6 Hz), 7.39 (1H, d, J= 5.2 Hz), 8.18 (1H, s), 8.48 (1H, d, J= 5.2 Hz), 8.72 (1H, t, J= 2.2 Hz), 8.80-8.94 (1H, m), 8.86 (1H, s), 9.09 2s (1H, d, J= 2.2 Hz),9.33 (1H, d, J= 2.2 Hz).
IR (KBr): 3233, 1669, 1551, 1435 c~ 1.
Example 44 Production of N-ethyl-5-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]nicotinamide 3o i) Production of 5-bromo-N-ethylnicotinamide By the reaction in the same manner as in Example 42-i) using 5-bromonicotinic acid (5.01 g), a solution (25 ml) of ethylamine in THF, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (7.30 g), 1-hydroxy-1H-benzotriazole monohydrate (3.97 g) and triethylamine (5.7 ml), the title compound (2.02 g) was obtained as colorless powder crystals.
1H-NMR (CDC13)b: 1.28 (3H, t, J= 6.3 Hz), 3.40-3.64 (2H, m), 6.14 (1H, brs), 8.26 (1H, t, J=2.2 Hz), 8.78 (1H, d, J=2.2 Hz), 8.85 (1H, d, J=2.2 Hz).
IR (KBr): 3301, 3027, 1640, 1537 c~ 1.
ii) Production of 5-cyano-N-ethylnicotinamide io By the reaction in the same manner as in Example 42-ii) using 5-bromo-N-ethylnicotinamide (580 mg) and copper cyanide (350 mg), the title compound (141 mg) was obtained as colorless powder crystals.
1H-NMR (CDC13+CD30D)S: 1.27 (3H, t, J=7.4 Hz), 3.48 (2H, q, J=7.4 Hz), 8.51 (1H, t, J=2.2 Hz), 8.95 (1H, d, J=2.2 Hz), 9.19 (2H, d, J=2.2 Hz).
IR (KBr): 3310, 3054, 2236, 1645, 1549 cm 1.
iii) Production of 5-(N-ethylaminocarbothionyl)nicotinamide By the reaction in the same manner as in Example 27-ii) zo using 5-cyano-N-ethylnicotinamide (120 mg), the title compound (99 mg) was obtained as a yellow powder.
1H-NMR (DMSO-d6)8: 1.15 (3H, t, J=7.1 Hz), 3.20-3.44 (2H, m), 8.55 (1H, t, J=2.2 Hz), 8.70-8.84 (1H, m), 9.20-9.12 (2H, m), 9.83 (1H, brs), 10.20 (1H, brs).
2s IR (KBr): 3285, 3146, 1663, 1545 cm 1.
iv) Production of N-ethyl-5-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]nicotinamide By the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromate 30 (104 mg) and 5-(N-ethylaminocarbothionyl)nicotinamide (70 mg), the title compound (60 mg) was obtained as colorless powder crystals.
1H-NMR (DMSO-d6)8: 1.17 (3H, t, J=7.2 Hz), 2.54 (3H, s), 3.20 -3.50 (2H, m), 7.39 (1H, d, J=4.8 Hz), 8.19 (1H, s), 8.48 (1H, d, J=4.8 Hz), 8.72 (1H, t, J=2.2 Hz), 8.87 (1H, s), 8.80 -8.99 (1H, m), 9.10 (1H, d, J=2.2 Hz), 9.33 (1H, d, J=2.2 Hz).
IR (KBr): 3148, 1738, 1657, 1549 cm 1.
s Example 45 Production of N-methyl-6-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]pyridine-2-carboxamide i) Production of 6-cyano-N-methylpyridine-2-carboxamide By the reaction in the same manner as in Example 30-ii) so using 6-bromo-N-methylpyridine-2-carboxamide (513 mg), tetrakistriphenylphosphinepalladium (70 mg) and zinc cyanide (315 mg), the title compound (200 mg) was obtained as colorless powder crystals.
1H-NN~t (CDC13)8: 3.06 (3H, d, J=5.1 Hz), 7.07-7.95 (1H, brs), is 7.82 (1H, dd, J=1.2, 7.8 Hz), 8.03 (1H, t, J=7.8 Hz), 8.43 (1H, dd, J=1.2, 7.8 Hz).
IR (KBr): 3366, 2247, 1680, 1537 cm 1.
ii) Production of 6-(aminocarbonothionyl)-N-methylpyridine-2-carboxamide 2o By the reaction in the same manner as in Example 25-ii) using 6-cyano-N-methylpyridine-2-carboxamide (192 mg), the title compound (208 mg) was obtained as a yellow powder.
1H-NMR (CDC13+CD30D)8: 3.03 (3H, s), 8.01 (1H, t, J=5.2 Hz), 8.31 (1H, dd, J=0.8, 5.2 Hz), 8.84 (1H, dd, J= 0.8, 5.2 Hz).
2s IR (KBr): 3162, 1651, 1622, 1541, 1456 cm 1.
iii) Production of N-methyl-6-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]pyridine-2-carboxamide By the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromate 30 (289 mg) and 6-(aminocarbonothionyl)-N-methylpyridine-2-carboxamide (144 mg), the title compound (121 mg) was obtained as pale-yellow powder crystals.
1H-NMR (CDC13)b: 2.56 (3H, s), 3.13 (3H, d, J= 3.4 Hz), 7.22-7.27 (1H, m), 7.53 (1H, s), 7.90-8.03 (1H, m), 7.99 (1H, t, J=
5.2 Hz), 8.27 (1H, dd, J= 0.8, 5.2 Hzj, 8.38 (1H, dd, J= 0.8, 5.2 Hz), 8.50 (1H, d, J= 3.2 Hz), 8.84 (1H, s).
IR (KBr): 3412, 3094, 1676, 1537 c~ 1.
s Example 46 Production of N-methyl-6-[4-(4-methylpyridin-3-ylj-1,3-thiazol-2-yl]nicotinamide i) Production of 6-chloro-N-methylnicotinamide By the reaction in the same manner as in Example 42-i) io using 6-chloronicotinic acid (5.67 g), a solution (2 M, 25 ml) of methylamine in THF, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (10.30 gj, 1-hydroxy-1H-benzotriazole monohydrate (5.90 g) and triethylamine (5.2 ml), the title compound (3.23 g) was obtained as colorless powder i5 crystals.
1H-NMR (CDC13)8: 3.03 (3H, d, J=4.8 Hz), 6.53 (1H, brs), 7.41 (1H, d, J=8.4 Hz), 8.10 (1H, dd, J=2.6, 8.4 Hz), 8.74 (1H, d, J=2.6 Hz).
IR (KBr): 3306, 3059, 1651, 1557 c~ 1.
2o ii) Production of 6-cyano-N-methylnicotinamide By the reaction in the same manner as in Example 30-iij using 6-chloro-N-methylnicotinamide (1.58 g), tetrakistriphenylphosphinepalladium (70 mg) and zinc cyanide (877 mg), the title compound (290 mg) was obtained as 2s colorless powder crystals.
1H-NMR (CDCI3jS: 3.07 (3H, d, J= 4.8 Hz), 6.34 (1H, brs), 7.80 (1H, dd, J= 0.6, 8.1 Hz), 8.27 (1H, dd, J= 2.2, 8.1 Hz), 9.04 (1H, dd, J= 0.6, 2.2 Hzj.
IR (KBr): 3293, 3092, 2236, 1645, 1559 cm 1.
3o iii) Production of 6-(aminocarbonothionyl)-N-methylnicotinamide By the reaction in the same manner as in Example 25-ii) using 6-cyano-N-methylnicotinamide (500 mg), the title compound (480 mg) was obtained as a yellow powder.
1H-NMR (DMSO-d6)S: 2.82 (3H, d, J=4.4 Hz), 8.32 (1H, dd, J=2.1, 8.4 Hz), 8.55 (1H, d, J=8.4 Hz), 8.70 - 8.88 (1H, m), 8.97 (1H, d, J=2.1 Hz), 10.03 (1H, brs), 10.29 (1H, brs).
s IR (KBr): 3370, 3333, 1640, 1599, 1551 cm 1.
iv) Production of N-methyl-6-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]nicotinamide By the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromate so (180 mg) and 6-(aminocarbonothionyl)-N-methylnicotinamide (109 mg), the title compound (92 mg) was obtained as a yellow amorphous compound.
1H-NMR (DMSO-d6)b: 2.54 (3H, s), 2.84 (3H, d, J=4.0 Hz), 7.38 (1H, d, J=5.0 Hz), 8.20 (1H, s), 8.29 (1H, d, J=8.4 Hz), 8.32 is - 8.42 (1H, m), 8.47 (1H, d, J=5.0 Hz), 8.70 - 8.84 (1H, m), 8.86 (1H, s), 9.05 (1H, t, J=0.9 Hz).
IR (KBr): 3312, 1645, 1593 cml.
Example 47 Production of 4-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-2o yl]isoindolin-1-one i) Production of 1-oxo-4-isoindolincarbonitrile By the reaction in the same manner as in Example 30-ii) using 4-bromoisoindolin-1-one (805 mg), tetrakistriphenylphosphinepalladium (140 mg) and zinc cyanide 2s (540 mg), the title compound (250 mg) was obtained as pale-yellow powder crystals.
1H-NMR (DMSO-d6)8: 4.59 (2H, s), 7.69 (1H, t, J=7.7 Hz), 8.00 (1H, d, J=7.7 Hz), 8.04 - 8.16 (1H, m), 8.92 (1H, brs).
IR (KBr): 3090, 2230, 1705 cm 1.
3o ii) Production of 4-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]isoindolin-1-one By the reaction in the same manner as in Example 25-ii) using 1-oxo-4-isoindolincarbonitrile (310 mg), 1-oxoisoindolin-4-carbothioamide was obtained as pale-green powder. Then, by the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromate (520 mg) and 1-oxoisoindolin-4-carbothioamide, s the title compound (51 mg) was obtained as colorless powder crystals.
1H-NMFt (DMSO-d6)8: 2.56 (3H, s), 4.79 (2H, s), 7.39 (1H, d, J=5.1 Hz), 7.68 (1H, t, J=7.3 Hz), 7.83 (1H, d, J=7.3 Hz), 8.16 (1H, s), 8.20 (1H, d, J=7.3 Hz), 8.47 (1H, d, J=5.1 Hz), io 8.80 (1H, brs), 8.90 (1H, s).
IR (KBr): 3077, 1698, 750 cm 1.
Example 48 Production of 2-methyl-4-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl)isoindolin-1-one is i) Production of 2-methyl-1-oxo-4-isoindolincarbonitrile By the reaction in the same manner as in Example 30-ii) using 4-bromo-2-methylisoindolin=1-one (808 mg), tetrakistriphenylphosphinepalladium (70 mg) and zinc cyanide (340 mg), the title compound (230 mg) was obtained as Zo colorless powder crystals.
1H-NMZt (DMSO-d6)S: 3.10 (3H, s), 4.68 (2H, s), 7.58 - 7.78 (1H, m), 7.99 (1H, d, J=7.2 Hz), 8.07 (1H, dd, J=0.8, 7.6 Hz).
IR (KBr): 2942, 2234, 1696 cm 1.
ii) Production of 2-methyl-4-[4-(4-methylpyridin-3-yl)-1,3-2s thiazol-2-yl)isoindolin-1-one By the reaction in the same manner as in Example 25-ii) using 2-methyl-1-oxo-4-isoindolincarbonitrile (364 mg), crude 2-methyl-1-oxoisoindolin-4-carbothioamide (603 mg) was obtained as a brown powder. Then, by the reaction in the same 3o manner as in Example 25-iii), 2-bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromate (500 mg) and 2-methyl-1-oxoisoindolin-4-carbothioamide (520 mg), the title compound (187 mg) was obtained as colorless powder crystals.

1H-NMR (DMSO-d6)S: 2.55 (3H, s), 3,14 (3H, s), 4.86 (2H, s), 7.40 (1H, d, J=4.2 Hz), 7.66 (1H, t, J=7.7 Hz), 7.81 (1H, d, J=7.7 Hz), 8.10 - 8.22 (2H, m), 8.48 (1H, d, J=4.2 Hz), 8.89 (1H, s).
s IR (KBr): 3079, 1701, 1468 cm 1.
Example 49 Production of 5-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]pyridin-2(1H)-one i) Production of 6-tert-butoxynicotinonitrile io By the reaction in the same manner as in Example 30-ii) using 6-bromonicotinonitrile (1.00 g), tetrakistriphenylphosphinepalladium (35 mg) and zinc cyanide (370 mg), the title compound (490 mg) was obtained as colorless needle crystals.
is 1H-NMR (CDC13)8: 1.60 (9H, s), 6.68 (1H, d, J=8.6 Hz), 7.70 (1H, dd, J=2.4, 8.6 Hz), 8.43 (1H, d, J=2.2 Hz).
IR (KBr): 2976, 2230, 1603, 1485 cm 1.
ii) Production of 6-tert-butoxy-3-pyridinecarbothioamide By the reaction in the same manner as in Example 25-ii) 2o using 6-tert-butoxynicotinonitrile (300 mg), the title compound (240 mg) was obtained as pale-yellow plate crystals.
1H-NMR (CDC13)8: 1.60 (9H, s), 6.63 (1H, dd, J=0.6, 8.8 Hz), 7.07 (1H, brs), 7.51 (1H, brs), 8.11 (1H, dd, J=2.7, 8.8 Hz), 8.64 (1H, dd, J=0.6, 2.7 Hz).
25 IR (KBr): 3144, 1620, 1595, 1323 c~ 1.
iii) 5-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]pyridin-2(1H)-one By the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromate 30 (188 mg) and 6-tert-butoxy-3-pyridinecarbothioamide (167 mg), the title compound (120 mg) was obtained as colorless powder crystals.
~H-NMR (DMSO-d6)8: 2.50 (3H, s), 6.49 (1H, d, J=9.6 Hz), 7.35 (1H, d, J=4.8 Hz), 7.90 (1H, s), 8.02 (1H, dd, J=2.7, 9.6 Hz), 8.11 (1H, d, J=2.7 Hz), 8.44 (1H, d, J=4.8 Hz), 8.01 (1H, s).
IR (KBr): 3090, 2768, 1682, 1601 cm 1.
Example 50 s Production of 3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]isoquinoline By the reaction in the same manner as in Example 25-iij using 3-isoquinolinecarbonitrile (1.07 g), crude isoquinoline-3-carbothioamide (1.26 g) was obtained as a yellow powder.
io Then, by the reaction in the same manner as in Example 25-iii), the title compound (449 mg) was obtained as colorless powder crystals from 2-bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromate (1.06 g) and isoquinoline-3-carbothioamide (795 mg).
is 1H-NMR (DMSO-d6)8: 2.58 (3H, s), 7.40 (1H, d, J=5.1 Hz), 7.71 -7.93 (2H, m), 8.12 (1H, s), 8.15 - 8.26 (2H, m), 8.48 (1H, d, J=5.1 Hz), 8.71 (1H, s), 8.90 (1H, s), 9.42 (1H, s).
IR (KBr): 3092, 1622, 1590, 1578 cm 1.
Example 51 2o Production of 1-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]isoquinoline i) Production of isoquinoline-1-carbothioamide By the reaction in the same manner as in Example 25-ii) using 1-isoquinolinecarbonitrile (1.01 g), the title compound Zs (1.08 g) was obtained as a pale-yellow powder.
1H-NI~t (DMSO-d6)b: 7.60 - 7.78 (2H, m), 7.84 (1H, d, J=5.6 Hz), 7.99 (1H, d, J=8.3 Hz), 8.26 (1H, d, J=8.3 Hz), 8.43 (1H, d, J=5.6 Hz), 10.00, (1H, brs), 10.43 (1H, brs).
IR (KBr): 3034, 1653, 1426, 835 cm 1.
3o ii) Production of 1-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]isoquinoline By the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromate (660 mg) and isoquinoline-1-carbothioamide (400 mg), the title compound (244 mg) was obtained as yellow powder crystals.
1H-NNgt (DMSO-d6)b: 2.60 (3H, s), 7.43 (1H, d, J=5.0 Hz), 7.80 -7.96 (2H, m), 8.02 (1H, d, J=5.6 Hz), 8.05 - 8.18 (1H, m), s 8.23 (1H, s), 8.51 (1H, d, J=5.0 Hz), 8.64 (1H, d, J=5.6 Hz), 8.93 (1H, s), 9.70 - 9.88 (1H, m).
IR (KBr): 3102, 1553, 1397, 949 cm 1.
Example 52 Production of 2,4-dimethoxy-5-[4-(4-methylpyridin-3-yl)-1,3-io thiazol-2-yl]pyrimidine i) Production of 2,4-dimethoxy-5-pyrimidinecarbonitrile By the reaction in the same manner as in Example 30-ii) using 5-bromo-2,4-dimethoxypyrimidine (4.97 g), tetrakistriphenylphosphinepalladium (200 mg) and zinc cyanide is (2.04 mg), the title compound (1.85 g) was obtained as colorless needle crystals.
1H-Nl~t (CDC13)b: 4.08, (3H, s), 4.12 (3H, s), 8.54 (1H, s).
IR (KBr): 2971, 2236, 1601, 1541 cm~l.
ii) Production of 2,4-dimethoxy-5-[4-(4-methylpyridin-3-yl)-Zo 1,3-thiazol-2-yl]pyrimidine By the reaction in the same manner as in Example 25-ii) using 2,4-dimethoxy-5-pyrimidinecarbonitrile (1.32 g), crude 2,4-dimethoxypyrimidine-5-carbothioamide {1.92 g) was obtained as a brown powder. Then, by the reaction in the same manner as zs in Example 25-iii) using 2-bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromate (1.07 g) and 2,4-dimethoxypyrimidine-5-carbothioamide (880 mg), the title compound (235 mg) was obtained as colorless powder crystals.
1H-NMR (CDC13)S: 2.55 (3H, s), 4.01 (3H, s), 4.24 (3H, s), 7.22 30 {1H, d, J=5.2 Hz), 7.44 (1H, s), 8.47 (1H, d, J=5.2 Hz), 8.81 (1H, s), 9.30 (1H, s).
IR {KBr): 3019, 1601, 1561 cm 1.
Example 53 Production of 3-[5-methyl-4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide i) Production of 1-(4-methylpyridin-3-yl)propan-1-one A solution of 4-methylnicotinonitrile (5.90 g) in diethyl s ether (75 ml) was cooled to 5°C and an ethylmagnesium bromide diethyl ether solution (3.0M, 25 ml) was gradually added thereto. The reaction mixture was heated under reflux for 2 hrs. and added to 1N hydrochloric acid (200 ml). The mixture was stirred at room temperature for 30 min. Sodium bicarbonate io was added to~neutralize the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried and concentrated, and the residue was subjected to silica gel column chromatography (eluent, hexane: ethyl acetate=3:1-2:1) for purification to give the title compound (5.07 g) as a is pale-red oil.
1H-NMR (CDC13)b: 1.23 (3H, t, J=7.3 Hz), 2.54 (3H, s), 2.98 (2H, q, J=7.3 Hz), 7.19 (1H, d, J=5.1 Hz), 8.54 (1H, d, J=5.1 Hz), 8.91 (1H, s).
IR (KBr): 2978, 1692, 1591 cm 1.
zo ii) Production of 2-bromo-1-(4-methylpyridin-3-yl)propane-1-one hydrobromate To a solution of 1-(4-methylpyridin-3-yl)propan-1-one (4.72 g) in acetic acid (35 ml) was added hydrobromic acid (5.5 ml) and the mixture was cooled to 10°C. A solution of zs bromine (5.0 g) in acetic acid (15 ml) was gradually added to the reaction mixture and the mixture was stirred at 80°C for one hr. The solvent was evaporated under reduced pressure and the residue was recrystallized from ethyl acetate to give the title compound (5.56 g) as a pale-yellow powder.
30 1H-NNBt (DMSO-d6)8: 1.82 (3H, d, J=6.6 Hz), 2.60 (3H, s), 5.81 (1H, q, J=6.6 Hz), 7.95 (1H, d, J=5.7 Hz), 8.88 (1H, d, J=5.7 Hz), 9.30 (1H, brs).
IR (KBr): 2573, 1705, 1636, 1595 cm 1.

' CA 02431171 2003-06-06 iii) Production of 3-[5-methyl-4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide By the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-methylpyridin-3-yl)propan-1-one s hydrobromate (379 mg) and 3-(aminocarbonothionyl)benzamide (216 mg), the title compound (242 mg) was obtained as colorless powder crystals.
1H-NI~t (DMSO-d6)S: 2.28 (3H, s), 2.41 (3H, s), 7.41 (1H, d, J=5.2 Hz), 7.53 (1H, brs), 7.59 (1H, t, J=7.8 Hz), 7.96 (1H, d, io J=7.8 Hz), 8.06 (1H, d, J=7.8 Hz), 8.20 (1H, brs), 8.34 - 8.40 (1H, m), 8.47 - 8.54 (2H, m).
IR (KBr): 3191, 1701, 1672, 1422, 1383 c~ 1.
Example 54 Production of 3-[5-isopropyl-4-(4-methylpyridin-3-yl)-1,3-is thiazol-2-yl]benzamide i) Production of 3-methyl-1-(4-methylpyridin-3-yl)butan-1-one A solution of 4-methylnicotinonitrile (5.00 g) .in diethyl ether (75 ml) was cooled to 5°C and a solution (ca. 0.8 M, 78 ml) of isobutylmagnesium bromide in diethyl ether was 2o gradually added thereto. The mixture was heated under reflux for 24 hrs. and added to 1N hydrochloric acid (400 ml). The mixture was stirred at room temperature for 2 hrs. The reaction mixture was neutralized, and extracted with ethyl acetate. The organic layer was dried and concentrated, and the 2s residue was subjected to silica gel column chromatography (eluent, hexane: ethyl acetate=3:1) for purification to give the title compound (3.20 g) as a pale-yellow oil.
1H-NMR (CDC13)b: 0.99 (6H, d, J=6.6 Hz), 2.16 - 2.40 (1H, m), 2.52 (3H, s), 2.81 (2H, d, J=7.0 Hz), 7.19 (1H, d, J=5.2 Hz), 30 8.53 (1H, d, J=5.2 Hz), 8.85 (1H, s).
IR (KBr): 2959, 1688, 1591 cm 1.
ii) Production of 2-bromo-3-methyl-1-(4-methylpyridin-3-yl)butan-1-one hydrobromate ' CA 02431171 2003-06-06 By the reaction in the same manner as in Example 53-ii) using 3-methyl-1-(4-methylpyridin-3-yl)butan-1-one (3.10 g) and bromine (2.68 g), the title compound (3.69 g) was obtained as a pale-yellow powder.
s 1H-NMR (DMSO-d6)b: 1.07 (3H, d, J=6.6 Hz), 1.09 (3H, d, J=6.4 Hz), 2.21 - 2.43 (1H, m), 2.58 (3H, s), 5.70 (1H, d, J=6.6 Hz), 7.92 (1H, d, J=5.9 Hz), 8.88 (1H, d, J=5.9 Hz), 9.31 (1H, s).
IR (KBr): 2710, 1711, 1636, 1588 cm 1.
iii) Production of 3-[5-isopropyl-4-(4-methylpyridin-3-yl)-io 1,3-thiazol-2-yl]benzamide By the reaction in the same manner as in Example 25-iii) using 2-bromo-3-methyl-1-(4-methylpyridin-3-yl)butan-1-one hydrobromate (387 mg) and 3-(aminocarbonothionyl)benzamide (271 mg), the title compound (32 mg) was obtained as a brown is amorphous compound.
1H-NNat (CDC13)8: 1.30 (6H, d, J=6.6 Hz), 2.30 (3H, s), 2.96 -3.16 (1H, m), 5.83 (1H, brs), 6.31 (1H, brs), 7.26 (1H, d, J=5.1 Hz), 7.53 (1H, t, J=7.7 Hz), 7.89 (1H, dt, J=7.7, 1.6 Hz), 8.08 (1H, dt, J=7.7, 1.6 Hz), 8.37 (1H, t, J=1.6 Hz), 20 8.49 (1H, s), 8.52 (1H, d, J=5.1 Hz).
IR (KBr): 3318, 3191, 2963, 1669, 1387 cm 1.
Example 55 Production of 3-[5-chloro-4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]-N,N-dimethylbenzamide zs To a solution of 3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]-N,N-dimethylbenzamide (400 mg) in D1~' (2 ml) was added trichloroisocyanuric acid (120 mg) and the mixture was stirred at room temperature for 30 min. The reaction mixture was diluted with aqueous sodium hydrogen carbonate-ethyl acetate.
3o The organic layer was separated and washed with water, aqueous sodium hydrogen carbonate and saturated brine. The organic layer was dried and concentrated, and the residue was subjected to silica gel column chromatography (eluent, hexane:ethyl acetate=2:1-0:1) for purification to give the title compound (140 mg) as a colorless amorphous compound.
1H-NMR (CDC13)8: 2.38 (3H, s), 3.01 (3H, s), 3.14 (3H, s), 7.20 - 7.30 (1H, m), 7.46 - 7.55 (2H, m), 7.88 - 8.00 (2H, m), 8.48 s - 8.60 (1H, m), 8.65 (1H, brs).
IR (KBr): 1638, 1595, 1397 cm 1.
Example 56 Production of 3-[5-methyl-4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzenesulfonamide io By the~reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-methylpyridin-3-yl)propan-1-one hydrobromate (520 mg) and 3-(aminosulfonyl)benzenecarbothioamide (361 mg), the title compound (376 mg) was obtained as colorless powder crystals.
i5 1H-NMR (DMSO-d6)S: 2.28 (3H, s), 2.41 (3H, s), 7.41 (1H, d, J=4.8 Hz), 7.53 (2H, brs), 7.71 (1H, t, J=8.2 Hz), 7.90 (1H, dt, J=8.4, 1.5 Hz), 8.10 (1H, dt, J=8.4, 1.5 Hz), 8.38 (1H, t, J=1.5 Hz), 8.46 - 8.56 (2H, m).
IR (KBr): 3177, 1599, 1341, 1159 cm 1.
2o Example 57 Production of 4-(5-methyl-4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzenesulfonamide By the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-methylpyridin-3-yl)propan-1-one as hydrobromate (510 mg) and 4-(aminosulfonyl)benzenecarbothioamide (355 mg), the title compound (322 mg) was obtained as colorless powder crystals.
1H-Nl~t (DMSO-d6)8: 2.28 (3H, s), 2.42 (3H, s), 7.41 (1H, d, J=4.8 Hz), 7.50 (2H, brs), 7.94 (2H, d, J=8.8 Hz), 8.11 (2H, d, 3o J=8.8 Hz), 8.46 - 8.55 (2H, m).
IR (KBr): 3297, 1341, 1157 cm 1.
Example 58 Production of 3-~2-[4-methylpyridin-3-yl]-1,3-thiazol-4-yl}benzamide 3-{2-[4-Methylpyridin-3-yl]-1,3-thiazol-4-yl}benzonitrile (100 mg) was dissolved in conc. hydrochloric acid (4 ml) and the mixture was stirred at 40°C for 16 hrs. The reaction s mixture was added to aqueous sodium hydrogen carbonate and extracted with ethyl acetate. The organic layer was dried and concentrated. The residue was recrystallized from ethyl acetate-methanol to give the title compound (72 mg) as pale-yellow powder crystals.
io 1H-Nl~t (DMSO-d6)S: 2.68 (3H, s), 7.40 - 7.68 (3H, m), 7.88 (1H, d, J=8.4 Hz), 8.12 (1H, brs), 8.20 (1H, d, J=7.6 Hz), 8.40 (1H, s), 8.48 - 8.63 (2H, m), 9.01 (1H, s).
IR (KBr): 3380, 3191, 1655, 1406 cm 1.
Example 59 is Production of 3-f2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl}benzamide By the reaction in the same manner as in Example 58 using 3-{2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl}benzonitrile (730 mg), the title compound (404 mg) was 20 obtained as colorless powder crystals.
1H-NMR (DMSO-d6)8:7.47 (1H, brs), 7.57 (1H, t, J=7.8 Hz), 7.87 (1H, d, J=7.8 8.00 (1H, d, J=5.3 Hz), 8.08 (1H, brs), Hz), 8.16 (1H, d, J=7.8Hz), 8.48 - 8.54 (2H, m), 9.03 (1H, d, J=5.3 Hz), 9.14 (1H, s).
2s IR (KBr): 3173, 1694, 1146 cm 1.
Example 60 Production of 2-fluoro-5-~2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl}benzamide 2-Fluoro-5-{2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-3o thiazol-4-yl}benzoic acid (205 mg) was dissolved in THF (5 ml) and thionyl chloride (0.06 ml) and DID (0.01 ml) were added.
The mixture was heated under reflux for 2 hrs. The reaction mixture was concentrated under reduced pressure and re-dissolved in THF (5 ml). 28$ Aqueous ammonia (3 ml) cooled to 5°C was gradually added. The reaction mixture was stirred at room temperature for 30 min. and extracted with ethyl. acetate.
The organic layer was dried and concentrated. The residue was s subjected to silica gel column chromatography (eluent, hexane:ethyl acetate=9:1-->ethyl acetate) for purification and recrystallized from ethyl acetate-diisopropyl ether to give the title compound (130 mg) as colorless powder crystals.
1H-NMR (CDC13)8: 5.92 (1H, brs), 6.78 (1H, brs), 7.19 - 7.32 iv (1H, m), 7.73 (1H, d, J=5.4 Hz), 7.80 (1H, s), 8.20 - 8.31 (1H, m), 8.62 (1H, dd, J=2.2, 7.4 Hz), 8.91 (1H, d, J=5.4 Hz), 9.06 (1H, s).
IR (KBr): 3193, 1678, 1607, 1144 cm 1.
Example 61 is Production of 2-fluoro-N-methyl-5-t2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl}benzamide By the reaction in the same manner as in Example 60 using 2-fluoro-5-~2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl}benzoic acid (200 mg), thionyl chloride (0.06 ml) and a 2o solution (2 M, 5 ml) of methylamine in THF, the title compound (145 mg) was obtained as colorless powder crystals.
1H-NMR (CDC13)8: 3.08 (3H, d, J=4.6 Hz), 6.65 - 6.90 (1H, m), 7.16 - 7.30 (1H, m), 7.72 (1H, d, J=5.1 Hz), 7.79 (1H, s), 8.16 - 8.26 (1H, m), 8.60 (1H, dd, J=2.6, 7.4 Hz), 8.90 (1H, d, 25 J=5.1 Hz), 9.06 (1H, s).
IR (KBr): 3399, 3090, 1657, 1647, 1316 cm 1.
Example 62 Production of 2-fluoro-N,N-dimethyl-5-{2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl}benzamide 3o By the reaction in the same manne-r as in Example 60 using 2-fluoro-5-(2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl}benzoic acid (201 mg), thionyl chloride (0.06 ml) and aqueous dimethylamine solution (50~, 5 ml), the title compound (90 mg) was obtained as a colorless amorphous compound.
1H-NN~t (CDC13)8: 2.99 (3H, s), 3.16 (3H, s), 7.19 (1H, t, J=8.8 Hz), 7.68 (1H, s), 7.72 (1H, d, J=5.0 Hz), 7.92 - 8.10 (2H, m), 8.90 (1H, d, J=5.0 Hz), 9.04 (1H, s).
s IR (KBr): 1644, 1483, 1319, 1159 cm 1.
Example 63 Production of N-ethyl-2-fluoro-5-~2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl}benzamide By the reaction in the same manner as in Example 60 using io 2-fluoro-5-{2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl}benzoic acid (202 mg), thionyl chloride (0.06 ml) and aqueous ethylamine solution (70~, 5 ml), the title compound (139 mg) was obtained as colorless powder crystals.
1H-NMR (CDC13)b: 1.29 (3H, t, J=7.2 Hz), 3.48 - 3.66 (2H, m), 15 6.74 (1H, brs), 7.14 - 7.30 (1H, m), 7.72 (1H, d, J=5.1 Hz), 7.78 (1H, s), 8.14 - 8.26 (1H, m), 8.59 (1H, dd, J=2.4, 7.6 Hz), 8.90 (1H, d, J=5.1 Hz), 9.06 (1H, s).
IR (KBr): 3295, 1636, 1325 cm 1.
Example 64 ao Production of 3-[4-(4-ethylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide i) Production of 4-ethylnicotinonitrile A solution of diisopropylamine (9.1 ml) in THF (50 ml) was cooled to -30°C and an n-butyllithium hexane solution (1.61 2s M, 37 ml) was added. The mixture was stirred for 30 min.
After cooling the reaction mixture to -78°C, a solutian of 4-methylnicotinonitrile (7.01 g) in THF (50 ml) was added dropwise and the mixture was stirred for 15 min. Methyl iodide (9.1 ml) was added and the mixture was heated to -40°C, and 3o saturated aqueous ammonium chloride solution was added. The reaction mixture was extracted with ethyl acetate and the organic layer was dried and concentrated. The residue was subjected to silica gel column chromatography (eluent, ' CA 02431171 2003-06-06 hexane: ethyl acetate=1:1) for purification to give the title compound (6.67 g) as a pale-yellow oil.
1H-NMR (CDC13)8: 1.34 (3H, t, J=7.7 Hz), 2.89 (2H, q, J=7.7 Hz), 7.31 (1H, d, J=5.2 Hz), 8.69 (1H, d, J=5.2 Hz), 8.80 (1H, s).
IR (KBr): 2976, 2230, 1591, 1406 cm 1.
ii) Production of 1-(4-ethylpyridin-3-yl)ethanone Magnesium (7.90 g) was suspended in t-butylmethyl ether (300 ml) and iodine (20 mg) was added. Methyl iodide (20 ml) was added dropwise while maintaining the mixture at not higher io than 25°C. The mixture was stirred at room temperature for 3 hrs. to give a solution of methylmagnesium iodide in t-butylmethyl ether. To a solution of 4-ethylnicotinonitrile (2.00 g) in toluene (30 ml), which was cooled to -10°C, was gradually added a solution (45 ml) of methylmagnesium iodide i5 in t-butylmethyl ether and the mixture was stirred at room temperature for 12 hrs. The reaction mixture was added to 1N
hydrochloric acid (80 ml) and the mixture was stirred at room temperature for 30 min. Sodium bicarbonate was added to neutralize the reaction mixture and the mixture was extracted ao with ethyl acetate. The organic layer was dried and concentrated. The residue was subjected to silica gel column chromatography (eluent, hexane:ethyl acetate=20:1-1:3) for purification to give the title compound (1.84 g) as a yellow oil.
25 1H-NMR (CDC13)8: 1.23 (3H, t, J=7.4 Hz), 2.64 (3H, s), 2.92 (2H, q, J=7.4 Hz), 7.24 (1H, d, J=5.2 Hz), 8.58 (1H, d, J=5.2 Hz), 8.91 (1H, s).
IR (KBr): 2975, 1688, 1590, 1269 cm 1.
iii) Production of 2-bromo-1-(4-ethylpyridin-3-yl)ethanone 3o hydrobromate By the reaction in the same manner as in Example 53-ii) using 1-(4-ethylpyridin-3-yl)ethanone (1.68 g) and bromine (1.60 g), the title compound (1.95 g) was obtained as a pale-brown powder.
1H-NMR (DMSO-d6)S: 1.21 (3H, t, J=7.5 Hz), 2.90 (2H, q, J=7.5 Hz), 5.03 (2H, s), 7.89 (1H, d, J=5.8 Hz), 8.88 (1H, d, J=5.8 Hz), 9.24 (1H, s).
s IR (KBr): 2978, 1713, 1638, 1584 cm 1.
iv) Production of 3-[4-(4-ethylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide By the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-ethylpyridin-3-yl)ethanone hydrobromate io (161 mg) and 3-(aminocarbonothionyl)benzamide (97 mg), the title compound (81 mg) was obtained as pale-yellow powder crystals.
1H-NMR (DMSO-d6)8: 1.19 (3H, t, J=7.6 Hz), 2.87 (2H, q, J=7.6 Hz), 7.41 (1H, d, J=5.2 Hz), 7.55 (1H, brs), 7.63 (1H, t, 15 J=8.0 Hz), 8.00 (1H, d, J=8.0 Hz), 8.05 (1H, s), 8.16 (1H, d, J=8.0 Hz), 8.22 (1H, brs), 8.46 (1H, s), 8.52 (1H, d, J=5.2 Hz), 8.74 (1H, s).
IR (KBr): 3152, 1684, 1383 ciril.
Example 65 ao Production of 3-[4-(4-ethylpyridin-3-yl)-1,3-thiazol-2-yl]-N-methylbenzamide By the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-ethylpyridin-3-yl)ethanone hydrobromate (162 mg) and 3-(aminocarbonothionyl)-N-methylbenzamide (110 Zs mg), the title compound (91 mg) was obtained as colorless powder crystals.
1H-NMR (DMSO-d6)8: 1.18 (3H, t, J=7.5 Hz), 2.82 (3H, d, J=4.8 Hz), 2.88 (2H, q, J=?.5 Hz), 7.40 (1H, d, J=4.8 Hz), 7.63 (1H, t, J=7.8 Hz), 7.96 (1H, d, J=7.8 Hz), 8.04 (1H, s), 8.15 (1H, 3o d, J=7.8 Hz), 8.42 (1H, s), 8.52 (1H, d, J=4.8 Hz), 8.63 -8.73 (1H, m), 8.73 (1H, s).
IR (KBr): 3266, 3189, 1669 cm 1.
Example 66 Production of 3-[4-(4-ethylpyridin-3-yl)-1,3-thiazol-2-yl]-N,N-dimethylbenzamide By the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-ethylpyridin-3-yl)ethanone hydrobromate s (163 mg) and 3-(aminocarbonothionyl)-N,N-dimethylbenzamide (110 mg), the title compound (110 mg) was obtained as a pale-brown oil.
1H-NMR (DMSO-d6)S: 1.18 (3H, t, J=7.2 Hz), 2.87 (2H, q, J=7.2 Hz), 2.95 (3H, s), 3.02 (3H, s), 7.40 (1H, d, J=5.1 Hz), 7.54 so (1H, dd, J=1.1, 7.5 Hz), 7.61 (1H, t, J=7.5 Hz), 7.99 (1H, d, J=1.1 Hz), 8.03 - 8.14 (2H, m), 8.52 (1H, d, J=5.1 Hz), 8.73 (1H, s).
IR (KBr): 2969, 1634, 1395 cm 1.
Example 67 is Production of 3-[4-(4-isopropylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide i) Production of 4-isopropylnicotinonitrile By the reaction in the same manner as in Example 64-i) using 4-ethylnicotinonitrile (2.95 g) and methyl iodide (7 ml), 2o the title compound (1.90 g) was obtained as a yellow oil.
1H-NMR (CDC13)b: 1.35 (6H, d, J=6.6 Hz), 3.22 - 3.46 (1H, m), 7.36 (1H, d, J=5.2 Hz), 8.72 (1H, d, J=5.2 Hz), 8.80 (1H, s).
IR (KBr): 2971, 2228, 1588, 1406 cm 1.
ii) Production of 1-(4-isopropylpyridin-3-yl)ethanone zs By the reaction in the same manner as in Example 64-i) using 4-isopropylnicotinonitrile (1.40 g) and solution (ca.
1.0 M, 30 ml) of methylmagnesium iodide in t-butyl methyl ether, the title compound (0.94 g) was obtained as a yellow oil.
30 1H-NMR (CDC13)&: 1.24 (6H, d, J=6.6 Hz), 2.64 (3H, s), 3.46 -3.70 (1H, m), 7.34 (1H, d, J=5.0 Hz), 8.60 (1H, d, J=5.0 Hz), 8.79 (1H, s).
IR (KBr): 2969, 1690, 1588, 1267 cm 1.

iii) Production of 3-[4-(4-isopropylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide By the reaction in the same manner as in Example 53-ii) using 1-(4-isopropylpyridin-3-yl)ethanone (0.90 g) and bromine s (0.63 g), crude 2-bromo-1-(4-isopropylpyridin-3-yl)ethanone hydrobromate (1.70 g) was obtained as a pale-brown amorphous compound. Then, by the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-isopropylpyridin-3-yl)ethanone hydrobromate (340 mg) and 3-io (aminocarbonothionyl)benzamide (240 mg), the title compound (59 mg) was obtained as colorless powder crystals.
1H-NMR (DMSO-ds)b: 1.23 (6H, d, J=6.2 Hz), 3.20 - 3.60 (1H, m), 7.42 - 7.70 (3H, m), 8.00 (2H, s), 8.07 - 8.28 (2H, m), 8.38 -8.68 (3H, m).
is IR (KBr): 3104, 1703, 1420, 1387 cmll.
Example 68 Production of 3-[4-(4-isopropylpyridin-3-yl)-1,3-thiazol-2-yl]-N,4-dimethylbenzamide By the reaction in the same manner as in Example 25-iii) Zo using 2-bromo-1-(4-isopropylpyridin-3-yl)ethanone hydrobromate (343 mg) and 3-(aminocarbonothionyl)-N,4-dimethylbenzamide (250 mg), the title compound (25 mg) was obtained as a pale-yellow amorphous compound.
1H-NMR ( CDC13 ) 8: 1. 25 ( 6H, d, J=7 . 0 Hz ) , 2 . 67 ( 3H, S ) , 3 . O1 ( 3H, zs d, J=4.8 Hz), 3.40 - 3.68 (1H, m), 6.58 - 6.76 (1H, brs), 7.20 - 7.48 (3H, m), 7.75 (1H, dd, J=1.8, 8.0 Hz), 8.21 (1H, d, J=1.8 Hz), 8.55 (1H, d, J=5.2 Hz), 8.65 (1H, s).
IR (KBr): 3285, 2967, 1645, 1557 cm 1.
Example 69 3o Production of 3-[4-(4-isopropylpyridin-3-yl)-1,3-thiazol-2-yl]-N,N-dimethylbenzamide hemifumarate After the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-isopropylpyridin-3-yl)ethanone hydrobromate (342 mg) and 3-(aminocarbonothionyl)-N,N-dimethylbenzamide (320 mg), a fumaric acid treatment was applied to give the title compound (100 mg) as colorless powder crystals.
s 1H-NMR (DMSO-ds)b: 1.22 (6H, d, J=6.6 Hz), 2.95 (3H, s), 3.02 (3H, s), 3.20 - 3.60 (1H, m), 6.63 (1H, s), 7.46 - 7.65 (3H, m), 7.92 - 8.09 (3H, m), 8.57 (1H, d, J=5.4 Hz), 8.63 (1H, s).
IR (KBr): 3083, 1705, 1657 cm 1.
Example 70 io Production of 3-[4-(4-ethylpyridin-3-yl)-1,3-thiazol-2-yl]benzenesulfonamide By the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-ethylpyridin-3-yl)ethanone hydrobromate (161 mg) and 3-(aminosulfonyl)benzenecarbothioamide (110 mg), I5 the title compound (67 mg) was obtained as colorless powder crystals.
1H-NMR (DMSO-d6)8: 1.18 (3H, t, J=7.5 Hz), 2.87 (2H, q, J=7.5 Hz), 7.41 (1H, d, J=5.0 Hz), 7.55 (2H, brs), 7.75 (1H, t, J=7.9 Hz), 7.94 (1H, dt, J=7.9, 1.6 Hz), 8.09 (1H, s), 8.21 20 (1H, dt, J=7.9, 1.6 Hz), 8.45 (1H, t, J=1.6 Hz), 8.53 (1H, d, J=5.0 Hz), 8.74 (1H, s).
IR (KBr): 3270, 1599, 1460, 1341, 1154 cm 1.
Example 71 Production of 4-[4-(4-ethylpyridin-3-yl)-1,3-thiazol-2-2s yl]benzenesulfonamide By the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-ethylpyridin-3-yl)ethanone hydrobromate (161 mg) and 4-(aminosulfonyl)benzenecarbothioamide (109 mg), the title compound (90 mg) was obtained as colorless powder 3o crystals.
1H-NMR (DMSO-d6)b: 1.19 (3H, t, J=7.5 Hz), 2.88 (2H, q, J=7.5 Hz), 7.41 (1H, d, J=4.8 Hz), 7.52 (2H, brs), 7.96 (2H, d, J=8.4 Hz), 8.11 (1H, s), 8.20 (2H, d, J=8.4 Hz), 8.53 (1H, d, J=4.8 Hz), 8.74 (1H, s).
IR (KBr): 3291, 1597, 1399, 1333, 1159 cm''.
Example 72 Production of 4-methyl-3-[2-(2-methyl-5-nitrophenyl)-1,3-s thiazol-4-yl]pyridine i) Production of 2-methyl-5-nitrobenzonitrile By the reaction in the same manner as in Example 30-ii) using 2-bromo-4-nitrotoluene (12.03 g), tetrakistriphenylphosphinepalladium (300 mg) and zinc cyanide to (4.22 g), the title compound (1.36 g) was obtained as pale-yellow powder crystals.
1H-NP~t ( CDC13 ) 8: 2 . 69 ( 3H, s ) , 7 . 54 ( 1H, d, J=8 . 4 Hz ) , 8 . 34 ( 1H, dd, J=2.6, 8.4 Hz), 8.48 (1H, d, J=2.6 Hz).
IR (KBr): 3077, 2236, 1615, 1524 cm l is ii) Production of 4-methyl-3-[2-(2-methyl-5-nitrophenyl)-1,3-thiazol-4-yl]pyridine By the reaction in the same manner as in Example 25-ii) using 2-methyl-5-nitrobenzonitrile (1.25 g), 2-methyl-5-nitrobenzenecarbothioamide was obtained as a yellow powder.
2o Then, by the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromate (1.35 g) and 2-methyl-5-nitrobenzenecarbothioamide, the title compound (460 mg) was obtained as colorless needle crystals.
1H-Nl~llt (CDC13)b: 2.56 (3H, s), 2.78 (3H, s), 7.24 (1H, d, JT5.0 2s Hz), 7.46 - 7.57 (2H, m), 8.20 (1H, dd, J=2.3, 8.4 Hzi, 8.49 (1H, d, J=5.0 Hz), 8.67 (1H, d, J=2.3 Hz), 8.84 (1H, s).
IR (KBr): 3038, 1530, 1343 cm 1.
Example 73 Production of 3-~2-[4-methylpyridin-3-yl]-1,3-thiazol-4-3o yl}benzonitrile i) Production of 3-(bromoacetyl)benzonitrile 3-Acetylbenzonitrile (5.33 g) and copper(II) bromide (16.40 g) were suspended in ethyl acetate (100 ml) and the mixture was heated under reflux for 2 hrs. After cooling the reaction mixture, the insoluble material was filtered off and the filtrate was washed with aqueous sodium hydrogen carbonate and saturated brine. The organic layer was dried and concentrated and the residue was recrystallized from ethyl acetate-diisopropyl ether to give the title compound (4.29 g) as colorless powder crystals.
1H-NI~t ( CDC13 ) b: 2 . 82 ( 2H, s ) , 6 . 06 ( 1H, t, J=7 . 8 Hz ) , 6 .29 ( 1H, d, J=7.8 Hz), 6.57 - 6.72 (2H, m).
io IR (KBr): 3104, 2942, 2230, 1709, 1599 cm 1.
ii) Production of 3-.(2-[4-methylpyridin-3-yl]-1,3-thiazol-4-yl}benzonitrile By the reaction in the same manner as in Example 25-iii) using 3-(bromoacetyl)benzonitrile (599 mg) and 4-is methylpyridine-3-thiocarboxamide (403 mg), the title compound (302 mg) was obtained as pale-yellow powder crystals.
1H-NNgt (DMSO-d6)8: 2.67 (3H, s), 7.46 (1H, d, J=5.2 Hz), 7.71 (1H, t, J=8.0 Hz), 7.85 (1H, d, J=8.0 Hz), 8.39 (1H, d, J=8.0 Hz), 8.50 (1H, s), 8.55 (1H, d, J=5.2 Hz), 8.56 (1H, s), 9.00 20 ( 1H, S ) .
IR (KBr): 3104, 2230, 1593, 1485 cm 1.
Example 74 Production of 3-~2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl~benzonitrile Zs By the reaction in the same manner as in Example 25-iii) using 3-(bromoacetyl)benzonitrile (913 mg) and 4-trifluoromethylpyridine-3-thiocarboxamide (840 mg), the title compound (1.03 g) was obtained as colorless powder crystals.
1H-Nl~t (CDC13)8: 7.52 - 7.70 (2H, m), 7.74 (1H, d, J=5.2 Hz), 30 7.80 (1H, s), 8.16 - 8.30 (2H, m), 8.93 (1H, d, J=5.2 Hz), 9.05 (1H, s).
IR (KBr): 3088, 2230, 1316, 1130 cm 1.
Example 75 r Production of 3-[4-(3-bromo-4-fluorophenyl)-1,3-thiazol-2-yl]-4-(trifluoromethyl)pyridine i) Production of 2-bromo-1-(3-bromo-4-fluorophenyl)ethanone By the reaction in the same manner as in Example 73-i) s using 3'-bromo-4'-fluoroacetophenone (8.00 g) and copper(II) bromide (16.50 g), the title compound (10.60 g) was obtained as a pale-yellow oil.
1H-NNBt (CDC13)8: 4.39 (2H, s), 7.20 - 7.28 (1H, m), 7.90 - 7.99 (1H, m), 8.23 (1H, dd, J=2.1, 6.6 Hz).
io IR (KBr): 1684, 1591, 1281, 1264 cm 1.
ii) Production of 3-[4-(3-bromo-4-fluorophenyl)-1,3-thiazol-2-yl]-4-(trifluoromethyl)pyridine By the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(3-bromo-4-fluorophenyl)ethanone (3.10 g) and is 4-trifluoromethylpyridine-3-thiocarboxamide (1.87 g), the title compound (1.50 g) was obtained as brown needle crystals.
1H-NMR (CDC13)8:7.20 (1H, t, J=8.5 Hz), 7.66 (1H, s), 7.73 (1H, d, J=5.2 Hz), 7.84 - 7.94 (1H, m), 8.18 (1H, dd, J=2.2, 6.6 Hz), 8.91 (1H, d, J=5.2 Hz), 9.04 (1H, s).
2o IR (KBr): 3063, 1472, 1319, 1127 cm 1.
Example 76 Production of ethyl 2-fluoro-5-.(2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl}benzoate 3-[4-(3-Bromo-4-fluorophenyl)-1,3-thiazol-2-yl]-4-as (trifluoromethyl)pyridine (1.48 g), 1,1'-bis(diphenylphosphino)ferrocene (680 mg), palladium acetate (270 mg) and triethylamine (0.77 ml) were suspended in a mixture of ethanol (15 ml)/THF (15 ml), and the mixture was vigorously stirred at 70°C for 3 hrs at 5 atm under a carbon 3o monoxide atmosphere. The reaction mixture was added to water and extracted with ethyl acetate. The organic layer was dried and concentrated. The residue was subjected to silica gel column chromatography (eluent, hexane: ethyl acetate=19:1-1:1) i for purification and recrystallized from ethyl acetate-diisopropyl ether to give the title compound (1.17 g) as colorless powder crystals.
1H-NMR ( CDC13 ) S: 1. 43 ( 3H, t, J=7 .1 Hz ) , 4 . 44 ( 2H, q, J=7 .1 Hz ) , s 7.18 - 7.30 (1H, m), 7.73 (1H, d, J=5.0 Hz), 7.73 (1H, s), 8.12 - 8.22 (1H, m), 8.49 (1H, dd, J=2.2, 7.0 Hz), 8.91 (1H, d, J=5.0 Hz), 9.06 (1H, s).
IR (KBr): 1728, 1318, 1291, 1146 cm 1.
Example 77 so Production of 2-fluoro-5-~2-[4-(trif luoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl}benzoic acid Ethyl 2-fluoro-5-f2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl}benzoate (1.00 g) was suspended in a mixture of ethanol (20 ml)/1N NaOH (5 ml) and the mixture was stirred is at room temperature for one hr. 1N Hydrochloric acid (5 ml) was added to the reaction mixture, and the precipitated crystals were collected by filtration and washed with water to give the title compound (0.86 g) as a pale-brown powder.
1H-NNgt (DMSO-d6)8: 7.40 - 7.60 (1H, m), 8.00 (1H, d, J=5.2 Hz), zo 8.20 - 8.38 (1H, m), 8.46 - 8.70 (2H, m), 9.03 (1H, d, J=5.2 Hz), 9.13 (1H, s).
IR (KBr): 1717, 1318, 1159 cm 1.
Example 78 Production of 4-methyl-3-[2-(4-methyl-pyridin-3-yl)-1,3-25 thiazol-4-yl]pyridine By the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromate (392 mg) and 4-methylpyridine-3-thiocarboxamide (152 mg), the title compound (112 mg) was obtained as colorless powder 3o crystals.
1H-Nl~t (CDC13)8: 2.56 (3H, s), 2.70 (3H, s), 7.20-7.30 (2H, m), 7.50 (1H, s), 8.49 (1H, d, J= 5.1 Hz), 8.53 (1H, d, J= 5.1 Hz), 8.84 (1H, s), 8.98 (1H, s).

IR (KBr): 3071, 1593, 1491, 1399 cm 1.
Example 79 Production of 4-methyl-3-[4-(pyridin-4-yl)-1,3-thiazol-2-yl]pyridine s By the reaction in the same manner as in Example 25-iii) using 2-bromo-1-(pyridin-4-yl)ethanone hydrobromate (460 mg) and 4-methylpyridine-3-thiocarboxamide (248 mg), the title compound (99 mg) was obtained as colorless powder crystals.
1H-NNBt (CDC13)8: 2.72 (3H, s), 7.28 (1H, d, J=S.OHz), 7.80-7.90 io (3H, m), 8.54 (1H, d, J=5.OHz), 8.64-8.74 (2H, m), 8.98 (1H, s) .
IR (KBr) : 1599, 1483, 1209 ciri 1.
Example 8D
Production of N-methyl-3-[2-(4-methylpyridin-3-yl)-1,3-is thiazol-4-yl]benzamide i) Production of ethyl 3-acetylbenzoate By the reaction in the same manner as in Example 76 using 3-bromoacetophenone (48.50 g), 1,1'-bis (diphenylphosphino)ferrocene (3.60 mg), palladium acetate Zo (1.30 g) and triethylamine (68 ml), the title compound (45.3 g) was obtained as colorless needle crystals.
1H-NNgt ( CDC13 ) b: 1. 43 ( 3H, t, J=7 . 2 Hz ) , 2 . 67 ( 3H, s ) , 4 . 42 ( 2H, q, J=7.2 Hz), 7.56 (1H, t, J=7.8 Hz), 8.15 (1H, dt, J=7.8, 1.6 Hz), 8.25 (1H, dt, J=7.8, 1.6 Hz), 8.60 (1H, t, J=1.6 Hz).
2s IR (KBr): 1723, 1692, 1302, 1236 cm 1.
ii) Production of ethyl 3-(bromoacetyl)benzoate By the reaction in the same manner as in Example 73-i) using ethyl 3-acetylbenzoate (30.0 g) and copper(II) bromide (67.5 g), a crude title compound (42.0 g) was obtained as a 3o brown oil.
1H-Nl~t ( CDC13 ) b : 1. 43 ( 3H, t, J=7 . 2 Hz ) , 4 . 43 ( 2H, q, J=7 . 2 Hz ) , 4.50 (2H, s), 7.60 (1H, t, J=8.0 Hz), 8.18 (1H, dt, J=8.0, 1.6 Hz), 8.29 (1H, dt, J=8.0, 1.6 Hz), 8.62 (1H, t, J=1.6 Hz).

IR (KBr): 1721, 1688; 1304, 1246 cm 1.
iii) Production of ethyl 3-[2-(4-methylpyridin-3-yl)-1,3-thiazol-4-yl]benzoate By the reaction in the same manner as in Example 25-iii) s using ethyl 3-(bromoacetyl)benzoate (18.10 g) and 4-methylpyridine-3-thiocarboxamide (8.11 g), the title compound (6.50 g) was obtained as pale-yellow powder crystals.
1H-NNBt (CDC13)8: 1.43 (3H, t, J=7.lHz), 2.73 (3H, s), 4.43 (2H, q, J=7.lHz), 7.25-7.30 (1H, m), 7.54 (1H, t, J=7.8Hz), 7.71 io (1H, s), 8.05 (1H, dt, J=7.8, l.2Hz), 8.19-8.26 (1H, m), 8.53 (1H, d, J=4.8Hz), 8.58-8.64 (1H, m), 9.00 (1H, s).
IR (KBr): 3059, 1713, 1285 cm 1.
iv) Production of 3-[2-(4-methylpyridin-3-yl)-1,3-thiazol-4-yl]benzoic acid i5 By the reaction in the same manner as in Example 77 using ethyl 3-[2-(4-methylpyridin-3-yl)-1,3-thiazol-4-yl]benzoate (6.50 g) and 1N NaOH (80 ml), the title compound (5.27 g) was obtained as a colorless powder.
1H-Nl~t (DMSO-ds)S: 2.68 (3H, s), 7.47 (1H, d, J= 5.OHz), 7.63 20 (1H, t, J=7.8Hz), 7.96 (1H, d, J=7.8Hz), 8.30 (1H, d, J=7.8Hz), 8.49 (1H, s), 8.55 (1H, d, J=5.OHz), 8.58-8.64 (1H, m), 8.99 (1H, s).
IR (KBr): 3088, 1703, 1601, 1292 cm 1.
v) Production of N-methyl-3-[2-(4-methylpyridin-3-yl)-1,3-2s thiazol-4-yl]benzamide By the reaction in the same manner as in Example 60 using 3-[2-(4-methyl-pyridin-3-yl)-1,3-thiazol-4-yl]benzoic acid (256 mg), thionyl chloride (0.09 ml) and aqueous methylamine solution (40%, 5 ml), the title compound (191 mg) was obtained 3o as colorless powder crystals.
1H-NNBt (DMSO-d6)b: 2.68 (3H, s), 2.83 (3H, d, J=4.6Hz), 7.47 (1H, d, J=4.6Hz), 7.58 (1H, t, J=7.8Hz), 7.83 (1H, d, J=7.8Hz), 8.19 (1H, d, J=7.8Hz), 8.40 (1H, s), 8.49 (1H, s), 8.51-8.63 (2H, m), 9.01 (1H, s).
IR (KBr): 3347, 3086, 1663, 1559 cm 1.
Example 81 Production of N,N-dimethyl-3-[2-(4-methylpyridin-3-yl)-1,3-s thiazol-4-yl]benzamide By the reaction in the same manner as in Example 60 using 3-[2-(4-methylpyridin-3-yl)-1,3-thiazol-4-yl]benzoic acid (248 mg), thionyl chloride (0.09 ml) and aqueous dimethylamine solution (50%, 5 ml), the title compound (200 mg) was obtained io as colorless~powder crystals.
1H-NMR (CDC13)S: 2.71 (3H, s), 3.04 (3H, s), 3.16 (3H, s), 7.24-7.30 (1H, m), 7.38-7.45 (1H, m), 7.50 (1H, t, J=8.lHz), 8.02-8.08 (2H, m), 8.52 (1H, d, J=5.4Hz), 8.98 (1H, s).
IR (KBr): 3079, 1634, 1395 cm 1.
i5 Example 82 .
Production of N-ethyl-3-[2-(4-methylpyridin-3-yl)-1,3-thiazol-4-yl]benzamide By the reaction in the same manner as in Example 60 using 3-[2-(4-methylpyridin-3-yl)-1,3-thiazol-4-yl]benzoic acid (259 2o mg), thionyl chloride (0.09 ml) and aqueous ethylamine solution (70%, 5 ml), the title compound (215 mg) was obtained as pale-brown powder crystals.
1H-NMR (DMSO-d6)8: 1.16 (3H, t, J=7.2Hz), 2.68 (3H, s), 3.24 3.60 (2H, m), 7.47 (1H, d, J=S.OHz), 7.58 (1H, t, J=7.9Hz), 2s 7.84 (1H, dt, J=7.9, l.6Hz), 8.19 (1H, dt, J=7.9, l.6Hz), 8.40 (1H, s), 8.49 (1H, t, J=l.6Hz), 8.55 (1H, d, J=5.OHz), 8.54-8.66 (1H, m), 9.01 (1H, s).
IR (KBr): 3308, 2978, 1634, 1545 cm-1.
Example 83 3o Production of 3-{4-[3-(1-azetidinylcarbonyl)phenyl]-1,3-thiazol-2-yl}-4-methylpyridine 3-[2-(4-Methylpyridin-3-yl)-1,3-thiazol-4-yl]benzoic acid (238 mg) was suspended in THF (10 ml) and thionyl chloride (0.09 ml) and D1~ (0.05 ml) were added. The mixture was heated under reflux for 1 hr. The reaction mixture was concentrated under reduced pressure and re-dissolved in THF (10 ml). To this solution was added a solution of azetidine hydrochloride s (0.54 g) dissolved in 1N NaOH (10 ml), and the mixture was stirred at room temperature for 30 min. The reaction mixture extracted with ethyl acetate and the organic layer was dried and concentrated. The obtained residue was subjected to silica gel column chromatography (eluent, ethyl acetate) for io purification~and recrystallized from ethyl acetate-diisopropyl ether to give the title compound (148 mg) as colorless powder crystals.
1H-NMR (DMSO-d6)8: 2.28 (2H, quintet, J=7.5Hz), 2.68 (3H, s), 4.09 (2H, t, J=7.5Hz), 4.35 (2H, t, J= 7.5Hz), 7.47 (1H, d, 15 J=5.OHz), 7.51-7.67 (2H, m), 8.18 (1H, d, J=7.OHz), 8.27 (1H, s), 8.47 (1H, s), 8.55 (1H, d, J=5.OHz), 8.99 (1H, s).
IR (KBr): 3056, 1634, 1437, 1404 coal.
Formulation Example 1 (1) compound No. 74 50 mg ao (2) lactose 34 mg (3) corn starch 10.6 mg (4) corn starch (paste) 5 mg (5) magnesium stearate 0.4 mg (6) calcium carboxymethylcellulose 20 mg Zs total 120 mg According to a conventional method, the above-mentioned (1)-(6) were mixed and tableted using a tableting machine to give tablets.
Formulation Example 2 30 (1) compound No. 78 10 mg (2) lactose 60 mg (3) corn starch 35 mg (4) gelatin 3 mg (5) magnesium stearate 2 mg A mixture of Example compound (10 mg), lactose (60 mg) and corn starch (35 mg) is passed through a 1 mm mesh sieve using a 10% aqueous gelatin solution (0.03 ml) (3 mg as gelatin) to give s granules. They are dried at 40°C and again passed through a sieve.
The thus-obtained granules are mixed with magnesium stearate (2.0 mg) and compressed. The resulting core tablets are sugar-coated with an aqueous suspension of sucrose, titanium dioxide, talc and acacia. The tablets subjected to the coating are glazed with bee so wax to give coated tablets.
Formulation Example 3 (1) compound No. 154 10 mg (2) lactose 70 mg (3) corn starch 50 mg is (4) soluble starch 7 mg (5) magnesium stearate 3 mg Example compound (10 mg) and magnesium stearate (3 mg) are granulated with an aqueous solution (0.07 ml) of soluble starch (7 mg as soluble starch), dried, and mixed with lactose (70 mg) 2o and corn starch (50 mg). The mixture is compressed to give tablets.
Formulation Example 4 (1) compound No. 137 5 mg (2) salt 20 mg 25 (3) distilled water amount to make the total amount 2 ml Example compound (5 mg) and salt (20 mg) are dissolved in distilled water, and water is added to the total amount (2 ml).
The solution is filtrated and filled in an ampoule (2 ml) under 3o aseptic conditions. The ampoule is sterilized and sealed to give a solution for injection.

Formulation Example 5 (1) compound No. 135 10 mg (2) lactose 90 mg (3) microcrystalline cellulose 70 mg s (4) magnesium stearate 10 mg per capsule 180 mg The total amount of the above-mentioned (1), (2) and (3) and (5 mg) of (4) were admixed and granulated. Thereto was added the remaining (4) (5 mg) and the whole mixture was ~o sealed in a gelatin capsule.
Experimental Example 1 Assay of steroid Cl~,2p-lyase-inhibitory activity in rat The assay was performed according to The Prostate, Vol.
26, 140-150 (1995). The orchis was removed from 13-week-old is male SD rat. The orchis was homogenized and centrifuged to prepare a microsome. The [1.2-3H]-17a-hydroxyprogesterone having a final concentration of 10 nM, NADPH solution and the test compound were was dissolved in a 100 mM phosphate buffer solution (10 w1, pH 7.4). Microsome protein (7 wg/10 ~,l) was 2o added and the mixture was incubated at 37°C for 7 min» Ethyl acetate (40 w1) was added and the mixture was centrifuged, and the substrate and the product (androstenedione and testosterone) in the supernatant were separated by silica gel thin layer chromatography (TLC). The spot was detected and 25 quantitatively assayed by a BAS 2000 bioimage analyzer. Taking the production amount when the test compound was not added (control) as 100%, the concentration (ICso) of the compound necessary for 50% inhibition of the product amount relative to the control was calculated. The results are shown in Table 16.

[Table 16]
__ In vitro enzyme inhibitory activity (IC5o Com . No. Rat C17 Zo-1 ase (nM) 53 <10 64 <10 78 <10 103 <10 Industrial Applicability s The compound of the present invention, a salt thereof and a prodrug thereof have a steroid Cl~,2o-lyase-inhibitory activity and are useful for the therapy and prophylaxis of various diseases such as primary cancer, metastasis or recrudescence of malignant tumor, various symptoms associated io with these cancers, prostatic hypertrophy, masculinism, hypertrichosis, male type baldness, male infant-type prematurity, endometriosis, hysteromyoma, mastopathy, polycystic ovary syndrome and the like in mammals.
This application is based on patent application No.
is 373868/2000 filed in Japan, the contents of which are hereby incorporated by reference.

Claims

WHAT IS CLAIMED IS

1. A steroid C17,20-lyase inhibitor comprising a compound represented by the formula:

wherein A1 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, one of A2 and A3 is a hydrogen atom, a halogen atom, a C1-4 aliphatic hydrocarbon group optionally having substituents or an optionally esterified carboxyl group, the other of A2 and A3 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, and at least one of A1, A2 and A3 is a 3-pyridyl group optionally having substituents, or a salt thereof or a prodrug thereof.

2. The steroid C17,20-lyase inhibitor of claim 1, wherein one of A1, A2 and A3 is a 3-pyridyl group optionally having substituents.

3. The steroid C17,20-lyase inhibitor of claim 2, wherein (1) A1 is a 3-pyridyl group optionally having substituents and A2 is a C6-14 aryl group optionally having substituents, or (2) A1 is a 3-pyridyl group optionally having substituents and A2 is a 3-pyridyl group optionally having substituents or (3) A1 is a C6-17 aryl group optionally having substituents and A2 is a 3-pyridyl group optionally having substituents.

4. The steroid C17,20-lyase inhibitor of claim 2, wherein one of A2 and A3 is 1) a hydrogen atom, 2) a C1-4 aliphatic hydrocarbon group optionally having substituents, 3) an optionally esterified carboxyl group or 4) a halogen atom, the substituent of the "3-pyridyl group optionally having substituents", which is one of A1, A2 and A3, is 1 to 4 groups selected from 1) a C1-6 aliphatic hydrocarbon group optionally having substituents, 2) an optionally esterified carboxyl group, 3) a carbamoyl optionally having 1 or 2 substituents, 4) a cyclic aminocarbonyl optionally having substituents, 5) an amino optionally having substituents, 6) a cyclic amino optionally having substituents, 7) an alkylthio optionally having substituents, 8) an alkoxy optionally having substituents and 9) a halogen, or one saturated or unsaturated divalent C3-5 carbon chain, and the other of A2 and A3 and the aromatic hydrocarbon group optionally having substituents or heterocyclic group optionally having substituents for A1 are (a) a C6-14 aryl optionally having, as a substituent, 1 to 5 groups selected from 1) a C1-4 alkyl optionally having substituents, 2) a phenyl optionally having substituents, 3) a C1-4 alkoxycarbonyl, 4) a carbamoyl optionally having substituents, 5) a C1-2 alkylenedioxy, 6) an amino optionally having substituents, 7) a nitro, 8) a hydroxy optionally having substituents, 9) an optionally esterified carboxyl, 10) an alkylsulfonyl, 11) a sulfamoyl optionally having substituents and 12) a halogen, or (b) a pyridyl.

5. The steroid C17,20-lyase inhibitor of claim 2, wherein one of A2 and A3 is 1) a hydrogen atom, 2) a C1-4 alkyl optionally substituted by hydroxy, 3) a carboxyl, 4) a C1-4 alkoxycarbonyl or 5) a halogen, and the other of A2 and A3 and the aromatic hydrocarbon group optionally having substituents or heterocyclic group optionally having substituents for A1 are (a) a C6-14 aryl optionally having, as a substituent, 1 to 5 groups selected from 1) a C1-4 alkyl optionally having halogen, 2) a phenyl optionally having C1-4 alkoxy, 3) a C1-4 alkoxycarbonyl, 4) a carbamoyl optionally having 1 or 2 C1-4 alkyl, 5) a C1-2 alkylenedioxy, 6) an amino optionally having 1 or 2 substituents selected from C1-4 alkyl, C1-6 alkanoyl and C1-4 alkylsulfonyl, 7) a nitro, 8) a hydroxy, 9) a C1-4 alkoxy, 10) a C1-4 alkanoyloxy, 11) a C1-4 alkylsulfonyl, 12) a sulfamoyl optionally having 1 or 2 substituents selected from C1-4 alkyl and benzyl and 13) a halogen or (b) a pyridyl, and the substituent of the "3-pyridyl group optionally having substituents", which is one of A1, A2 and A3, is 1 to 4 selected from 1) a C1-6 alkyl group optionally having, as a substituent, halogen or hydroxy, 2) a carboxyl group, 3) a C1-4 alkoxycarbonyl group, 4) a carbamoyl optionally having, as a substituent, 1 or 2 C1-4 alkyl, 5) a 4-benzylpiperidinocarbonyl, 6) an amino optionally having, as a substituent, 1 or 2 groups selected from carbamoylmethyl, C1-4 alkyl and benzyl, 7) a morpholino, 8) a 4-(4-chlorophenyl)-4-hydroxypiperidino, 9) a C1-4 alkylthio, 10) a C1-4 alkoxy, 11) a halogen and 12) a butadienylene.

6. The steroid C17,20-lyase inhibitor of claim 2, wherein one of A2 and A3 is a hydrogen atom, a methyl group, a chlorine atom or a fluorine atom, the other of A2 and A3 and the aromatic hydrocarbon group optionally having substituents or heterocyclic group optionally having substituents for A1 are 1) a phenyl group optionally having, as a substituent, 1 or 2 groups selected from methyl, methoxycarbonyl, carbamoyl, trifluoromethyl, diethylamino, acetylamino, methylsulfonylamino, hydroxy, methoxy, sulfamoyl, methylsulfamoyl, fluorine and chlorine, 2) a naphthyl group or 3) a 3-pyridyl group, and the substituent of the "3-pyridyl group optionally having substituents", which is one of A1, A2 and A3, is methyl, ethyl, trifluoromethyl, 1-hydroxy-1-methylethyl, carbamoylmethylamino, dimethylamino, morpholino, methylbenzylamino, methylthio, methoxy, isopropoxy or butadienylene.

7. The steroid C17,20-lyase inhibitor of claim 3, wherein the 3-pyridyl group optionally having substituents is a 4-methyl-3-pyridyl group or a 4-trifluoromethyl-3-pyridyl group.

8. The steroid C17,20-lyase inhibitor of claim 2, wherein A3 is a hydrogen atom, a halogen atom, a C1-4 alkyl group or a C1-4 alkoxycarbonyl group.

9. The steroid C17,20-lyase inhibitor of claim 3, wherein 3-pyridyl group optionally having substituents is a 3-pyridyl group, a 4-methyl-3-pyridyl group, a 4-trifluoromethyl-3-pyridyl group, a 4-methoxy-3-pyridyl group, a 4,5-butadienylene-3-pyridyl group, a 4-dimethylamino-3-pyridyl group, a 4-methylthio-3-pyridyl group, a 4-benzylmethylamino-3-pyridyl group, a 4-isopropoxy-3-pyridyl group, a 5-ethoxycarbonyl-3-pyridyl group, a 4-morpholino-3-pyridyl group, a 1-hydroxyisopropyl-3-pyridyl group, a 6-dimethylcarbamoyl-3-pyridyl group, a 4-hydroxy-4-(4-chlorophenyl)piperidino-3-pyridyl group, a 4-(N-methylcarbamoyl)-3-pyridyl group, a 4-ethyl-3-pyridyl group, a 4-carbamoylmethylamino-3-pyridyl group, a 4-carbamoyl-3-pyridyl group or a 4-(4-benzylpiperidinocarbonyl)-3-pyridyl group, and the C6-14 aryl group optionally having substituents is a phenyl group, a 4-phenylphenyl group, a 3-nitrophenyl group, a 4-nitrophenyl group, a 4-hydroxyphenyl group, a 2-chlorophenyl group, a 3-chlorophenyl group, a 4-chlorophenyl group, a 3,4-dichlorophenyl group, a 2-fluorophenyl group, a 3-fluorophenyl group, a 4-fluorophenyl group, a 4-bromophenyl group, a 4-methylphenyl group, a 2,4-dimethylphenyl group, a 3,4-dimethylphenyl group, a 4-trifluoromethylphenyl group, a 2,4-bistrifluoromethylphenyl group, a 2-methoxyphenyl group, a 3-methoxyphenyl group, a 4-methoxyphenyl group, a 2,4-dimethoxyphenyl group, a 4-aminophenyl group, a 4-diethylaminophenyl group, a 4-methoxycarbonylphenyl group, a 4-ethoxycarbonylphenyl group, a 3-methylcarbamoylphenyl group, a 4-sulfamoylphenyl group, a 4-methylsulfamoylphenyl group, a 3,4-ethylenedioxyphenyl group, a 4-acetoxyphenyl group, a 4-methylsulfonylphenyl group, a 4-dibenzylsulfamoylphenyl group, 3-acetylaminophenyl group, a 4-acetylaminophenyl group, a 4-methylsulfonylaminophenyl group, a 3-methylsulfonylaminophenyl group, a 4-carbamoylphenyl group or a 2-naphthyl group.

10. The steroid C17,20-lyase inhibitor of claim 2, which is a prophylactic or therapeutic agent of a sex hormone dependent disease.

11. The steroid C17,20-lyase inhibitor of claim 2, which is a prophylactic or therapeutic agent of prostatic hypertrophy, masculinism, hypertrichosis, male-type baldness, male infant-type prematurity, endometriosis, hysteromyoma, adenomyosis of uterus, mastopathy or polycystic ovary syndrome.

12. An androgen or estrogen reducing agent, which comprises a steroid C17,20-lyase inhibitor and an LHRH receptor modulator in combination.

13. An androgen or estrogen reducing agent comprising a compound represented by the formula:

wherein A1 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, one of A2 and A3 is a hydrogen atom, a halogen atom, a C1-4 aliphatic hydrocarbon group optionally having substituents or an optionally esterified carboxyl group, the other of A2 and A3 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, and at least one of A1, A2 and A3 is a 3-pyridyl group optionally having substituents, or a salt thereof or a prodrug thereof, and an LHRH receptor modulator in combination.

14. A method for inhibiting steroid C17,20-lyase, which comprises administering an effective amount of a compound represented by the formula:

wherein A1 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, one of A2 and A3 is a hydrogen atom, a halogen atom, a C1-4 aliphatic hydrocarbon group optionally having substituents or an optionally esterified carboxyl group, the other of A2 and A3 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, and at least one of A1, A2 and A3 is a 3-pyridyl group optionally having substituents, or a salt thereof or a prodrug thereof.

15. Use of a compound represented by the formula:

wherein A1 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, one of A2 and A3 is a hydrogen atom, a halogen atom, a C1-4 aliphatic hydrocarbon group optionally having substituents or an optionally esterified carboxyl group, the other of A2 and A3 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, and at least one of A1, A2 and A3 is a 3-pyridyl group optionally having substituents, or a salt thereof or a prodrug thereof for the production of a steroid C17,20-lyase inhibitor.

16. A compound represented by the formula:

wherein n is an integer of 1 to 5, R1a is a sulfamoyl group optionally having substituents or an alkylsulfonyl group optionally having substituents, or two R1a substituting adjacent carbon atoms are bonded to designate a C1-2 alkylenedioxy group, and when n is not less than 2, R1a in the number of n may be the same or different, m is an integer of 1 to 5, R2 is 1) a hydrogen atom, 2) a C1-4 aliphatic hydrocarbon group optionally having substituents, 3) an optionally esterified carboxyl group, 4) a carbamoyl group optionally having substituents, 5) an amino group optionally having substituents, 6) a cyclic amino group, 7) an alkylthio group optionally having substituents or 8) an alkoxy group optionally having substituents, or two R2 substituting adjacent carbon atoms may be bonded to form 9) a saturated or unsaturated divalent C3-5 carbon chain, and when m is not less than 2, R2 in the number of m may be the same or different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, or a salt thereof.

17. The compound of claim 16, wherein R1a is 1) a sulfamoyl group optionally having C1-4 alkyl or C7-9 aralkyl as a substituent or 2) a C1-4 alkylsulfonyl group, or two R1a substituting adjacent carbon atoms are bonded to designate a C1-2 alkylenedioxy group, R2 is 1) a hydrogen atom, 2) a C1-4 alkyl optionally having halogen or hydroxy as a substituent, 3) a carboxyl group, 4) a C1-4 alkoxycarbonyl group, 5) a carbamoyl group optionally having C1-4 alkyl or C7-9 aralkyl as a substituent, 6) an amino group optionally having C1-4 alkyl, carbamoyl-C1-4 alkyl or C7-10 aralkyl as a substituent, 7) a piperidino group, 8) a morpholino group, 9) a C1-4 alkylthio group or 10) a C1-4 alkoxy group, or two adjacent R2 are bonded to form 11) a butadienylene group, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 alkyl group, 4) a carboxyl group or 5) a C1-4 alkoxycarbonyl group.

18. The compound of claim 16, wherein R1a is a sulfamoyl group, a methylsulfamoyl group, a dibenzylsulfamoyl group or a methylsulfonyl group, or two R1a substituting adjacent carbon atoms are bonded to designate an ethylenedioxy group, R2 is a hydrogen atom, a methyl group, a trifluoromethyl group or a methoxy group, or two adjacent R2 are bonded to form a butadienylene group, and R3 is a hydrogen atom or a chlorine atom.

19. A prodrug of a compound represented by the formula:

wherein n is an integer of 1 to 5, R1a is a sulfamoyl group optionally having substituents or an alkylsulfanyl group optionally having substituents, or two R1a substituting adjacent carbon atoms are bonded to designate a C1-2 alkylenedioxy group, and when n is not less than 2, R1a in the number of n may be the same or different, m is an integer of 1 to 5, R2 is 1) a hydrogen atom, 2) a C1-4 aliphatic hydrocarbon group optionally having substituents, 3) an optionally esterified carboxyl group, 4) a carbamoyl group optionally having substituents, 5) an amino group optionally having substituents, 6) a cyclic amino group, 7) an alkylthio group optionally having substituents or 8) an alkoxy group optionally having substituents, or two R2 substituting adjacent carbon atoms may be bonded to farm 9) a saturated or unsaturated divalent C3-5 carbon chain, and when m is not less than 2, R2 in the number of m may be the same or different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, or a salt thereof.

20. A compound represented by the formula:

wherein n is an integer of 1 to 5, R1a is a sulfamoyl group optionally having substituents or an alkylsulfonyl group optionally having substituents, or two R1a substituting adjacent carbon atoms are bonded to designate a C1-2 alkylenedioxy group, and when n is not less than 2, R1a in the number of n may be the same or different, R2a and R2b are the same or different and each is 1) a hydrogen atom, 2) a C1-4 aliphatic hydrocarbon group optionally having substituents, 3) an optionally esterified carboxyl group, 4) a carbamoyl group optionally having substituents, 5) an amino group optionally having substituents, 6) a cyclic amino group, 7) an alkylthio group optionally having substituents or 8) an alkoxy group optionally having substituents, or R2a and R2b may be bonded to form 9) a saturated or unsaturated divalent C3-5 carbon chain, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, or a salt thereof.

21. The compound of claim 20, wherein R1a is 1) a sulfamoyl group optionally having C1-4 alkyl or a C7-9 aralkyl as a substituent or 2 ) a C1-4 alkylsulfonyl group, or two R1a substituting adjacent carbon atoms are bonded to designate a C1-2 alkylenedioxy group, R2a and R2b are the same or different and each is 1) a hydrogen atom, 2) a C1-4 alkyl optionally having halogen or hydroxy as a substituent, 3) a carboxyl group or a C1-4 alkoxycarbonyl group, 4) a carbamoyl group optionally having C1-4 alkyl or C7-9 aralkyl as a substituent, 5) an amino group optionally having C1-4 alkyl, carbamoyl-C1-4 alkyl or C7-10 aralkyl as a substituent, 6) a piperidino group or morpholino group, 7) a C1-4 alkylthio group or 8) a C1-4 alkoxy group, or R2a and R2b are bonded to form a butadienylene group, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 alkyl group, 4) a carboxyl group or 5) a C1-4 alkoxycarbonyl group.

22. The compound of claim 20, wherein R1a is a sulfamoyl group, a methylsulfamoyl group, a dibenzylsulfamoyl group or a methylsulfonyl group, or two R1a substituting adjacent carbon atoms are bonded to designate an ethylenedioxy group, R2a is a hydrogen atom, a methyl group, a trifluoromethyl group or a methoxy group, R2b is a hydrogen atom, or R2a and R2b are bonded to form a butadienylene group, and R3 is a hydrogen atom or a chlorine atom.

23. A prodrug of a compound represented by the formula:

wherein n is an integer of 1 to 5, R1a is a sulfamoyl group optionally having substituents or an alkylsulfonyl group optionally having substituents, or two R1a substituting adjacent carbon atoms are bonded to designate a C1-2 alkylenedioxy group, and when n is not less than 2, R1a in the number of n may be the same or different, R2a and R2b are the same or different and each is 1) a hydrogen atom, 2) a C1-4 aliphatic hydrocarbon group optionally having substituents, 3) an optionally esterified carboxyl group, 4) a carbamoyl group optionally having substituents, 5) an amino group optionally having substituents, 6) a cyclic amino group, 7) an alkylthio group optionally having substituents or 8) an alkoxy group optionally having substituents, or R2a and R2b may be bonded to form 9) a saturated or unsaturated divalent C3-5 carbon chain, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, or a salt thereof.

24. A compound represented by the formula:
wherein n is an integer of 1 to 5, R1b is 1) a sulfamoyl group optionally having substituents, 2) a carbamoyl group optionally having substituents, 3) an alkyl group optionally having substituents, 4) an optionally esterified carboxyl group, 5) a halogen atom, 6) an amino group optionally having substituents, 7) a nitro group, 8) a hydroxy group optionally having substituents or 9) an alkylsulfonyl group optionally having substituents, or two R1b substituting adjacent carbon atoms are bonded to designate a C1-2 alkylenedioxy group, and when n is not less than 2, R1b in the number of n may be the same or different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, or a salt thereof.

25. The compound of claim 24, wherein R1b is 1) a sulfamoyl group optionally having C1-4 alkyl or C7-9 aralkyl as a substituent, 2) a carbamoyl group optionally having C1-4 alkyl or C7-9 aralkyl as a substituent, 3) a C1-4 alkyl group optionally having halogen as a substituent, 4) a carboxyl group, 5) a C1-4 alkoxycarbonyl group, 6) a halogen atom, 7) an amino group optionally having C1-6 alkanoyl, C1-4 alkyl or C1-4 alkylsulfonyl as a substituent, 8) a nitro group, 9) a hydroxy group optionally having C1-4 alkyl or C1-6 alkanoyl as a substituent or 10) a C1-4 alkylsulfonyl group, or two R1b substituting adjacent carbon atoms are bonded to designate a C1-2 alkylenedioxy group, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 alkyl group, 4) a carboxyl group or 5) a C1-4 alkoxycarbonyl group.

26. The compound of claim 24, wherein R1b is a sulfamoyl group, a methylsulfamoyl group, a dibenzylsulfamoyl group, a carbamoyl group, a methylcarbamoyl group, an ethylcarbamoyl group, a dimethylcarbamoyl group, an azetidine-1-ylcarbonyl group, a methyl group, a trifluoromethyl group, a carboxyl group, an ethoxycarbonyl group, a chlorine atom, a fluorine atom, a nitro group, a hydroxy group, a methoxy group or a methylsulfonyl group, or two R1b substituting adjacent carbon atoms are bonded to designate an ethylenedioxy group, and R3 is a hydrogen atom, a chlorine atom, a fluorine atom or a methyl group.

27. A prodrug a compound represented by the formula:

wherein n is an integer of 1 to 5, R1b is 1) a sulfamoyl group optionally having substituents, 2) a carbamoyl group optionally having substituents, 3) an alkyl group optionally having substituents, 4) an optionally esterified carboxyl group, 5) a halogen atom, 6) an amino group optionally having substituents, 7) a nitro group, 8) a hydroxy group optionally having substituents or 9) an alkylsulfonyl group optionally having substituents, or two R1b substituting adjacent carbon atoms are bonded to designate a C1-2 alkylenedioxy group, and when n is not less than 2, R1b in the number of n may be the same or different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, or a salt thereof.

28. A compound represented by the formula:
wherein m is an integer of 1 to 5, R2 is 1) a hydrogen atom, 2) a C1-4 aliphatic hydrocarbon group optionally having substituents, 3) an optionally esterified carboxyl group, 4) a carbamoyl group optionally having substituents, 5) an amino group optionally having substituents, 6) a cyclic amino group, 7) an alkylthio group optionally having substituents or 8) an alkoxy group optionally having substituents, or two R2 substituting adjacent carbon atoms may be bonded to form 9) a saturated or unsaturated divalent C3-5 carbon chain, and when m is not less than 2, R2 in the number of m may be the same or different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, or a salt thereof.

29. The compound of claim 28, wherein R2 is 1) a hydrogen atom, 2) a C1-4 alkyl optionally having halogen or hydroxy as a substituent, 3) a carboxyl group, 4) a C1-4 alkoxycarbonyl group, 5) a carbamoyl group optionally having C1-4 alkyl or C7-9 aralkyl as a substituent, 6) an amino group optionally having 4 alkyl, carbamoyl-C1-4 alkyl or C7-10 aralkyl as a substituent, 7) a piperidino group, 8) a morpholino group, 9) a C1-4 alkylthio group or 10) a C1-4 alkoxy group, or two adjacent R2 are bonded to form 11) a butadienylene group, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 alkyl group, 4) a carboxyl group or 5) a C1-4 alkoxycarbonyl group.

30. The compound of claim 28, wherein R2 is a hydrogen atom, a methyl group or a trifluoromethyl group, and R3 is a hydrogen atom.

31. A prodrug of a compound represented by the formula:

m is an integer of 1 to 5, R2 is 1) a hydrogen atom, 2) a C1-4 aliphatic hydrocarbon s group optionally having substituents, 3) an optionally esterified carboxyl group, 4) a carbamoyl group optionally having substituents, 5) an amino group optionally having substituents, 6) a cyclic amino group, 7) an alkylthio group optionally having substituents or 8) an alkoxy group optionally having substituents, or two R2 substituting adjacent carbon atoms may be bonded to form 9) a saturated or unsaturated divalent C3-5 carbon chain, and when m is not less than 2, R2 in the number of m may be the same or different, and is R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, or a salt thereof.

32. A compound represented by the formula:
wherein p is 0 or an integer of 1 to 5, R a and R b are the same or different and each is a hydrogen atom, a C1-6 lower alkyl group, or R a and R b may be bonded together with a nitrogen atom to form a ring, R1d is 1) a hydrogen atom, 2) a C1-4 aliphatic hydrocarbon group optionally having substituents, 3) a sulfamoyl group optionally having substituents, 4) a carbamoyl group optionally having substituents, 5) an optionally esterified carboxyl group, 6) a halogen atom, 7) an amino group optionally having substituents, 8) a cyclic amino group, 9) a hydroxy group optionally having substituents, 10) an alkylthio group optionally having substituents, 11) a nitro group, 12) an alkylsulfonyl group optionally having substituents, or 13) two R1d substituting adjacent carbon atoms may be bonded to form 13a) a C1-2 alkylenedioxy group or 13b) a saturated or unsaturated divalent C3-5 carbon chain, and when p is not less than 2, R1d in the number of p may be the same or different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, or a salt thereof.

33. The compound of claim 32, wherein R a and R b are the same or different and each is hydrogen atom, a methyl group or an ethyl group, or R a and R b are bonded together with a nitrogen atom to designate an azetidin-1-yl group, R1d is a hydrogen atom, and R3 is a hydrogen atom.

34. A prodrug of a compound represented by the formula:

wherein p is 0 or an integer of 1 to 5, R a and R b are the same or different and each is a hydrogen atom, a C1-6 lower alkyl group, or R a and R b may be bonded together with a nitrogen atom to form a ring, R1d is 1) a hydrogen atom, 2) a C1-4 aliphatic hydrocarbon group optionally having substituents, 3) a sulfamoyl group optionally having substituents, 4) a carbamoyl group optionally having substituents, 5) an optionally esterified carboxyl group, 6) a halogen atom, 7) an amino group optionally having substituents, 8) a cyclic amino group, 9) a hydroxy group optionally having substituents, 10) an alkylthio group optionally having substituents, 11) a nitro group, 12) an alkylsulfonyl group optionally having substituents, or 13) two R1d substituting adjacent carbon atoms may be bonded to form 13a) a C1-2 alkylenedioxy group or 13b) a saturated or unsaturated divalent C3-5 carbon chain, and when p is not less than 2, R1d in the number of p may be the same or different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, or a salt thereof.

35. A compound represented by the formula:

wherein n is an integer of 1 to 5, R1C is a carbamoyl group optionally having substituents or an alkylsulfonyl group optionally having substituents, or two R1C substituting adjacent carbon atoms are bonded to designate a C1-2 alkylenedioxy group, and when n is not less than 2, R1C in the number of n are the same or different, m is an integer of 1 to 5, R2 is 1) a hydrogen atom, 2) a C1-4 aliphatic hydrocarbon group optionally having substituents, 3) an optionally esterified carboxyl group, 4) a carbamoyl group optionally having substituents, 5) an amino group optionally having substituents, 6) a cyclic amino group, 7) an alkylthio group optionally having substituents or 8) an alkoxy group optionally having substituents, or two R2 substituting adjacent carbon atoms may be bonded to form 9) a saturated or unsaturated divalent C3-5 carbon chain, and when m is not less than 2, R2 in the number of m may be the same or different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, or a salt thereof.

36. The compound of claim 35, wherein R1C is 1) a carbamoyl group optionally having C1-4 alkyl or C7-9 aralkyl as a substituent or 2) a C1-4 alkylsulfonyl group, or two R1b substituting adjacent carbon atoms are bonded to designate a C1-2 alkylenedioxy group, R2 is 1) a hydrogen atom, 2) a C1-4 alkyl optionally having halogen or hydroxy as a substituent, 3) a carboxyl group, 4) a C1-4 alkoxycarbonyl group, 5) a carbamoyl group optionally having C1-4 alkyl or C7-9 aralkyl as a substituent, 6) an amino group optionally having C1-4 alkyl, carbamoyl-C1-4 alkyl or C7-10 aralkyl as a substituent, 7) a piperidino group, 8) a morpholino group, 9) a C1-4 alkylthio group or 10) a C1-4 alkoxy group, or two R2 substituting adjacent carbon atoms are bonded to form 11) a butadienylene group, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 alkyl group, 4) a carboxyl group or 5) a C1-4 alkoxycarbonyl group.

37. The compound of claim 35, wherein R1C is a carbamoyl group, a methylcarbamoyl group, or a dimethylcarbamoyl group, R2 is a hydrogen atom, a methyl group, an ethyl group or an isopropyl group, and R3 is a hydrogen atom, a chlorine atom, a methyl group or an isopropyl group.

38. A prodrug of a compound represented by the formula:
wherein n is an integer of 1 to 5, R1C is a carbamoyl group optionally having substituents or an alkylsulfonyl group optionally having substituents, or two R1C substituting adjacent carbon atoms are bonded to designate a C1-2 alkylenedioxy group, and when n is not less than 2, R1C in the number of n are the same or different, m is an integer of 1 to 5, R2 is 1) a hydrogen atom, 2) a C1-4 aliphatic hydrocarbon group optionally having substituents, 3) an optionally esterified carboxyl group, 4) a carbamoyl group optionally having substituents, 5) an amino group optionally having substituents, 6) a cyclic amino group, 7) an alkylthio group optionally having substituents or 8) an alkoxy group optionally having substituents, or two R2 substituting adjacent carbon atoms may be bonded to form 9) a saturated or unsaturated divalent C3-5 carbon chain, and when m is not less than 2, R2 in the number of m may be the same or different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 aliphatic hydrocarbon group optionally having is substituents or 4) an optionally esterified carboxyl group, or a salt thereof.

39. A compound represented by the formula:
wherein n is an integer of 1 to 5, R1C is a carbamoyl group optionally having substituents or an alkylsulfonyl group optionally having substituents, or two R1c substituting adjacent carbon atoms are bonded to designate a C1-2 alkylenedioxy group, and when n is not less than 2, R1c in the number of n are the same or different, R2a and R2b are the same or different and each is 1) a hydrogen atom, 2) a C1-4 aliphatic hydrocarbon group optionally having substituents, 3) an optionally esterified carboxyl group, 4) a carbamoyl group optionally having substituents, 5) an amino group optionally having substituents, 6) a cyclic amino group, 7) an alkylthio group optionally having substituents or 8) an alkoxy group optionally having substituents, or R2a and R2b may be bonded to form 9) a saturated or unsaturated divalent C3-5 carbon chain, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, or a salt thereof.

40. The compound of claim 39, wherein R1c is 1) a carbamoyl group optionally having C1-4 alkyl or C7-9 aralkyl as a substituent or 2) a C1-4 alkylsulfonyl group, or two R1b substituting adjacent carbon atoms are bonded to designate a C1-2 alkylenedioxy group, R2a and R2b are the same or different and each is 1) a hydrogen atom, 2) a C1-4 alkyl optionally having halogen or hydroxy as a substituent, 3) a carboxyl group or C1-4 alkoxycarbonyl group, 4) a carbamoyl group optionally having C1-4 alkyl or C7-9 aralkyl as a substituent, 5) an amino group optionally having C1-4 alkyl, carbamoyl-C1-4 alkyl or C7-10 aralkyl as a substituent, 6) a piperidino group or morpholino group, 7) a C1-4 alkylthio group or 8) a C1-4 alkoxy group, or R2a and R2a are bonded to form a butadienylene group, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 alkyl group, 4) a carboxyl group or 5) a C1-4 alkoxycarbonyl group.

41. The compound of claim 39, wherein R1c is a carbamoyl group, a methylcarbamoyl group, or a dimethylcarbamoyl group, R2a is a methyl group, an ethyl group or an isopropyl group, R2b is a hydrogen atom, and R3 is a hydrogen atom, a chlorine atom, a methyl group or an isopropyl group.

42. A prodrug of a compound represented by the formula:
wherein n is an integer of 1 to 5, R1c is a carbamoyl group optionally having substituents or an alkylsulfonyl group optionally having substituents, or two R1c substituting adjacent carbon atoms are bonded to designate a C1-2 alkylenedioxy group, and when n is not less than 2, R1c in the number of n are the same or different, R2a and R2b are the same or different and each is 1) a hydrogen atom, 2) a C1-4 aliphatic hydrocarbon group optionally having substituents, 3) an optionally esterified carboxyl group, 4) a carbamoyl group optionally having substituents, 5) an amino group optionally having substituents, 6) a cyclic amino group, 7) an alkylthio group optionally having substituents or 8) an alkoxy group optionally having substituents, or R2a and R2b may be bonded to form 9) a saturated or unsaturated divalent C3-5 carbon chain, and R3 ~is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, or a salt thereof.

43. A compound represented by the formula:
wherein n ~is an integer of 1 to 5, R1b ~is 1) a sulfamoyl group optionally having substituents, 2) a carbamoyl group optionally having substituents, 3) an alkyl group optionally having substituents, 4) an optionally esterified carboxyl group, 5) a halogen atom, is 6) an amino group optionally having substituents, 7) a nitro group, 8) a hydroxy group optionally having substituents or 9) an alkylsulfonyl group optionally having substituents, or two R1b substituting adjacent carbon atoms are bonded to designate a C1-2 alkylenedioxy group, and when n is not less than 2, R1b in the number of n may be the same or different, and R3 ~is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, or a salt thereof.

44. The compound of claim 43, wherein R1b is 1) a sulfamoyl group optionally having C1-4 alkyl or C7-9 aralkyl as a substituent, 2) a carbamoyl group optionally having C1-4 alkyl or C7-9 aralkyl as a substituent, 3) a C1-4 alkyl group optionally having halogen as a substituent, 4) a carboxyl group, 5) a C1-4 alkoxycarbonyl group, 6) a halogen atom, 7) an amino group optionally having C1-6 alkanoyl, C1-4 alkyl or C1-4 alkylsulfonyl as a substituent, 8) a nitro group, 9) a hydroxy group optionally having C1-4 alkyl or C1-6 alkanoyl as a substituent or 10) a C1-4 alkylsulfonyl group, or two R1b substituting adjacent carbon atoms are bonded to designate a C1-2 alkylenedioxy group, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 alkyl group, 4) a carboxyl group or 5) a C1-4 alkoxycarbonyl group.

45. The compound of claim 43, wherein R1b is a sulfamoyl group, a carbamoyl group, a methylcarbamoyl group, a dimethylcarbamoyl group, a pyrrolidin-1-ylcarbonyl group, a methyl group, a chlorine atom, a fluorine atom, an acetylamino group, a formylamino group or nitro group, and R3 is a hydrogen atom, a chlorine atom, a methyl group or an isopropyl group.

46. A prodrug of a compound represented by the formula:
wherein n is an integer of 1 to 5, R1b is 1) a sulfamoyl group optionally having substituents, 2) a carbamoyl group optionally having substituents, 3) an alkyl group optionally having substituents, 4) an optionally esterified carboxyl group, 5) a halogen atom, 6) an amino group optionally having substituents, 7) a nitro group, 8) a hydroxy group optionally having substituents or 9) an alkylsulfonyl group optionally having substituents, or two R1b substituting adjacent carbon atoms are bonded to designate a C1-2 alkylenedioxy group, and when n is not less than 2, R1b in the number of n may be the same or different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, or a salt thereof.

47. A compound represented by the formula:
wherein m is an integer of 1 to 5, R2 is 1) a hydrogen atom, 2) a C1-4 aliphatic hydrocarbon group optionally having substituents, 3) an optionally esterified carboxyl group, 4) a carbamoyl group optionally having substituents, 5) an amino group optionally having substituents, 6) a cyclic amino group, 7) an alkylthio group optionally having substituents or 8) an alkoxy group optionally having substituents, or two R2 substituting adjacent carbon atoms are bonded to form 9) a saturated or unsaturated divalent C3-5 carbon chain, and when m is not less than 2, R2 in the number of m may be the same or different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, or a salt thereof.

48. The compound of claim 47, wherein R2 is 1) a hydrogen atom, 2) a C1-4 alkyl optionally having halogen or hydroxy as a substituent, 3) a carboxyl group, 4) a C1-4 alkoxycarbonyl group, 5) a carbamoyl group optionally having C1-4 alkyl or C7-9 aralkyl as a substituent, 6) an amino group optionally having C1-4 alkyl, carbamoyl-C1-4 alkyl or C7-10 aralkyl as a substituent, 7) a piperidino group, 8) a morpholino group, 9) a C1-4 alkylthio group or 10) a C1-4 alkoxy group, or two adjacent R2 are bonded to form 11) a butadienylene group, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 alkyl group, 4) a carboxyl group or 5) a C1-4 alkoxycarbonyl group.

49. The compound of claim 47, wherein R2 is a hydrogen atom, a methyl group or an ethyl group and R3 is a hydrogen atom or a methyl group.

50. A prodrug of a compound represented by the formula:

wherein m is an integer of 1 to 5, R2 is 1) a hydrogen atom, 2) a C1-4 aliphatic hydrocarbon group optionally having substituents, 3) an optionally esterified carboxyl group, 4) a carbamoyl group optionally having substituents, 5) an amino group optionally having substituents, 6) a cyclic amino group, 7) an alkylthio group optionally having substituents or 8) an alkoxy group optionally having substituents, or two R2 substituting adjacent carbon atoms are bonded to form 9) a saturated or unsaturated divalent C3-5 carbon chain, and when m is not less than 2, R2 in the number of m may be the same or different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, or a salt thereof.

51. A compound represented by the formula:

p is 0 or an integer of 1 to 5, R a and R b are the same or different and each is a hydrogen atom or a C1-6 lower alkyl group, or R a and R b may be bonded together with a nitrogen atom to form a ring, R1d is 1) a hydrogen atom, 2) a C1-4 aliphatic hydrocarbon group optionally having substituents, 3) a sulfamoyl group optionally having substituents, 4) a carbamoyl group optionally having substituents, 5) an optionally esterified carboxyl group, 6) a halogen atom, 7) an amino group optionally having substituents, 8) a cyclic amino group, 9) a hydroxy group optionally having substituents, 10) an alkylthio group optionally having substituents, 11) a nitro group, 12) an alkylsulfonyl group optionally having substituents, or 13) two R1d substituting adjacent carbon atoms may be bonded to form 13a) a C1-2 alkylenedioxy group or 13b) a saturated or unsaturated divalent C3-5 carbon chain, and when p is not less than 2, R1d in the number of p may be the same or different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, or a salt thereof.

52. The compound of claim 51, wherein R a and R b are the same or different and each is a hydrogen atom or a methyl group, or R a and R b are bonded together with a nitrogen atom to form a pyrrolidin-1-yl group, R1d is a hydrogen atom, a methyl group, a chlorine atom or a fluorine atom, and R3 is a hydrogen atom, a chlorine atom, a methyl group or an isopropyl group.

53. A prodrug of a compound represented by the formula:

wherein p is 0 or an integer of 1 to 5, R a and R b are the same or different and each is a hydrogen atom or a C1-6 lower alkyl group, or R a and R b may be bonded together with a nitrogen atom to form a ring, R1d is 1) a hydrogen atom, 2) a C1-4 aliphatic hydrocarbon group optionally having substituents, 3) a sulfamoyl group optionally having substituents, 4) a carbamoyl group optionally having substituents, 5) an optionally esterified carboxyl group, 6) a halogen atom, 7) an amino group optionally having substituents, 8) a cyclic amino group, 9) a hydroxy group optionally having substituents, 10) an alkylthio group optionally having substituents, 11) a nitro group, 12) an alkylsulfonyl group optionally having substituents, or 13) two R1d substituting adjacent carbon atoms may be bonded to form 13a) a C1-2 alkylenedioxy group or 13b) a saturated or unsaturated divalent C3-5 carbon chain, and when p is not less than 2, R1d in the number of p may be the same or different, and R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, or a salt thereof.

54. A compound represented by the formula:

wherein q is 0 or an integer of 1 to 5, R1b is 1) a sulfamoyl group optionally having substituents, 2) a carbamoyl group optionally having substituents, 3) an alkyl group optionally having substituents, 4) an optionally esterified carboxyl group, 5) a halogen atom, 6) an amino group optionally having substituents, 7) a nitro group, 8) a hydroxy group optionally having substituents or 9) an alkylsulfonyl group optionally having substituents, or 10) two R1b substituting adjacent carbon atoms are bonded to designate a C1-2 alkylenedioxy group, and when q is not less than 2, R1b in the number of q may be the same or different, R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, and A a, A b and A c are the same or different and each is a nitrogen atom or a methine group, or a salt thereof.

55. The compound of claim 54, wherein R1b is a sulfamoyl group, a carbamoyl group, a methylcarbamoyl group, a dimethylcarbamoyl group, an ethylcarbamoyl group, a pyrrolidin-1-ylcarbonyl group, a methyl group, a chlorine atom, a fluorine atom, an acetylamino group, a formylamino group or a nitro group, R3 is a hydrogen atom, a chlorine atom, a methyl group or an isopropyl group, and A a, A b and A c are the same or different and each is a nitrogen atom or a methine group.

56. A prodrug of a compound represented by the formula:

wherein q is 0 or an integer of 1 to 5, R1b is 1) a sulfamoyl group optionally having substituents, 2) a carbamoyl group optionally having substituents, 3) an alkyl group optionally having substituents, 4) an optionally esterified carboxyl group, 5) a halogen atom, 6) an amino group optionally having substituents, 7) a nitro group, 8) a hydroxy group optionally having substituents or 9) an alkylsulfonyl group optionally having substituents, or 10) two R1b substituting adjacent carbon atoms are bonded to designate a C1-2 alkylenedioxy group, and when q is not less than 2, R1b in the number of q may be the same or different, R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, and A a, A b and A c are the same or different and each is a nitrogen atom or a methine group, or a salt thereof.

57. A compound represented by the formula:

wherein q is 0 or an integer of 1 to 5, R1b is 1) a sulfamoyl group optionally having substituents, 2) a carbamoyl group optionally having substituents, 3) an alkyl group optionally having substituents, 4) an optionally esterified carboxyl group, 5) a halogen atom, 6) an amino group optionally having substituents, 7) a nitro group, 8) a hydroxy group optionally having substituents or 9) an alkylsulfonyl group optionally having substituents, or 10) two R1b substituting adjacent carbon atoms are bonded to designate a C1-2 alkylenedioxy group, and when q is not less than 2, R1b in the number of q are the same or different, R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, and A a, A b and A c are the same or different and each is a nitrogen atom or a methine group, or a salt thereof.

58. The compound of claim 57, wherein R1b is a sulfamoyl group, a methylsulfamoyl group, a dibenzylsulfamoyl group, a carbamoyl group, a methylcarbamoyl group, an ethylcarbamoyl group, a dimethylcarbamoyl group, an azetidin-1-ylcarbonyl group, a methyl group, a trifluoromethyl group, a carboxyl group, an ethoxycarbonyl group, a chlorine atom, a fluorine atom, a nitro group, a hydroxy group, a methoxy group or a methylsulfonyl group, or two R1b substituting adjacent carbon atoms are bonded to designate an ethylenedioxy group, R3 is a hydrogen atom, a chlorine atom, a fluorine atom or a methyl group, A a is a methine, A b is a nitrogen atom or a methine, and A c is a nitrogen atom or a methine.

59. A prodrug of a compound represented by the formula:

wherein q is 0 or an integer of 1 to 5, R1b is 1) a sulfamoyl group optionally having substituents, 2) a carbamoyl group optionally having substituents, 3) an alkyl group optionally having substituents, 4) an optionally esterified carboxyl group, 5) a halogen atom, 6) an amino group optionally having substituents, 7) a nitro group, 8) a hydroxy group optionally having substituents or 9) an alkylsulfonyl group optionally having substituents, or 10) two R1b substituting adjacent carbon atoms are bonded to designate a C1-2 alkylenedioxy group, and when q is not less than 2, R1b in the number of q are the same or different, R3 is 1) a hydrogen atom, 2) a halogen atom, 3) a C1-4 aliphatic hydrocarbon group optionally having substituents or 4) an optionally esterified carboxyl group, and A a, A b and A c are the same or different and each is a nitrogen atom or a methine group, or a salt thereof.

60. 3-[4-(4-Chlorophenyl)-1,3-thiazol-2-yl]-4-methylpyridine, 3-[4-(4-fluorophenyl)-1,3-thiazol-2-yl]-4-methylpyridine, 4-[2-(4-methyl-pyridin-3-yl)-1,3-thiazol-4-yl]benzenesulfonamide, 3-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]-4-methylpyridine, 4-[4-(4-methyl-pyridin-3-yl)-1,3-thiazol-2-yl]benzenesulfonamide or a salt thereof.